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Abstract 
Recent studies have suggested an increasingly important and therapeutically relevant 
role for CD4+ T cells as direct effectors in immunotherapy. It has also become clear that 
antigens can access the MHC-II pathway via non-classical endogenous routes such as 
autophagy. The aims of this project were to investigate endogenous MHC-II processing 
of tumour antigens and explore methods that, by enhancing such processing, could 
increase T cell recognition of tumour cells. The frequency and diversity of T cell 
responses to the tumour antigen WT1 in healthy individuals and cancer patients was 
investigated. T cell responses were rare and only one epitope-specificity was identified 
in these donors. The Epstein Barr Virus Nuclear Antigen 1 (EBNA1), a protein that 
becomes more efficiently processed by autophagy when relocalised from the nucleus 
into the cytoplasm, was also investigated. When EBNA1-positive cells were treated with 
the CDK inhibitor Roscovitine, previously reported to relocalise EBNA1 into the 
cytoplasm, presentation of an autophagy-dependent indicator epitope was decreased. 
Roscovitine did not affect autophagy activity but decreased cellular levels of several 
autophagy adaptor proteins. siRNA Knock down of each autophagy adaptor showed 
CALCOCO2, NBR1 and OPTN were involved in the generation of an autophagy-
dependent epitope from EBNA1; a control epitope was unaffected. Finally, efforts were 
made to define fundamental rules determining why only a subset of potential MHC-II 
epitopes are generated from an antigen by autophagy. Resistance to degradation by 
lysosomal peptidases was shown to be an important factor determining whether an 
MHC-II epitope can be generated by autophagy.  
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1. INTRODUCTION 
The human immune system is of vital importance in protecting against disease. It 
functions by discriminating self from non-self and killing or disabling foreign agents. 
These agents may be invading pathogens but cancerous cells, which have undergone 
extensive genetic mutation due to failure of DNA repair mechanisms, can also be 
considered to be foreign to the host.  
The immune system can be divided into two categories, innate and adaptive immunity  
1.1 Innate immunity 
The innate immune system acts as an initial defence against pathogens. It functions as a 
rapid but relatively non-specific method of responding to infection and is classically 
considered to contain no element of memory. Innate immunity is primarily driven by 
myeloid cells but the system comprises several different elements. First, pathogen 
access is prevented by physical barriers such as epithelia, which are sealed by tight 
junctions and skin that is keratinised (Citi and Cordenonsi, 1998; Friedman, 2006). 
Second, internal epithelia maintain a constant flow over their surfaces by peristalsis, 
cilia or fluids such as saliva to remove invading pathogens (Sheehan et al., 2006). Third, 
serum proteins such as the complement system have multiple functions including 
causing direct killing of pathogens (Sarma and Ward, 2011). Fourth, phagocytosis of 
pathogens is performed by cells such as dendritic cells and neutrophils and is aided by 
binding of complement to pathogens. More recently,  γδ-T cells, usually considered to be 
part of the adaptive immune system, have also been shown to be capable of 
phagocytosis (Wu et al., 2009). Fifth, natural killer (NK) cells mediate spontaneous 
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cytotoxicity against infected cells but also play an important role in shaping adaptive 
immune responses (Laouar et al., 2005). Other cells of the innate immune system 
include eosinophils, mast cells and basophils. As well as having a direct role in 
protection against pathogens a key role of the innate immune system is to alert and arm 
the adaptive immune system. 
1.2 Adaptive immunity 
Adaptive immunity is a system of much greater complexity having evolved later in the 
tree of life (Beutler, 2004; Pancer et al., 2004). On first encountering a pathogen the 
adaptive immune response occurs more slowly than the innate. The adaptive immune 
system is truly differentiated from the innate system by its intrinsic ability to generate 
pools of cells specific to previous infections, so called memory cells. The maintenance of 
memory cells allows a much more rapid and robust immune response to be generated 
upon reencountering a pathogen. Adaptive immunity is driven mainly by lymphocytes 
and can be further subdivided into two categories: cellular immunity, driven mainly by T 
cells and humoral immunity driven by antibodies produced by B cells. 
1.2.1 The role of T cells in immunity 
T and B lymphocytes were discovered in the 1960s and fundamental differences 
between the two cell types were quickly identified. The activation of B cells in-vitro was 
shown to require antigen alone, while the activation of T cells required an accessory cell 
(Alter and Bach, 1970). In the mid-1970s it was discovered that T cells recognise 
antigens presented by MHC molecules on antigen presenting cells (Blanden et al., 1975). 
This seminal observation showed that T cell recognition was fundamentally different 
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from B cell recognition, however it was not until the 1980s that T cells were shown to 
possess a unique receptor for this role known as the T cell receptor (TCR) (Allison et al., 
1982; Haskins et al., 1983; Meuer et al., 1983). The structure of the TCR was later 
resolved and revealed it consisted of a heterodimer of two different polypeptide chains. 
For the majority of T cells these two chains are the α and β chains and cells that express 
these chains are therefore known as αβ-T cells (hereafter referred to simply as T cells). 
A minority of T cells possess γ and δ delta chains instead and these are therefore known 
as γδ-T cells (Brenner et al., 1986; Lew et al., 1986). TCRs associate with two accessory 
molecules, the CD3- and ζ-chains forming the T cell receptor complex. Upon binding to 
an MHC-peptide complex the TCR signals via the two accessory chains to activate the 
cell. This activation triggers multiple immunological processes that can result in the 
killing of pathogens or pathogen-infected cells, either directly via a cytotoxic response or 
indirectly by providing help to other immune cells. 
1.2.2 T cell development 
T cell development is a highly complex process with multiple stages occurring in 
different areas of the body, each requiring signals and assistance from many different 
cell types. The process is unique among haematopoietic development in its requirement 
for a specific organ, the thymus (Miller, 1961) . Another unique property of T cell 
development is that the haematopoietic stem cells (HSCs) that T cells are derived from 
do not differentiate where they reside. Like all other HSCs they are produced throughout 
life and reside in the bone marrow. T cell development begins with progenitor T cells 
migrating from the bone marrow to the thymus under the direction of chemokines such 
as CCL21, which is produced by thymic epithelial cells (TECs) (Calderon and Boehm, 
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2011). Once in the thymus IL-7 and DL4 that are also produced by TECs induce 
proliferation and differentiation of the progenitor cells (Koch et al., 2008). The 
progenitor cells then migrate through the thymus and development proceeds through a 
number of pre-T cell stages. During the first of these pre-T cell stages the progenitor 
cells, known as thymocytes, are negative for TCR, CD4 and CD8. T cell development 
switches on the expression of these molecules but also triggers changes within the 
genomes of thymocytes to generate a diverse repertoire of T cells each expression a 
distinct TCR. 
1.2.3 Generation of the T cell repertoire 
Enormous variety exists in the pathogens that the immune system can encounter. 
Pathogens are also constantly evolving in response to pressure exerted by immune 
responses. As pathogen encounters cannot be predicted, the immune system must 
prepare for every possible pathogen in advance of encountering it. To meet this 
challenge the immune system must generate an almost limitless repertoire of TCR 
specificities. However all TCRs are generated from a single region of the genome that 
contains a limited number of genes. To overcome this problem thymocytes employ a 
complex series of random genetic rearrangements to generate genetically different TCRs 
in each thymocyte. The TCR is encoded as non-contiguous segments in the genome of 
progenitor cells. Three gene segments within this region, the variable (V), diversity (D) 
and joining (J) gene segments are rearranged in a process known as V(D)J 
recombination. The random joining of any V, D, and J segments followed by insertion of 
non-germline encoded nucleotides at the joining regions is directed by recognition 
sequences that flank VDJ sections and act as substrates for V(D)J recombinase (Gellert, 
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2002). This process creates genetically distinct TCR chains. Finally the random 
combination of an α and β chain creates a fully functional TCR molecule that is unique to 
the individual thymocyte. Early, low level expression of the TCR provides stimulus to 
induce the expression of CD4 and CD8 co-receptors creating TCRlowCD4+CD8+ cells 
(Yamasaki and Saito, 2007). 
V(D)J recombination creates an effectively limitless pool of TCR specificities. However, 
without control over this process not all T cells will express an immunologically relevant 
TCR. Some T cells will express TCRs that cannot bind MHC complexes and others will 
express TCRs specific to self-antigens, creating the potential to trigger autoimmunity. 
Therefore before naive T cells leave the thymus they are subject to positive and negative 
selection to remove redundant and autoreactive T cells respectively 
The thymic cortex induces TCR mediated positive selection of thymocytes that engage 
MHC complexes at intermediate levels of avidity. MHC class I binding downregulates 
CD4 producing a CD8+ T cell whereas MHC class II binding downregulates CD8 
producing a CD4+ T cell. Binding to MHC is vital as it triggers intracellular signals in 
developing thymocytes that overcome a default pathway of programmed cell death. This 
pathway “death by neglect” occurs in cells that do not bind to peptide-MHC complexes 
(Rosenheimer-Goudsmid et al., 2000). 
This process generates a pool of single positive thymocytes that is then subjected to 
negative selection to remove T cells that would react against self-antigens. Medullary 
TECs and dendritic cells present a diverse set of self antigens to single positive 
thymocytes. In the thymic medulla, high affinity binding to self peptide MHC complexes 
Chapter 1 - Introduction 
 
6 
 
triggers pro-apoptotic molecules that led to the death of the cell thereby removing self-
reactive T cells (Suen and Baldwin, 2012). 
1.2.4 T cell responses 
As with all adaptive immune responses, the T cell response is initiated in peripheral 
lymphoid tissues. As infection can arise anywhere in the body, it is vital that dendritic 
cells (DCs) deliver pathogenic antigens to these lymphoid tissues in order to stimulate T 
cells (Reis e Sousa, 2004). Naïve T cells circulating in the blood stream enter lymph 
nodes, spleen and other lymphoid tissues where they come into contact with thousands 
of DCs and sample the peptide MHC complexes expressed on the surface of them. The 
original interaction between T cell and DC is transient and non-antigen specific. If the T 
cell does not encounter a peptide-MHC complex able to stimulate its TCR, it is released 
and continues to sample other DCs and eventually returns to the blood stream. When a T 
cell does encounter a peptide-MHC complex able to activate its TCR it stops migrating. 
Following this encounter the T cell receives a number of different signals. The first signal 
is a direct MHC-peptide to TCR signal; however this signal is not sufficient to stimulate a 
response. Costimulatory signals are also produced by DCs to stimulate T cell. DCs 
express the ligand B7 which acts on CD28 on T cells and causes proliferation via IL-2 
production. Other signals also trigger differentiation of the T cell into the different 
effector phenotypes. It is this differentiation into effector phenotype that will allow the T 
cell to carry out its immune function upon subsequently encountering an infected target 
cell (Lanzavecchia and Sallusto, 2001). Once a T cell takes on an effector phenotype it 
can be activated by MHC I-peptide complexes and is no longer dependent on 
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costimulatory molecules expressed by antigen presenting cells (Kaech and Ahmed, 
2001; van Stipdonk et al., 2001). 
1.2.5 Effector phenotypes 
Naïve T cells are divided into two pools, CD8+ and CD4+. Naïve CD8+ T cells are destined 
to become cytotoxic T lymphocytes (CTLs) that function to directly kill target cells. Naïve 
CD4+ T cells can differentiate into a number of different effectors cells subsets. The main 
subsets are TH1, 2 and 17. Once differentiated into an effector phenotype, T cells will 
migrate to sites of infection to mount immune responses. Here they transiently bind 
target cells in a non peptide-specific manner. Then, if the cell expresses the correct 
peptide MHC complex the T cell will bind more tightly and initiate its effector function. 
Another important subset of CD4+ T cells are the regulatory T cells (Tregs). These cells 
act to suppress the immune system and are important in establishing peripheral 
tolerance to self-antigens. 
1.2.6 The CD8+ T cell response 
Activation of naive CD8+ T cells results in their differentiation into CTLs. CTLs are 
marked by their ability to produce cytokines such as interferon-γ (IFN-γ) and tumour 
necrosis factor-α (TNF-α) and their ability to exhibit cytolytic activity (Bachmann et al., 
1999; Opferman et al., 1999). These highly specialised cells recognise peptides 
presentenced on MHC class I molecules which are expressed on the surface of all 
nucleated cells. Therefore all proteins within cells are potentially available to display on 
the cell surface and interrogation by CTLs. CTLs that encounter a non-self peptide MHC 
complex are able to rapidly kill the presenting cell by two mechanisms: granule- or Fas- 
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mediated killing. Both these pathways trigger a caspase cascade resulting in apoptosis 
and death of the target cell. Granule mediated killing involves the exocytosis of effector 
proteins from cytotoxic granules in a calcium-dependent manner. Cytotoxic granules are 
modified lysosomes that contain at least three classes of effector proteins. The first, 
perforin, permits the delivery of the other two proteins into the cytoplasm of the 
infected cell (Lowin et al., 1994). The second class, the granzymes, are a family of serine 
protease that act in the cytoplasm to induce the target cell to undergo apoptosis 
(Darmon et al., 1995). The third class consists of granulysin that has a direct 
antimicrobial function but is also thought to be pro-apoptotic (Stenger et al., 1998). In 
contrast to granule exocytosis, Fas mediated killing is triggered by the upregulation of a 
protein, Fas ligand (FasL), on the surface of the CTL. FasL binds to Fas on the surface of 
target cells and triggers caspase mediated apoptosis (Ju et al., 1995). 
In their role as CTLs, CD8+ T cells are vital in the control of intracellular parasites, 
especially viruses. They are vital for the clearance of all acute viral infections as well as 
controlling reactivation of viruses in the case of persistent infection. 
1.2.7 The CD4+ T cell response 
Upon antigen encounter, naive CD4+ T cells also differentiate into effector cells. In the 
late 1980s Mossman and Coffman identified differences in these effector cells and 
described two phenotypes, Th1 and Th2 cells (Mosmann and Coffman, 1989). These two 
subsets are classified according to the cytokines they secrete. Th1 cells are marked by 
the secretion of IFN-γ, interleukin-2 (IL-2) and lymphotoxin-α (LTa), whereas Th2 cells 
are defined by the secretion of IL4, 5, 10 and 13 (Mosmann et al., 2005). Th1 cells 
provide help to the cellular arm of the immune system. They stimulate other cells such 
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as macrophages and in instances where pathogen infection does not trigger a strong 
inflammatory response, Th1 cells are vital in the stimulation of the CD8+ T cell response 
by providing signals such as IL-2 (Simon et al., 1986). Th2 cells provide help to the 
humoral arm of the immune system. They stimulate B cells to upregulate antibody 
production and undergo class switching (Lebman and Coffman, 1988). More recently a 
third subset of T helper cells namely Th17 cells has been defined. These cells are marked 
by the secretion of IL17, 21 and 22. They are vital for pathogen clearance and inducing 
tissue inflammation (Veldhoen et al., 2006). 
CD4+ T cells recognise peptides in the contexts of MHC class II complexes. Under normal 
circumstances expression of MHC class II molecules is limited to specialist antigen 
presenting cells (APC), meaning that CD4+ T cells cannot bind directly to non-immune 
cells. This limitation has led to the establishment of the dogma that CD4+ T cells function 
only to provide help to other cells of the immune system. However this is not the case 
and increasingly reports of CD4+ T cells with direct effector function are appearing in the 
literature. Many different cell types have now been shown to upregulate the expression 
of MHC class II molecules under certain conditions, one such example being virus 
infection (Debbabi et al., 2005). The expression of MHC class II molecules on virus 
infected cells suggests a direct role for CD4+ T cells in anti-viral immunity. Indeed CD4+ T 
cells have now been shown to control infection of many viruses including gamma herpes 
viruses, murine influenza and west Nile virus amongst others (Brien et al., 2008; Sparks-
Thissen et al., 2004; Stuller et al., 2010). A number of reports have shown isolation of 
virus-specific CD4+ T cells, including cytotoxic CD4+ T cells specific to viral antigens such 
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as those of Epstein-Barr virus (EBV) (Khanna et al., 1997; Long et al., 2005; Munz et al., 
2000). 
Cytotoxic CD4+ T cells are capable of killing target cells by the same two mechanisms 
employed by CD8+ CTLs, namely granule-mediated cytolysis or FasL-Fas signalling or 
indeed both (Brown et al., 2006; Brown et al., 2012; Ishikawa et al., 2009). Interestingly 
the cytotoxic activity of CD4+ T cells does not depend on Th1 polarisation. As with Th1 
cells, IL-2 is required as a differentiation signal but cytotoxic CD4+ T cells do not use the 
transcription factor T-bet. Instead the T-box transcription factor Eomesodermin has 
been shown to be critical for inducing the cytotoxic marker granzyme B (Brown et al., 
2009; Qui et al., 2011). These key differences have led to the suggestion that cytotoxic 
CD4+ T cells should be considered a separate functional T cell subset (Swain et al., 2012). 
1.3 Antigen processing 
As previously discussed, the ability of a T cell to function relies on its intrinsic capacity 
to recognise target cells that are infected by a pathogen or have internalised pathogen-
derived proteins. To facilitate this recognition, cells express MHC molecules that bind 
peptide fragments derived from proteins contained within the cell. These peptide-MHC 
complexes are then displayed on the cell surface. In order for this to occur antigen 
processing is required to degrade proteins within cells and generate these peptide 
fragments. 
In the classical model of antigen processing, MHC class I molecules bind peptides 
derived from endogenous nuclear and cytoplasmic proteins whereas MHC class II 
molecules bind peptides derived from extracellular proteins that have been 
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phagocytosed by the cell. However this model has proved to be an oversimplification of 
reality and additional non-classical processing pathways have been described. Both 
classical and non-classical processing will be discussed in the following section. 
1.3.1 MHC class I processing 
Classical MHC class I processing involves the degradation of proteins in the cytosol via 
the proteasome and subsequent transport into the endoplasmic reticulum (ER) for 
loading onto MHC class I molecules. MHC class I processing is therefore vital for the 
immune response against many intracellular parasites including viruses that hijack the 
cellular machinery to express viral proteins within the cytosol. 
1.3.2 Generation of MHC class I epitopes  
Intracellular proteins are constantly degraded as part of the normal process of turnover 
and recycling of proteins and organelles within cell. Degradation is a tightly regulated 
process and different proteins have different half-lives that can range from minutes to 
weeks. Within the cytosol degradation is mostly carried out by the 26S proteasome 
which targets proteins labelled by conjugation to ubiquitin moieties (Hershko et al., 
1980). 
The 26S proteasome is a multi-catalytic protease complex. It contains a barrel-shaped 
proteolytic core complex, the 20S proteasome and is capped at either one or both ends 
by 19S regulatory complexes, which recognize ubiquitinated proteins (Voges et al., 
1999). The proteasome degrades proteins within its lumen and generates peptides 
suitable for binding to MHC class I molecules (Niedermann et al., 1999). 
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In the context of infection, interferons in the cell alter the proteasome to increase levels 
of antigen processing. IFN-γ causes a conformational change in the proteasome and 
triggers the exchange of proteases in the complex, forming a new structure, the 
immunoproteasome (Aki et al., 1994). The proteases in the immunoproteasome cleave 
peptides in a specific manner so that they are more readily transported into the antigen 
presentation pathway and bind MHC complexes with greater affinity. The 
conformational change in the barrel structure also increases the rate of peptide 
production meaning a greater number of peptides can be presented more rapidly 
(Cerundolo et al., 1995). 
The source of proteins for MHC class I processing is a widely contested issue. The 
proteasome is known to degrade stable, mature proteins and these proteins are 
represented in the repertoire of MHC class I peptides presented on the cell (Rock et al., 
2002). However a second source of peptides also exists. Defective ribosomal products 
(DRiPs) are the product of erroneous mRNA translation. Yewdell has proposed that the 
majority of peptides are not products of stable protein degradation, but instead come 
from the degradation of DRiPs (Yewdell et al., 1996). This hypothesis is supported by the 
fact that MHC class I peptide complexes can appear rapidly after induction of antigen 
and peak before steady state levels of mature protein had been reached (Mackay et al., 
2009). 
Once generated by the proteasome, peptides are released into the cytosol. These 
peptides must then bind MHC I molecules to be displayed on the surface of cells. 
Chapter 1 - Introduction 
 
13 
 
1.3.3 The MHC class I molecule 
The MHC class I molecule is a heterodimer composed of an MHC heavy chain in 
association with a second, smaller protein, beta-2-microglobin (β2m). The extracellular 
region of the heavy chain folds into three domains, with β2m forming a fourth. Two of 
the extracellular domains form the peptide binding grove, which binds peptide epitopes 
about 8-11 amino acids in length (Garrett et al., 1989). To generate diversity in the 
repertoire of presented peptides, MHC class I molecules are highly polymorphic. 
Heterozygous individuals can express up to 6 different alleles, that will each bind and 
display a different pool of peptides (Lund et al., 2004). 
1.3.4 Formation of MHC class I-peptide complexes 
Upon synthesis, polypeptides of the MHC complex are translocated into the lumen of the 
endoplasmic reticulum (ER). Here they bind the chaperones calnexin and calreticulin 
that facilitate folding of the MHC molecule. Once the heterodimer is formed it is rapidly 
recruited into the peptide loading complex, a multi-protein complex that retains MHC 
molecules within the ER in a peptide receptive state.  
To gain access to MHC class I complexes, peptides in the cytosol bind chaperones and 
are transported to the ER membrane. Here they bind a protein of the peptide loading 
complex, the transporter associated with antigen processing (TAP) and are transported 
into the ER lumen (Abele and Tampe, 1999). Though TAP-dependent transport is 
required for the majority of MHC class I peptides it should be noted that MHC class I 
processing can occur in the absence of TAP (Lautscham et al., 2001). 
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Once within the ER, binding of high affinity peptides to peptide-receptive MHC class I 
molecules is catalysed by another protein contained within the peptide loading complex, 
tapasin. Peptide loading causes a conformational change in MHC class I molecules 
causing them to be released from the peptide loading complex. Once released they can 
be transported to the cell surface via the golgi network (Wearsch and Cresswell, 2008). 
1.3.5 Alternative MHC class I processing: exogenous proteins 
As previously discussed, CD8+ T cells recognise pathogen infected cells through MHC 
class I molecules. However, CTLs cannot gain cytotoxic function without first being 
primed by DCs. This priming occurs through MHC class I but this creates a problem for 
the immune system: not all pathogens infect DCs. The solution to this fundamental 
problem is provided by cross priming, a non-classical processing pathway 
Cross priming and was first described in the 1970s. It occurs in DCs and is of vital 
importance in priming CD8+ T cells responses. Classically, cross priming is thought to 
take place via two routes. The first involves processing of antigens and peptide loading 
in endocytic vesicles using MHC class I molecules recycled from the plasma membrane. 
The second pathway involves retrograde translocation of proteins from endosomes into 
the cytosol where they can be processed by the classical MHC class I processing 
machinery. However more recently a more complicated mechanism involving interplay 
of endosomal and cytoslic pathways as well as hybrid compartments has been suggested 
(Segura and Villadangos, 2011). 
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1.3.6 MHC class II processing 
Peptides from the cytosol of infected cells are presented on MHC class I molecules. 
However many pathogen-derived proteins do not enter the cytosol. Some parasites live 
in intracellular vesicles whereas others are completely extra cellular. Proteins that have 
been internalised into endocytic vesicles upon uptake by professional antigen 
presenting cells do not enter the cytosol and therefore never encounter free MHC class I 
molecules. A different system is therefore required to present them to the immune 
system, MHC class II presentation.  
MHC class II molecules are expressed on the surface of a small subset of specialised cells, 
APCs. The main function of APCs is to sample the extra cellular environment as well as 
the contents of other cells and present peptides from all pathogens including those that 
subvert the MHC class I pathway. The process by which pathogenic proteins are 
presented as peptides on class II molecules is very different from the class I system and 
occurs mainly in the endocytic vesicles of APCs. 
1.3.7 Antigen uptake 
Exogenous antigens are taken into cells by many different endocytic pathways. Soluble 
antigens are most often internalised by clathrin mediated endocytosis. In this process 
cargo receptors bind antigens and cluster in clathrin coated pits. The pit then 
invaginates, pinches off from the membrane and forms a clathrin coated vesicle 
containing receptor and cargo. A small quantity of extra cellular fluid is also internalised 
in this process. 
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A second mechanism of soluble antigen uptake is macropinocytosis. This is a non-
selective form of endocytosis and involves actin-dependent formation of large, endocytic 
vacuoles called macropinosomes. Macropinoctosis is highly active in macrophages and 
DCs where it is the major pathway for the capture of antigens (Norbury, 2006). 
In contrast to soluble antigens, particulate antigens are internalised via a number of 
different phagocytic pathways. Fc-receptor mediated phagocytosis involves the 
extension of large membrane protrusions around antibody coated particles. A second 
mechanism complement mediated phagocytosis involves the invagination of the cell 
membrane to take in particles coated with complement proteins. 
Once internalised, vesicles are directed into different stages of the endocytic pathway 
according to their contents. Vesicles can be targeted to early endosomes where they may 
be recycled back to the cell surface or they can be targeted for degradation in mature 
endosomes and other compartments with much lower pH (McMahon and Boucrot, 
2011). 
1.3.8 Generation of MHC class II epitopes 
Proteins contained within the endocytic pathway are degraded by a range of acidic 
proteases. Cathepsins are a key group of acidic proteases that reside within 
endosomal/lysosomal compartments. They fall into two main categories, aspartyl and 
cysteine proteases. Many cathepsins have been implicated in MHC class II processing, 
either in peptide generation or MHC class II peptide loading (Table 1.1). 
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Table 1.1 Cathepsins involved in antigen processing 
a. Cysteine Proteases 
   
            
Protease Proteolytic activity Distribution Location 
AEP Asparaginase APCs Lysosome 
Cathepsin S Endoprotease APCs Endosome (E) 
Cathepsin L Endoprotease Widespread Late E, lysosome 
Cathepsin B Carboxypeptidase Widespread Early E 
Cathepsin H Aminopeptidase Widespread Lysosome 
    b. Aspartyl Proteases 
   
            
Protease Proteolytic activity Distribution Distribution 
Cathepsin D Endoprotease Widespread Lysosome 
Cathepsin E Endoprotease Restricted Endosomes 
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Cathepsins B, D, E, F,K, L and S and the asparagine-specific endopeptidase (AEP) have all 
been shown to participate in antigen processing. The specific roles of many cathepsins 
are still poorly understood and it appears that redundancy exists within this repertoire, 
as individual cathepsins appear to be dispensable. Only Cathepsins L and S have been 
shown to have distinct and non-redundant roles in endosomal presentation in-vivo. 
Cathepsin L has been shown to be critical in the generation of some epitopes required 
for T cell maturation. Cathepsin S has been shown to be vital for the generation of both 
exogenous and self peptides in B cells and DCs. 
Lessons from AEP have shown there is a fine balance between epitope peptide 
generation and epitope peptide degradation. As well as being required for the 
generation of some peptides, AEP is able to destroy epitopes of myelin basic protein 
(MBP)(Manoury et al., 2002). Expression of cathepsins is tightly controlled and varies 
between cell lines. Differential expression of cathepsins between cell types may 
contribute to diversity of peptides presented by the MHC class II processing pathway. 
1.3.9 The MHC class II molecule 
MHC class II molecules are heterodimers like MHC class I. However, MHC class II 
molecules are composed of two homogenous chains, the MHC encoded alpha and beta 
chains. The two chains form an extracellular peptide binding groove and a membrane 
proximal region comprised of two conserved domains, homologous to Ig constant 
domains. Unlike the closed groove of the MHC class I molecule, the ends of the MHC-II 
groove are open meaning bound peptides can overhang at either end. This open 
conformation allows the binding of peptides much longer than the short peptides that 
are bound to MHC class I molecules. As with MHC class I, the MHC class II genes are 
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highly polymorphic. This variation allows for considerable variation in the peptides 
presented by the MHC-II molecules. 
1.3.10 Formation of MHC class II-peptide complexes 
Upon translation, the nascent MHC class II molecule forms a complex with a second 
protein the MHC class II invariant chain (Ii). After assembly, MHC class II-Ii complexes 
are trafficked to the endocytic pathway by the Ii di-leucine motif (Landsverk et al., 
2009). Once within an acidic endosomal compartment peptidases such as cathepsins 
cleave the Ii at two sites leaving a 20 amino acid peptide in the peptide binding groove. 
Removal of this peptide, known as CLIP (class II invariant chain peptide) is catalysed by 
another MHC-encoded heterodimeric glycoprotein, HLA-DM (Denzin and Cresswell, 
1995; Morris et al., 1994). HLA-DM is homologous to other MHC-class II molecules but it 
does not have an accessible peptide binding groove. Instead, DM binds to MHC-II 
molecules triggering a conformational change in the MHC-II molecule releasing CLIP. 
This opens the peptide binding groove allowing antigenic peptide binding. As well as 
removing CLIP, DM can remove any low affinity peptides. Therefore repeat DM-MHC-II 
interactions refine the repertoire of peptides bound to MHC-II molecules resulting in a 
pool of high affinity peptide-MHC complexes. This process is in part controlled by a third 
MHC encoded, MHC-II like molecule, HLA-DO. DO binds tightly to DM inhibiting DM-
MHC-II binding. DO is expressed in B cells and some dendritic cells and it appears to 
alter the repertoire of antigenic peptides presented by MHC class II molecules. However, 
a clear biological role for HLA-DO had not yet been defined (Denzin et al., 2005). 
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1.3.11  Alternative MHC class II processing: endogenous proteins 
Although the MHC class II pathway classically presents peptides from extracellular 
proteins, it is now well established that endogenous proteins can also access this 
pathway. Analysis of peptides presented by MHC-II molecules reveals a significant 
portion of these peptides are derived from endogenous antigens (Rammensee et al., 
1999). As previously discussed, many CD4+ T cells have been shown to be capable of 
direct cytotoxic activitiy, therefore the presentation of endogenous antigens to CD4+ T 
cells via the MHC class II processing pathway could provide the immune system with 
another way to recognise and eliminate pathogen-infected cells. 
To date, three pathways for MHC class II restricted presentation of endogenous proteins 
have been described and all have been implicated in the generation of epitopes from 
intracellular pathogens such as murine influenza and Epstein-Barr virus. Each pathway 
has been shown to generate a different repertoire of epitopes leading some to speculate 
that the pathways exist to maximize the diversity of MHC-II peptides available for CD4+ 
T cell recognition (Eisenlohr et al., 2011). A diverse repertoire of epitopes may be vital 
in controlling large viruses such as the herpesviruses and poxviruses. Although the 
differences in epitope generation between different pathways has been assessed, the 
extent to which they contribute to natural CD4+ T cell responses has not been well 
studied. 
One such pathway for MHC class II-restricted presentation of endogenous proteins was 
identified by studying the processing of an influenza epitope from the NA protein, NA79. 
The molecular mechanisms of this pathway are poorly understood but inhibitor 
experiments have shown this NA79 eptiope to be processed in a manner more similar to 
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the MHC class I pathway. NA79 is highly susceptible to endosomal proteases and is 
destroyed in acidic compartments and therefore would not have access to class II 
molecules within the endocytic pathway. Processing of NA79 requires delivery into the 
cytosol and activity of the proteasome, with loading most likely occurring in the ER or 
directly onto MHC-II molecule in endosomes via TAP (Eisenlohr et al., 2011). 
Two other mechanisms for MHC class II restricted presentation of endogenous proteins 
have recently been elucidated. These two mechanisms are much better defined and 
involve chaperone-mediated or macro-autophagy. 
1.4 Autophagy 
Autophagy is an evolutionarily conserved mechanism in eukaryotes, where cytoplasmic 
cargo is delivered to lysosomes for degradation. This process of self-eating functions to 
remove misfolded and long-lived proteins as well as redundant and damaged organelles. 
In addition to this catabolic function, autophagy provides nutrients and energy to the 
cell in response to various stresses. 
Christian de Duve first described the process of self-eating in the 1960s and coined the 
term autophagy (De Duve and Wattiaux, 1966). Early studies on autophagy focussed on 
morphological analysis and demonstrated that autophagy occurred in normal cells but 
was enhanced under starvation conditions (Novikoff et al., 1964). Further studies by 
Seglen and Gordon on the induction of autophagy identified the initial sequestering 
vesicle that develops into the autophagosome, the phagophore (Gordon and Seglen, 
1988). As well as this, they identified 3-MA as the first specific inhibitor of autophagy 
(Seglen and Gordon, 1982). 
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The initial molecular analyses of autophagic processes were carried out in the 1990s. 
These studies focused on manipulation of genes in yeast and led to the identification of a 
number of key autophagy (Atg) genes, such as ATG1 (Matsuura et al., 1997). Later, 
studies in higher eukaryotes identified the first mammalian Atg genes such as Atg5 and 
Atg12. These studies also revealed many mammalian homologues of yeast genes, such as 
the Atg 8 homologue LC3 (Kabeya et al., 2000; Mizushima et al., 1998) 
These early studies, particularly those carried out in yeast cells, focussed on macro-
autophagy but in mammalian cells three autophagy pathways have been identified, 
namely macroautophagy, microautophagy and chaperone-mediated autophagy (CMA). 
These three pathways are differentiated by the mechanisms by which they deliver cargo 
into the lumen of lysosomes. The contribution of each of these pathways to antigen 
processing and presentation will be discussed individually. 
1.4.1 Microautophagy 
By far the least studied and least well understood of the three autophagy pathways is 
microautophagy, a process in which the lysosomal membrane invaginates, capturing 
portions of cytoplasm. Microautophagy involves five sequential stages, demarcated by 
morphological changes. Firstly, segregation of lipids and exclusion of large 
transmembrane proteins from an area of the lysosomal membrane causes it to bulge 
inwards. This process is initiated by GTPases and requires the calcium binding protein 
Calmodulin (Uttenweiler et al., 2005). This invagination forms a characteristic shape 
known as an autophagic tube. Secondly, due to a high density of lipids and low density of 
proteins, a vesicle forms at the top of the tube. Thirdly the vesicle expands due to further 
separation of lipids and proteins drawing cytoplasmic contents up the tube into the 
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vesicle. Fourthly, under the control of Atg1, enzymes bind to the inside of the vesicle and 
trigger vesicle scission (Bellu et al., 2001). Finally V-ATPases acidify the vesicle by 
pumping H+ into the vesicle lumen. Lysosomal hydrolases then break down the 
membrane releasing its contents into the lumen of the lysosome (Muller O. et al., 2000; 
Sattler and Mayer, 2000). 
A recent discovery shows microautophagy does not appear to be exclusive to lysosomes. 
Sahu et al. showed cytosolic contents can be delivered into late endosomes during 
mulitvesicular body formation, in a process termed endosomal microautophagy (Sahu et 
al., 2011) 
Despite delivering many different proteins to multiple endocytic compartments, to date, 
no role for microautophagy in antigen processing and presentation has been revealed. 
1.4.2 Chaperone-Mediated Autophagy 
Chaperone mediated autophagy (CMA) is a selective process. It is very different from 
micro- and macroautophagy in that delivery of proteins to the lysosome does not 
involve the formation of autophagic vesicles. Instead, cargo is directly targeted to the 
lysosome membrane where it is transported directly into the lumen of the lysosome. 
Proteins are targeted according to the presence of a pentapeptide motif, KFERQ, within 
the protein. Around 30% of cytosolic proteins contain a KRERQ-like domain and 
therefore are potential targets for CMA (Dice J.F, 1990).  
CMA substrates containing a KRERQ-like motif bind to a complex of proteins containing 
Hsc70, Hsp90 and several other co-chaperones associated with the lysosomal receptor 
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LAMP-2A (Chiang et al., 1989). Cargo is transported directly through the membrane into 
the lumen of the lysosome for degradation.  (Dice J. F., 2007).  
CMA has been shown to generate MHC class II epitopes from intracellular proteins. 
Manipulating expression of LAMP-2A or heat shock cognate protein Hsc70 was shown to 
alter the presentation MHC class II epitopes derived from cytoplasmic proteins such as 
Glutamate decarboxylase 65(GAD65) (Zhou et al., 2005). These results revealed a novel 
role for the lysosomal proteins LAMP-2A and Hsc70 in promoting antigen presentation. 
To date, no pathogen-derived antigens have been shown to be presented by CMA. This 
may be due to its requirement for a KFERQ-like motif that could be easily mutated in 
pathogen-derived proteins to allow them to avoid CMA-dependent antigen presentation. 
1.4.3 Macroautophagy 
Macroautophagy (hereafter referred to simply as autophagy) is the best described of the 
three autophagic pathways and can be divided into six sequential steps: initiation, 
nucleation, elongation, closure, maturation and degradation. Each step is a highly 
regulated process involving the coordinated action of numerous autophagy related 
proteins. Initiation occurs upon activation of the ULK1 and UKL2 complexes after 
release of their inhibition by the mTOR complex. Nucleation depends on Beclin-1, which 
modifies membranes which then act in the recruitment of multiple other autophagy-
related proteins defining the site for the autophagic membrane to begin to form within 
the cytoplasm (Liang et al., 1999). Elongation of the autophagic membrane around a 
portion of cytoplasm involves the recruitment of more proteins and lipidation of the 
microtubule associated protein, Light Chain 3 (LC3) by the E2-like enzyme ATG3 
(Itakura and Mizushima, 2010). Closure of the membrane completes the formation of the 
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double-membrane vacuole, called an autophagosome, which contains a portion of 
cytoplasm within its lumen. The autophagosome then undergoes maturation by fusing 
with lysosomes to form an autophagolysosome (Gordon et al., 1985). This process is 
again mediated by Beclin-1 (Kimura et al., 2007). Following maturation, the captured 
cytoplasmic contents are degraded by lysosomal proteases for reuse by the cell. 
Autophagy was originally considered to be a non-selective pathway for bulk degradation 
of cytosolic contents. However, mounting evidence now suggests that autophagy is a 
selective process. Recent reports have shown a number of different and distinct 
macrostructures within cells can be directly targeted for autophagic destruction. These 
specific degradative processes have been named according to the structures they target. 
Aggrephagy is the degradation of protein inclusions caused by aggregate-prone or 
misfolded proteins, mitophagy the degradation of mitochondria, pexophagy 
(perioxisome), reticulophagy (ER), ribophagy (ribosomes) and finally xenophagy 
describes the degradation of bacteria and viruses (Lamark and Johansen, 2012; 
Lemasters, 2005; Scott and Klionsky, 1998; Talloczy et al., 2006; Tasdemir et al., 2007; 
Yang and Chiang, 1997). 
From these reports an important role for a new class of proteins, “autophagy adaptors” 
has emerged. Autophagy adaptors act as cargo receptors for the degradation of 
autophagy substrates and are themselves degraded by autophagy. The first discovered 
and most well studied autophagy adaptor is P62/SQSTM1 (sequestersome 1) (Shin, 
1998). P62 is a 440 amino acid protein containing many functional domains. The key 
domains for its function as an autophagy adaptor are a PB1 domain, a ubiquitin 
associated (UBA) domain and an LC3 interacting region (LIR). The PBI domain facilitates 
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protein-protein interactions. It allows p62 to bind to protein kinases and other 
autophagy adaptors such as NBR1, as well as allowing homopolymerisation of p62 
(Nakamura et al., 2010; Wilson et al., 2003). The UBA domain binds multiple different 
forms of ubiquitin (Ub) and is key in allowing p62 to target ubiquitinated proteins for 
degradation (Vadlamudi et al., 1996). The LIR domain confers p62 binding to LC3. As 
LC3 is present on the internal membrane of the phagophore and retained within 
autophagosomes, binding to LC3 targets p62 for autophagic degradation along with any 
other proteins in complex with p62 (Ichimura et al., 2008; Pankiv et al., 2007). 
Interestingly p62 contains both a nuclear localisation sequence (NLS) and a nuclear 
export signal (NES), this allows p62 to shuttle between the nucleus and the cytoplasm 
(Pankiv et al., 2010). Note that due to its rapid nuclear export, p62 appears to be wholly 
cytoplasmic in the absence of nuclear export inhibitors.  
Increasing evidence shows that selective autophagic degradation of protein aggregates 
requires Ub as a signal (Kirkin et al., 2009a). A simple model for selective degradation 
has recently been described and involves five sequential steps. First, substrates are 
identified by chaperones or other cellular sorting systems such as Hsc70 or Bag-3 
(Gamerdinger et al., 2009). Second, the substrate is ubiquitinated by E3 ligases 
(Lelouard et al., 2004). Third, p62 is recruited, binds to Ub and aggregates substrates 
forming a large complex known as a p62 body (Komatsu et al., 2007; Szeto et al., 2006). 
Fourth, p62 recruits the phagophore to the site of aggregation through its interaction 
with LC3 (Ichimura et al., 2008). Finally the autophagosome forms around the p62 body 
enclosing the substrates within. 
Chapter 1 - Introduction 
 
27 
 
To date, most models of selective autophagy been shown to require ubiquitination of 
substrates. However some examples of Ub-independent, selective autophagy have been 
observed. P62 has been shown to bind to some substrates directly, independently of Ub 
to degrade them by autophagy (Gal et al., 2009). As well as Ub-independent, selective 
autophagy, some mechanisms of selective autophagy are p62-independent. Two 
pathways of mitophagy have been identified in mammals, one of which involves the 
autophagy adaptor Nix and does not require p62 (Novak et al., 2010; Sandoval et al., 
2008) .  
As previously mentioned p62 is the best-studied autophagy adaptor but many others 
have been discovered, including: neighbour of Brca1 (NBR1), nuclear dot protein 52 
NDP52, also referred to as CALCOCO2 and optineurin (OPTN) (Figure 1.1). 
NBR1 shows similar domain organisation to p62. It is recruited to Ub-positive protein 
aggregates and is degraded by autophagy according to its interaction with LC3 via its 
LIR domains (Waters et al., 2009). NBR1 can interact and form aggregates with p62 but 
it is also able to function as an individual autophagy adaptor in the absence of p62 
(Kirkin et al., 2009b) 
CALCOCO2 has been shown to bind to a number of different substrates and is able to 
bind to Salmonella enteric to target it for autophagic degradation (xenophagy). 
CALCOCO2 can bind Ub substrates or can act independently of Ub by binding a second 
protein Galectin 8 (Li et al., 2013; Thurston et al., 2009) 
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Figure 1.1 Domain architecture of mammalian autophagy adaptors 
Architecture of major mammalian autophagy adaptor proteins with 
annotated domains: PB1 (Pox and Bern 1), NLS (nuclear localisation 
sequence), NES (Nuclear export sequence), LIR (LC3-interacting region), UBA 
(ubiquitin associated). 
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OPTN is another autophagy adaptor with both Ub-dependent and independent 
functions. Optineurin is present in many protein inclusion bodies and is required for 
degradation of such structures. More recently, Optineurin has shown to be able to bind 
directly to protein aggregates via a C-terminal coiled coil domain in a Ub-independent 
manner. This binding is required to target such aggregates for degradation (Korac et al., 
2013; Tumbarello et al., 2012) 
1.4.4 Macroautophagy and antigen processing 
As previously described, a significant proportion of antigens presented on MHC class II 
molecules are derived not from extracellular proteins but from cytosolic or nuclear 
antigens. In 1997 Brazil and colleagues made the landmark observation that autophagy 
can generate MHC class II epitopes from a self-antigen (Brazil et al., 1997). Since this 
time, mounting evidence now suggests that autophagy makes an important contribution 
to the presentation of a wide range of endogenous epitopes. Dengjel and colleagues 
showed that starvation-induced autophagy can upregulate MHC class II presentation of 
nuclear and cytosolic proteins in favour of membrane proteins. Among these proteins 
were the autophagy proteins LC3 and GABARAP (Dengjel et al., 2005; Suri et al., 2008). 
As LC3 and GABARAP are present on the inner membrane of autophagosome this 
suggests that autophagosomes fuse with MHC class II loading compartments (MIICs). In 
a later study Schmid et al. confirmed this result, showing that 70-80% of 
autophagosomes fuse with MIICs. Further to this, tagging antigens with LC3, targets 
proteins to autophagosomes and dramatically enhances their presentation on MHC class 
II molecules (Comber et al., 2011; Schmid et al., 2007). 
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In addition to self-antigens being processed by autophagy, pathogen derived antigens 
are also processed by autophagy. The classic example of autophagic presentation of a 
pathogen derived antigen is Epstein Barr Virus Nuclear antigen 1 (EBNA1). EBNA1 is the 
genome maintenance protein of Epstein Barr Virus (EBV). It is expressed in all known 
states of EBV expression and is a key viral antigen in that it contains multiple CD4+ and 
CD8+ T cell epitopes (Hislop et al., 2007; Long et al., 2005). EBNA1 has been shown to be 
processed by an intracellular route for MHC class II processing (Munz et al., 2000). 
Paludan et al. later showed the presentation of EBNA1 requires autophagy (Paludan et 
al., 2005). 
Other pathogen-derived proteins have also been shown to be presented by autophagy. 
Neomycin phosphtransferase (NeoR) has been shown to be sequestered in 
autophagsomes resulting in the presentation of a NeoR epitope via MHC class II 
(Nimmerjahn et al., 2003) A third example comes from the mycobacterium protein 
Ag85B. Autophagy stimulation causes this protein to be better presented by MHC class II 
molecules on DCs (Jagannath et al., 2009). 
As shown by these examples, autophagy makes a significant contribution to the 
presentation of MHC class II epitopes. Both macroautophagy and CMA generate MHC 
class II epitopes from self-proteins. But only macroautophagy has so far been shown to 
generate MHC class II epitopes from pathogen derived proteins (Figure 1.2). 
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Figure 1.2 Generation of MHC class II epitopes via the different 
autophagy pathways 
Three autophagy pathways exist to import proteins into the endocytic 
pathway. Macroautophagy (left) has been shown to generate MHC-II epitopes 
from both self- and pathogen-derived proteins. Chaperone mediated 
autophagy (right) has been shown to generate MHC-II epitopes from self-
derived proteins. A role for microautophagy (centre) in the production of 
MHC class II processing has not yet been revealed. 
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As well as these examples of MHC class II presentation, autophagy has now been shown 
to play an important role in the presentation of some MHC class I epitopes. In 2009 
English et al. showed that presentation of an MHC class I restricted epitope from the 
viral glycoprotein B of herpes simplex virus 1 (HSV-1) was sensitive to bafilomycin and 
3-MA. This suggests a role for the endosomal processing pathway and autophagy in the 
generation of this epitope. This work also identified a novel form of autophagy marked 
by four layered membrane structures, containing LC3 and originating from the nucleus 
(English et al., 2009). In support of this role of autophagy in MHC class I processing, Tey 
and Khanna recently showed that an epitope from Human Cytomegalovirus (HCMV) 
latency-associated protein, pUL138 required autophagy for its presentation via a TAP-
independent class I processing pathway (Tey and Khanna, 2012). 
Although autophagy is able to generate a wide range of epitopes, the factors that 
determine which peptides are generated from an antigen have not been examined.  
Studies on EBNA1 showed that some but not all EBNA1 MHC class II epitopes were 
generated by autophagy. Leung and colleagues showed that CD4+ T cell clones specific 
for two epitopes could recognise LCLs expressing natural levels of the EBNA1 protein, 
while clones specific for a third epitope could not (Leung et al., 2010). The avidity of the 
clones was not responsible for these differences and experiments showed that the two 
epitopes presented by LCLs were indeed endogenously accessing the MHC-II pathway, 
confirming previous findings (Paludan et al., 2005). Interestingly, only one of these two 
epitopes was autophagy-dependent. Over-expression of EBNA1 was shown to increase 
the presentation of both epitopes, but this did not affect processing routes. However, 
relocalising EBNA1 to a cytoplasmic protein, through mutation of its nuclear localization 
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sequence (NLS), caused all three epitopes to be processed by autophagy. This striking 
result was shown to be a direct result of EBNA1’s cytoplasmic localisation since 
introducing a heterologous NLS reversed the effect (Leung et al., 2010). This work 
suggests that nuclear localisation confers some protection to EBNA1 from autophagic 
MHC class II presentation. However whether other nuclear-localised proteins are 
similarly protected from autophagy is still debated.  
The huntingtin and ataxin-1 proteins each contain a large poly-glutamine repeat that can 
cause these proteins to aggregate in cells. When these proteins aggregate in the 
cytoplasm they are degraded by autophagy, but aggregates in the nucleus are not 
degraded by autophagy (Iwata et al., 2005). Further support for this nuclear protection 
comes from the work of Wang et al. They showed that a mutant form of the cellular 
protein, CDC27, was better recognised by CD4+ T cells. This increased recognition was 
due to a mutation in the protein’s nuclear localisation sequence which caused the 
protein to relocalise to the cytoplasm (Wang R. F. et al., 1999). Furthermore, antigens 
fused to YopE, a Yersinia protein that is injected into the cytosol, are have been shown to 
be processed for MHC class II presentation by a mechanism involving lysosomes and 
autophagy (Russmann et al., 2010). 
In contrast to these examples, presentation of an autophagy-dependent epitope from the 
NeoR protein was not reduced by the addition of a heterologous NLS (Riedel et al., 
2008). The reason for this different result is unclear, but one possibility is that it might 
reflect different rates of nuclear import between EBNA1 which is rapidly imported into 
the nucleus and NeoR where import rates were not studied but may be much slower 
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since only a minimal NLS was used; flanking sequences can increase dramatically the 
rate of nuclear import. 
The results of EBNA1 relocalisation suggest that manipulation of antigen processing 
could increase CD4+ T cell responses to pathogens. This hypothesis is supported by the 
work of Jagannath and co-workers who showed that stimulating autophagy caused DCs 
to better present epitopes and upon adoptive transfer of these DCs, CD4+ T cell 
responses were more efficiently primed (Jagannath et al., 2009). 
Manipulation of antigen processing to increase T cell presentation could be used to 
improve the clearance of pathogens but could also be exploited in cancer therapy where 
CD4+ T cell responses have been shown to be very important. 
1.5 Cancer Immunology 
The first evidence for an immunological role in the control of cancer was revealed in the 
late 19th century when William Coley, an American physician, began treating cancer 
patients with a “mixed bacterial vaccine”. This vaccine, termed Coley’s toxins, made of 
live Streptococcus pyogenes and Serratia marcescens, gave a generic boost to the immune 
system and triggered regression in 18 cancer patients (Coley, 1893). In 1957, Burnet 
and Thomas developed the immune surveillance theory of cancer. They postulated that 
an immunological mechanism existed to eliminate or inactivate malignant cells (Burnet 
M., 1957). Later they suggested that lymphocytes carried out this function (Burnet F. M., 
1970). 
Later experiments in mice showed animals could be immunised against transplanted, 
syngeneic tumour cells, revealing tumours were immunologically distinguishable (Old 
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and Boyse, 1964). These experiments and others established the existence of tumour-
specific antigens (Klein, 1966). If it was possible to immunise against tumours there 
must be tumour-specific antigens that elicit a memory response. Early work on tumour 
transplants in mice revealed that tumours are immunogenic and could be eradicated by 
the immune system.  
This theory of immunesurveillance was thoroughly tested and many results supported a 
role for the immune system in protection against cancer. Further experiments in mice 
showed that IFN-γ was key in controlling tumours. Neutralising IFN-γ with specific 
antibodies was shown to cause tumours to grow more rapidly and IFN-γ (-/-) mice 
developed more tumours more regularly (Dighe et al., 1994; Kaplan et al., 1998). Later 
experiments revealed perforin, a key molecule in T and NK cell killing was also vital, in 
that perfornin (-/-) mice showed higher rates of spontaneous tumours (Street et al., 
2001). 
Support for the immune surveillance theory in humans began in the 1970s. Multiple 
studies showed that patients who were immunodeficient or immunosuppressed after 
transplant showed higher relative risk of developing cancer (Gatti and Good, 1971; Penn 
et al., 1971). It was later noted that many of these tumours were of viral aetiology (Penn, 
1999). And later, after the AIDs epidemic many of these viral associated malignancies 
became common in AIDs patients (Boshoff and Weiss, 2002). 
Mechanistic evidence supporting immune surveillance came later. It was shown that a 
positive correlation between lymphocyte infiltration in tumours and increased survival 
existed (Clemente et al., 1996). Later work then showed that this was linked specifically 
to infiltrating CD8+ T cells (Naito et al., 1998). 
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Many studies in human cancer immunology originate from studies on melanoma. 
Rosenberg et al. showed that adoptive transfer of tumour infiltrating lymphocytes and 
IL-2, a key cytokine for T cell function, resulted in the regression of tumours in 30% of 
melanoma patients, providing strong evidence that T cells play a critical role in tumour 
regression (Rosenberg et al., 1988). 
Since these early experiments in melanoma, similar results have been observed in the 
context of many other cancers. To further understand the molecular basis of immune-
dependent regression of tumours, much effort has been devoted to the identification of 
tumour antigens recognized by T cells with an antitumor activity in-vivo. 
1.5.1 Tumour antigens 
A key hallmark of cancer is genomic instability (Hanahan and Weinberg, 2011). This 
results in aberrant gene expression of normal as well as mutated proteins. These 
proteins are often not represented in the array of proteins presented in the thymus 
during the establishment of central tolerance and are therefore often immunogenic. The 
first tumour antigen specifically recognised by T cells was Mage a1 which encodes the 
antigen MZ2E (van der Bruggen et al., 1991). Melanoma was the first tumour model to 
show CD4+ and CD8+ T cell specificity to tumour antigens gp100 and tyrosinase 
(Topalian et al., 1994; Touloukian et al., 2000). 
Since these early studies tumours antigens have been identified in many self-proteins 
and can roughly be separated into four groups. The first group are the tissue-specific 
tumour antigens. These antigens are derived from proteins that are expressed at low 
levels in a small subset of tissues but not in other normal healthy tissues. They are 
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expressed at high levels in a small subset of cancers often linked to the organ of 
restriction. Examples of such antigens include Melan-A and gp100 which are both 
overexpressed in melanoma (Kawakami et al., 1994a; Kawakami et al., 1994b). 
The second group of antigens, similar to the tissue-specific antigens, are the tumour-
specific shared antigens otherwise known as Cancer-testis (CT) antigens. These antigens 
are expressed in a wide range of tumours as well as the immune-privileged site of 
normal testis. One such CT antigen is NY-ESO-1. This gene is expressed in melanoma, 
breast, prostate, bladder and lung carcinoma as well as others (Chen et al., 1997; Lee L. 
et al., 1999; Wang R. F. et al., 1998). 
The third group of tumour antigens are the mutated antigens. Genomic instability in 
tumours results in the expression of many mutated proteins which have the potential to 
be highly immunogenic as they are specific to the tumour itself. Surprisingly due to their 
highly immunogenic potential, mutated proteins represent a very small subset of 
tumour antigens. Many CTLs raised against mutated proteins such as Ras and p53 fail to 
recognise tumours (Cheever et al., 1995). However some epitopes have been identified. 
One example being cyclin-dependent kinase 4, where a point mutation results in a new 
epitope recognized by CTLs (Wolfel et al., 1995)  
Proteins in the fourth group of tumour antigens contain T cell epitopes derived from 
alternative open reading frames. TRP-1/gp75 represents the first demonstration that T 
cells may respond to gene products derived from alternative open reading frames 
(Wang R. F. et al., 1996). 
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As well as tumour antigens that originate from self-proteins some tumours express 
antigens from pathogens. This is best represented in the case of virus-associated 
cancers. Many of these cancers express viral proteins and the immune system can 
recognise these proteins in the context of cancer in the same way it would recognise 
them in the context of viral infection. These viral tumour antigens therefore have the 
potential to serve as excellent therapeutic targets as high avidity T cells should be 
present in donors, though if virus-associated tumours have arisen it is clear the immune 
response to these antigens has failed in some way. 
Most work to date has focussed on harnessing CD8+ T cells as the effectors of anti-
tumour immunity. CD4+ T cells, which provide immune help to support the generation of 
sustained effective immune responses, are now also starting to be seen as effectors 
against tumours that bear MHC-II molecules (Mumberg et al., 1999; Wang L. X. and 
Plautz, 2010). Since inflammatory cytokines can upregulate MHC-II expression a wide 
range of malignancies are potentially targetable via CD4+ T cells (Garrido et al., 1993; 
Wang L. X. and Plautz, 2010). 
The evidence presented so far shows that tumours can be highly immunogenic and T 
cells are able to eradicate tumour cells in certain settings; despite these facts cancers 
still arise. Many immunotherapies are able to improve immune recognition of cancer but 
often these therapies ultimately fail and patients succumb to their disease. Recent 
attempts to improve immunotherapies have focussed on increasing the efficacy of T cells 
in the tumour microenvironment. However an alternative does exist, if tumours could be 
manipulated to increase antigen processing of tumour antigens, these tumours may be 
more susceptible to immunotherapies.  
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Therefore in this study I will examine the antigen processing and presentation of two 
tumour antigens with the ultimate aim of improving the presentation of these antigens 
to increase T cell recognition of tumour cells. The two tumour antigens I will focus on 
are WT1 and EBNA1. 
1.5.2 WT1 - a cellular tumour antigen 
The Wilms’ tumour gene 1 (WT1) is the gene believed to be responsible for the 
childhood renal neoplasm, Wilms’ tumour. Wilms’ tumours arise from an inactivation of 
both alleles of the WT1 gene; this fact led to WT1 first being classified as a tumour 
suppressor gene. Unlike more classical tumour suppressor genes such as p53, which are 
ubiquitously expressed, WT1 is restricted to a limited set of tissues, including gonads, 
uterus, kidney and mesothelium. 
More recently an alternative role for WT1 as an oncogene in leukaemia and various solid 
tumours has been suggested. This is supported by a number of recent findings. WT1 
expression is high in leukemic blast cells as well as many solid tumours including: 
breast, lung, gastric and bladder. Increased levels of WT1 expression in leukaemia 
correlates with poor disease prognosis and WT1 expression is further increased in 
relapsed patients. Further to this, inhibition of WT1 using anti-sense oligomers and 
WT1-specific siRNAs leads to reduction in leukaemogenesis and growth of solid cancer 
cells. Forced expression of the WT1 gene also promotes cell growth, suppresses 
apoptosis and induces leukaemia in transgeneic mice. 
High levels of WT1 in leukaemia and solid tumours led to WT1 being investigated as a 
potential tumour antigen. Gaiger et al. showed that immunisation with WT1 peptides 
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induced WT1-specific responses in mice and that these T cells were capable of killing 
WT1-expressing tumour cells (Gaiger et al., 2000). Others have shown that immunised 
mice can reject challenge with WT1-expressing leukemic blasts and importantly that 
WT1 immunisation shows no damage to WT1 expressing organs or haematopoietic stem 
cells. 
Since these original experiments peptide stimulation of WT1-specific T cells in humans 
has been widely studied. Oka et al. and others first identified class I epitopes in the WT1 
protein by peptide stimulation of PBMCs. WT1 peptides were shown to induce WT1-
specific CD8+ T cells in a number of donors (Gao et al., 2000; Ohminami et al., 2000; Oka 
et al., 2000). These T cells were shown to recognise naturally expressed WT1, to kill 
WT1 expressing leukemic cells, caused no damage to haematopoietic stem cells and did 
not inhibit colony formation of normal bone marrow. 
Research into the identification of class II epitopes in WT1 has been slower than that of 
class I epitopes. Knights et al. first identified an MHC class II epitope. Peptide stimulation 
showed this epitope stimulated CD4+ T cells capable of producing IFN-γ in response to 
WT1 (Knights et al., 2002). Since then multiple MHC class II epitopes have been 
identified (Guo et al., 2005; Kobayashi et al., 2006; May et al., 2007; Muller L. et al., 
2003). 
1.5.3 EBNA1 - a viral tumour antigen 
As described previously EBNA1 is the genome maintenance protein of EBV. EBV is a 
ubiquitous γ-herpes virus; following primary infection in childhood or early adulthood it 
establishes a lifelong asymptomatic infection in B-cells. In the vast majority of EBV-
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infected individuals, T cell responses successfully control infection and limit replication 
and growth-transforming ability of the virus. However in a small subset of individuals a 
number of malignancies can arise in association with EBV. These malignancies include 
post-transplant lymphoproliferative disease (PTLD), Burkitt’s lymphoma, Hodgkin’s 
lymphoma, natural killer/T cell lymphoma, nasopharyngeal carcinoma and gastric 
carcinoma. In some cases such as PTLD, development of these cancers is directly caused 
by the growth transforming ability of EBV and occurs as a failure of the T cell response 
to control the virus (Young and Rickinson, 2004). 
In its role as the genome maintenance protein, EBNA1 is the one EBV antigen expressed 
in all EBV-infected cells, including all EBV-associated malignancies. As EBV is able to 
persist in humans, EBNA1 was long thought to go undetected by the immune system. 
However this was shown not to be the case when EBNA1-specific CD4+ T cells were 
identified (Khanna et al., 1997). Since this first study CD4+ T cell responses to EBNA1 
have been shown to be very common in healthy individuals(Leen et al., 2001; Munz et 
al., 2000). EBNA1-specific CD4+ T cells are often of Th1 phenotype and are able to 
directly recognise and kill EBV-infected cells (Bickham et al., 2001; Munz et al., 2000). As 
well as CD4+ T cells, EBNA1-specific CD8+ T cells have been identified (Lee S. P. et al., 
2004; Tellam et al., 2004; Voo et al., 2004). EBV’s requirement for EBNA1 may represent 
an Achilles heel for the virus in that efficient targeting of EBNA1 could be an effective 
immunotherapy against EBV-associated malignancies. 
1.6 Aims 
The main aim of this body of work was to study MHC class II processing of tumour 
antigens and subsequent presentation to CD4+ T cells. A particular focus will be placed 
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on the non-classical MHC-II processing pathways involved in processing of endogenous 
antigens. I will aim to apply the knowledge of MHC class II processing to develop novel 
strategies to improve both the range and levels of MHC class II epitopes presented to 
tumour-specific CD4+ T cells.
Chapter2 – Materials and Methods 
 
43 
 
2. MATERIALS AND METHODS 
2.1 Eukaryotic cell culture 
2.1.1 Cell culture media and reagents 
RPMI-1640 supplemented with 0.2M L-glutamine (Gibco) was used for the culture of all 
lymphocyte lines and stored at 4°C. 
DMEM (Gibco) was used for the culture of all epithelial lines and stored at 4°C. 
EBSS (Gibco) was used for culturing cells under starvation conditions and stored at 
room temperature.  
Foetal calf serum (FCS) (PAA) was stored at -20°C. 
Penicillin-streptomycin solution (pen/strep) (Gibco) containing 5000IU/ml penicillin 
and 5000µg/ml streptomycin was stored at -20°C. 
Optimen (Gibco) was stored at 4°C. 
Phosphate buffered saline solution (PBS) (8.2mM Na2HPO4, 1.5mM KH2PO4, 139mM 
NaCl, 3mM KCl) was prepared using Dulbecco PBS tablets (Oxoid) 
Cyclosporin A (Sandimmun) was reconstituted in RPMI 1640 to 10µg/ml and stored at 
4°C. 
MLA-144 supernatant (MLA) was derived from Gibbon derived MLA-144 cell line. Cells 
were cultured in RPMI 1640 + 10% FCS and 1% pen/strep. After two weeks the cell 
supernatant was harvested by centrifuging at 1600rpm for 10min, followed by filtration 
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through Millipore Steritop 0.22µm vacuum driven disposable bottle top filters and 
stored at -20°C. 
Recombinant interleukin-2 (IL-2) (Peprotech) was reconstituted in water to 105IU/ml 
and stored at -20°C. 
Doxycycline (dox) was prepared from doxycycline hyclate powder (Sigma) dissolved in 
water to 100µg/ml and stored in the dark at 4°C. 
Synthetic peptides (Alta bioscience, Birmingham, UK) were dissoloved in dimethyl 
sulphoxide (DMSO) (Fisher Scientific) and stored at -20°C. 
LCLs media: RPMI 1640 + 10% FCS + 1% pen/strep 
Epithelial cell culture media: DMEM + 10% FCS + 1% pen/strep 
T cells media: RPMI 1640 + 30% MLA + 10% FCS + 1% human serum + IL-2 (50IU/ml) + 
1% pen/strep 
2.1.2 Tissue culture techniques 
LCLs and epithelial cells were grown in culture flasks (Iwaki or Corning) and T cells 
were grown in 24-well culture plates (Iwaki). Cells were incubated in a cell culture 
incubator with 5% CO2 at 37°C. Cells were fed with fresh media twice weekly and split 
depending on confluency. Cell manipulation was performed in a class II biological safety 
cabinet. 
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2.1.3 Mycoplasma testing 
MycoAlert Mycoplasma detection assay kit (Cambrex) was used to routinely test for 
mycoplasma infection in cell cultures according to the manufacturer’s instructions. 
2.1.4 Cryopreservation of cells 
Cells to be preserved were pelleted, resuspended in freezing media (RPMI-1640 + 10% 
DMSO + 20% FCS) and transferred into sterile 1ml cryovials (Nunc). These were then 
stored at -80°C for 16h. Cryovials were then transferred into liquid nitrogen freezers 
To revive cells, 1ml cryrovials were placed into a 37°C waterbath to thaw. Following this 
cells were washed with standard media (RPMI-1640 + 10% FCS), resuspended in 
appropriate media and transferred into an appropriate plate or flask, for culturing in a 
37°C, 5% CO2 incubator 
2.1.5 Blood donors 
Blood was taken from healthy donors and multiple myeloma patient samples were 
obtained from Birmingham Queen Elisabeth Hospital with ethical consent according to 
the human tissue act. Peripheral blood was collected from donors into a syringe with 
heparin and then diluted with 1 part RPMI-1640. 
2.1.6 Preparation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were separated by layering 35ml blood/RPMI onto 15ml lymphoprep and 
centrifugation at 1800rpm with no break. Cells were then washed and either used for 
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downstream experiments or cryopreserved. All experiments were approved by an ethics 
committee and donors provided consent. 
2.2 Cellular Assays 
2.2.1 Peptides 
Peptides were synthesised by either peptide 2.0 or Alta biosciences, dissolved in DMSO 
to obtain a concentration of 5mg/ml and stored at -20°C. 
Pepmixes spanning Actin, WT1 and influenza A nuclear protein were acquired from JPT, 
Berlin.  
2.2.2 T cell assay 
T cell recognition of target antigen presenting cells was measured by IFN-γ production 
in an ELISA assay. T cells (0.5 or 1x104/well) were incubated with target cells (5 x104) at 
37°C, 5% CO2 in RPMI + 8%FCS. After 16 hours culture supernatant was collected and 
IFN-γ was measured using IFN-γ ELISA kit according to manufactures protocol. 
2.2.3 IFN-γ ELISA 
MaxiSorp plates were washed with wash buffer (PBS-0.05% tween-20) and then 
blocked with 200µl of blocking buffer (PBS-0.05% tween-20 + 10% BSA) for two hours 
at room temperature. Following this, plates were washed four times with wash buffer 
and then 100µl of cell supernatant from the overnight assay was harvested and added to 
the MaxiSorp plates. 100µl of an IFN-γ standard was also added, in triplicate, this was 
done using doubling dilutions (2000pg/ml – 31.25pg/ml) of recombinant IFN-γ 
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(peprotech). Plates were then incubated at room temperature for 3-4 hours after which, 
plates were washed four times with wash buffer. 50µl of biotinylated anti-human IFN 
(Sigma), diluted in blocking buffer, was added to each well and plates were incubated for 
1 hour at room temperature. Following this, plates were washed 4 times in wash buffer 
and then 50µl of streptavidin-peroxidase (ExtraAvidin-Peroxidase, Sigma), diluted 
1/1000 in blocking buffer, was added to each well and plates were incubated at room 
temperature for 30min. Plates were then washed 8-times in wash buffer and 100µl of  
peroxidase substrate (3, 3’, 5, 5’-tetramethylbenzidine (TMB) solution, Tebu-bio 
Laboratories) was added and the plates incubated for 30 minutes to allow for colour 
development. To stop the reaction, 100µl of 1M hydrochloric acid was added, resulting 
in a soluble yellow product. Plates were then read using dual wavelengths of 450nm and 
695nm. Using the results from the IFN-γ standard curve, the level of IFN-γ  release could 
be calculated as IFN-γ release in pg/ml. 
2.2.4 ELIspot assay 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor and 
multiple myeloma patient blood samples. 5x105PBMCs/well were stimulated with 
pepmixes or phytohaemagglutinin for 24 hours at 37°C, 5% CO2 in RPMI + 8% foetal calf 
serum (FCS). The frequency of IFN-γ producing cells was then detected with an IFN-γ 
ELIspot kit (Mabtech, MAriemont) according to manufactures protocol 
2.2.5 Tetramer assay 
A pretitrated volume of MHC-II tetramer (0.5–1.0 μl) was added to relevant cells, or no 
tetramer to control tubes, which were incubated at 37°C for 2 h during which the cells 
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were resuspended periodically by agitating the tubes. After an additional two washes, 
the cells were stained for surface markers by incubation for 30 min on ice with 
predetermined saturating amounts of FITC-conjugated CD4 mAb (BD), After two 
subsequent washes, stained cells were either analyzed immediately or fixed in 2% 
paraformaldehyde for later analysis, on an LSRII flow cytometer (Beckman Coulter). 
CD3+CD4+ cells falling within the lymphocyte gate were analyzed for tetramer and 
surface antigen staining. All data were processed using FlowJo software (Tree Star). 
2.2.6 Overexpression of EBNA1 constructs 
To transfect LCLs, cells were washed in 10ml PBS and resuspended in 0.3ml OPTI-MEM 
(Gibco) containing 15µg plasmid DNA. The cells were transferred to 4mm 
electroporation curvettes and electroporated at 230V and 0.975mF using a Gene Pulser 
II (Bio-Rad). 
Protein expression from dox-regulated plasmids in stably transfected cell lines was 
achieved by the addition of dox to the cell cultures. 
MJS cells were transfected with specified quantities of plasmid DNA using lipofectamine 
(Life technologies) according to the manufacturer’s protocol. 
2.2.7 siRNA Knock down 
siRNA oligos (Sigma) were electroporated (5µM) into LCLs according to the previous 
protocol. siRNAs were delivered to MJS cells using oligofectamine (Life technologies) 
according to the manufacturer’s protocol. 
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2.3 Biochemical methods 
2.3.1 Preparation of cell lysates 
1x106 cells were pelleted in 1.5ml eppendorf tubes and washed twice with PBS. Pellets 
were immediately frozen at -80°C. Pellets were later resuspended in 5M Urea buffer and 
sonicated for 30s at 50% power in a misonix microson ultrasonic cell disruptor. 
Insoluble material was removed by centrifugation and protein concentrations in the 
lysates determined by BCA protein determination assay kit (Pierce). 
2.3.2 Nuclear cytoplasmic fractionation 
Lysis of cells was performed using the NEPER nuclear and cytosolic extraction reagents 
(Pierce Biotechnology). CERII was added to samples, vortexed and incubated for on ice 
for an additional minute. Lysates were then centrifuged for 5 minutes at 13000rpm and 
4°C, the pellet contained the nuclei and the supernatant, which was removed and 
transferred to a clean eppendorf, the cytosolic fraction. The nuclear pellet was 
resuspended in 50μl of NERI on ice and vortexed for 15 seconds every 10 minutes for 40 
minutes. Samples were then centrifuged as before and the supernatant containing the 
nuclear fraction removed and transferred to clean pre-chilled 1.5ml eppendorf tube. 
2.3.3 Sodium Dodecyl Sulphate-Polyacrylamide gel electrophoresis 
Cell lysates were separated in either 4-12% or 12% Tris SDS-PAGE gels under reducing 
conditions using the Life technologies precast gel system. 
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2.3.4 Western Blotting 
Polypeptides separated by SDS-PAGE were transferred to a nitrocellulose membrane. 
Membranes were blocked in 5% milk, PBS tween and probed with specific antibody. 
After washing, the membranes were incubated with HRP-conjugated anti-mouse or anti-
rabbit IgG and subjected to chemiluminescent detection using the millipore ECL 
detection kit (Millipore, Billerica). 
2.3.5 RNA extraction 
Up to 5x106 cells were washed in PBS by centrifuging at 1600rpm for 5 minutes, cells 
were then resuspended in 1ml PBS, transferred into a 1.5ml eppendorf and pelleted. 
Cellular RNA was then extracted and purified using RNAeasy kit (Nugen), according to 
the manufacturer’s protocol. RNA was quantified using a Nanodrop machine (thermo 
scientific) and stored at -80°C until needed.   
2.3.6 Quantitative reverse transcriptase-polymerase chain reaction 
The presence of mRNA transcripts in cell lines was measured by qRTPCR. cDNA was 
produced by incubating RNA with reverse transcriptase and random hexamer primers. 
transcripts were detected by qRTPCR using WT1 or p62-specific primers and probes 
(BD biosciences, New Jersey). All results were expressed relative to levels of GAPDH 
2.3.7 RT-PCR 
Five microliters cDNA preparation was used for polymerase chain reaction (PCR) 
amplification in a 50-μL volume of final reaction mixture containing 2.5 U Taq DNA 
polymerase (Qiagen), 1mmol/L dNTP and 20 OD/ml primer. Amplification of the human 
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WT1 coding region was achieved using sense primers located in exon 7 (21 mer 58-ggc 
atc tga gac cag tga gaa-38) and antisense primers in exon 10 (22 mer 58-gag agt cag act 
tga aag cag t-38). RNA integrity was verified by amplifying the human c-ABL gene in 
every sample using intron-spanning primers: 22 mer sense 58-ccc aac ctt ttc gttgca ctg t-
38; 22 mer antisense 58-cgg ctc tcg gag gag acg atg a-38. Hot-start PCR was performed 
for 35 cycles with a thermal cycler under the following conditions: denaturing at 95°C 
for 1 minute, primer annealing at 56°C for 1 minute and chain elongation at 72°C for 2 
minutes. The cycling was initiated by a 5-minute denaturation step at 95°C to heat 
inactivate the reverse transcriptase and it was terminated by a 10-minute final 
extension at 72°C.PCR products were electrophoresed through 1.5% agarose gels. 
2.3.8 Isolation of lysosomes 
1x108 – 7x109 cells were isolated and washed three times in fractionation buffer: 10mM 
tris(hydroxymethyl)aminomethane/acetic acid pH7.0, 250mM sucrose. Pellets were 
resuspended in 1.5ml fractionation buffer and homogenised using 30 strokes in a 
dounce homogeniser. Cell homogenate was centrifuged at 1000 X g (2500 RPM GH3.8 
rotor) for 10 min to pellet debris and undestroyed cells. Supernatant were transferred 
to a ultracentrifuge tube, pellets were washed with twice the pellet weight of 
fractionation buffer and centrifugation repeated. Supernatants were combined in the 
ultracentrifuge tube and centrifuged at 4000 X g (9500 RPM TLA55 rotor) for 10 min to 
pellet a crude fraction containing plasma membrane and nuclei. Supernatant were 
transferred to a fresh tube and pellets washed with twice the pellet weight of 
fractionation buffer and centrifugation repeated. Supernatants were combined and 
centrifuged at 50,000 X g (33500 RPM TLA55) for 10 min to pellet mitochondria, 
Chapter2 – Materials and Methods 
 
52 
 
endosomes and lysosomes The pellet was resuspended in three to five times the pellet 
volume of distilled water depending on cells and incubated for 10min. Tubes were 
centrifuged at 50,000 X g for 10min to pellet mitochondria and endosomes and 
supernatants containing lysosomal material were transferred to a fresh tube. 
2.4 Molecular biological methods 
2.4.1 Bacterial culture media and reagents 
LB (Luria Broth) media was prepared by dissolving 20g/L of LB powder (Invitrogen) in 
SDW. This was then sterilised by autoclaving at 121°C for 20 minutes at 15psi. 
LB agar was prepared by dissolving 20g/L of LB agar powder (Invitrogen) in SDW and 
sterilising by autoclaving at 121°C for 20 minutes at 15psi. 
Ampicillin was made up as a 1000x stock at 100mg/ml in distilled water and stored at -
20°C. 
2.4.2 Preparation of plasmid DNA 
For generation of plasmids, competent bacteria (XL-1 blue) were transformed using 
purified plasmid DNA (50-100ng). This was added to 200µl of competent bacteria in a 
1.5ml eppendorf and incubated on ice for 30 minutes. Following this, bacteria was heat 
shocked for 90 seconds at 42°C and then placed briefly on ice. 800µl of LB broth was 
then added and samples were incubated in a shaker at 37°C for one hour. For each 
transformation the bacteria were plated by spreading 200µl and 20µl onto two different 
agar plates (containing the appropriate antibiotic) and a final plate of concentrated 
bacteria. Plates were then incubated overnight at 37°C. 
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2.5 Microscopy 
LCLs were harvested, washed and resuspended in PBS, spotted onto glass slides and air 
dried or cytopspun onto slides. Cells were then fixed in 4% paraformaldehyde (PFA) and 
permeabilised in 0.5% Trition X-100. Residual PFA was absorbed by incubating slides in 
20μM glycine. Cells were then incubated with antibodies for 16 hours at 4°C. After 
rinsing with PBS, slides were incubated with alexa-fluor 594-conjugated goat anti-rabbit 
antibody for 1 hour at 37°C. Vectorshield + dapi mounting solution (vector labs 
Peterborough), was applied and cells were analysed by fluorescent microscopy. 
2GL9 cells were cultured on microscopy slides fixed in 4% paraformaldehyde (PFA). 
Residual PFA was absorbed by incubating slides in 20μM glycine. Vectorshield + dapi 
mounting solution (vector labs Peterborough), was applied and cells were analysed by 
fluorescent microscopy. 
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3. ANALYSIS OF WILM’S TUMOUR 1 AS A TARGET ANTIGEN FOR T 
CELL RECOGNITION 
As previously discussed, WT1 is a classic example of a cellular tumour antigen. It is 
expressed at low levels in a small subset of normal cells but is over expressed in a wide 
range of tumours and is therefore an attractive target for immunotherapy. Indeed, WT1 
has recently been listed as the number one antigen in a priority-ranked list of cancer 
vaccine target antigens (Cheever et al., 2009). WT1 contains both CD8+ and CD4+ T cell 
epitopes and has been used as a tumour antigen in many clinical trials. 
Although it is considered to be an excellent therapeutic target, relatively few CD8+ and 
CD4+ T cell epitopes have been defined in WT1. Furthermore, little is known about how 
WT1 is processed and presented within tumour cells. As well as being expressed in 
primary tumour tissue a number of papers have reported that WT1 is expressed in 
transformed cell lines. One such paper by Kobayashi et al. reported that WT1 is 
expressed in EBV transformed lymphoblastoid cells lines (LCLs) (Kobayashi et al., 
2006). These cells are transformed B cells that express both HLA class I and class II 
molecules and have intact and fully functioning antigen processing and presentation 
pathways. LCLs therefore represent an ideal model in which to study the processing and 
presentation of natively expressed WT1. 
A second aim of this work was to further study the expression of WT1 in other types of 
cancer. It is known that EBV transformation of B cells is concurrent with the initiation of 
WT1 expression in-vitro but WT1 expression in EBV-related malignancies has not been 
Chapter 3 - Results 
 
55 
 
well studied. Therefore I aimed to analyse the level of expression of WT1 in a range of 
EBV-associated malignancies. 
A third aim of this study was to further investigate the range and frequency of WT1 T 
cell responses in healthy individuals as well as cancer patients. This work may identify 
new CD8+ and CD4+ T cell epitopes in the WT1 protein since few have been described in 
the literature. 
The ultimate aim of this work was to develop strategies to enhance the immunogenicity 
of cellular tumour antigens using WT1 as a therapeutically relevant model. In this 
regard, WT1 is located in the nucleus of normal cells and some tumours but in other 
tumours WT1 has been observed in the cytoplasm (Drakos et al., 2005). As previously 
discussed, protein subcellular localisation may be an important factor in the recognition 
of antigens by CD4+ T cells. A previous report indicates that the pharmacological 
compound forskolin can relocalise WT1 from the nucleus to the cytoplasm (Ye et al., 
1996). I aim to further study this finding in WT1 positive antigen presenting cells and 
investigate how this relocalisation affects the processing and presentation of WT1. I 
hypothesise forskolin-mediated relocalisation of WT1 will enhance presentation of the 
antigen to WT1-specific CD4+ T cells. 
3.1 Expression of WT1 in LCLs 
Kobayashi et al. detected WT1 protein in three LCLs, each derived from a different 
donor. It is not however known if WT1 is expressed in all LCLs. Therefore in order to 
further define the experimental system, the variability of WT1 expression between 
different LCLs was tested. The expression of WT1 in seven LCLs, each derived from a 
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different donor was assessed by western blotting using the WT1-specific antibody 6F-
H2 (Figure 3.1a). The CML line K562 was included as a positive control as it had 
previously been reported to express WT1 (Kobayashi et al., 2006). A band with 
approximate molecular weight 52kDA was detected in four of the seven LCLs (LCLs 2-5) 
and was also detected in K562. This was considered to be the 497 amino acid, canonical 
WT1 isoform. Levels of expression of this canonical WT1 isoform varied between the 
four positive LCLs, with LCL3 showing the lowest level of expression. The remaining 
three LCLs showed no expression of canonical WT1; however bands of different 
molecular weight were detected in all seven LCLs. These extra bands could reflect the 
presence of alternative transcripts as well as post transcriptional modification of WT1 
or they may represent non-specific recognition by the 6F-H2 antibody. 
To confirm this result, the same seven LCLs were tested for WT1 expression using a 
second WT1-specific antibody, C-19. This time the melanoma cell line, 624-mel was used 
as a negative control and again, K562 was used as a positive control (Figure 3.1b). As 
previously seen, four LCLs (LCLs 2-5) showed expression of canonical WT1. These were 
the same four LCLs that showed expression of canonical WT1 using 6F-H2. Bands of 
different molecular weight were again detected in all LCLs with the exception of LCL 7 
where no bands were observed. One of these alternative bands, at a low molecular 
weight, was also detected in 624-mel. This suggests this band was due to non-specific 
recognition by the antibody. It should be noted that the band detected in K562 using C-
19 appeared to be of slightly lower molecular weight than the canonical WT1 band 
detected in LCLs. This could suggest that C-19 was detecting a different WT1 isoform in 
the different cell lines. 
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These data show that WT1 expression varies between LCLs however it is not known if 
WT1 expression is stable or if the variation between LCLs observed is due to WT1 
expression changing over time. To investigate the stability of WT1 expression, samples 
of cells were taken over 14 days from two LCLs, one of which had tested positive for 
WT1, the other had not. The expression of WT1 in each sample was assessed by western 
blotting using the WT1-specific antibody 6F-H2. Figure 3.2a shows WT1 expression in 
LCL 4, previously shown to be WT1 positive. Canonical WT1 was detected at all time 
points across 14 days and level of expression appeared to be similar. Figure 3.2b shows 
expression in LCL 1, previously shown to be WT1-negative. No canonical WT1 
expression was detected at any time point, though it should be noted bands of low 
molecular weight were observed at all time points. 
These two experiments show that levels of canonical WT1 remained constant over all 
time points showing that these differences in expression are fixed for each LCL. 
3.2 Expression of WT1 in EBV-associated malignancies 
The previous experiments confirm that WT1 is expressed in some LCLs; such LCLs 
therefore could be used to study the processing and presentation of WT1.  
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Figure 3.1 Expression of WT1 protein in LCLs 
Western blot analysis of WT1 protein expression in seven different LCLs. a. 
WT1 protein was detected using the WT1-specific monoclonal antibody 6F-
H2. Canonical WT1 was detected in four of seven LCLs. Alternative bands 
were detected in all seven LCLs. b. WT1 protein was detected using the WT1-
specific polyclonal antibody C-19. Canonical WT1 was detected in the same 
four LCLs. Alternative transcripts were detected in all LCLs except LCL7. 624-
mel was used as a negative control and K562 as a positive control. Expression 
of actin protein was used as a loading control.   
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Figure 3.2 Expression of WT1 protein in LCLs over time 
Western blot analysis of WT1 protein expression in two different LCLs, using 
the WT1-specific monoclonal antibody 6F-H2. a. Expression of WT1 protein in 
the previously WT1-positive LCL, LCL4. b. Expression of WT1 protein in the 
previously WT1-negative LCL, LCL1. Expression of WT1 protein remained 
constant in both LCLs across all time points. K562 was used as a positive 
control. Expression of actin protein was used as a loading control. 
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I next examined whether other EBV-associated malignancies express WT1. 
To determine if WT1 is expressed in other EBV-associated malignancies, a range of EBV-
transformed NPC and NK/T cell lymphoma cell lines were assayed by western blot 
analysis for expression of WT1 protein. As WT1 expression varied between LCLs 
multiple cell lines for each malignancy were tested. WT1 expression in three NPC lines 
and five NK/T cell lymphoma cell lines was tested using the WT1-specific antibody 6F-
H2 (Figure 3.3a). The three NPC cell lines HK1, HONE-1 and HOU-1 showed no 
expression of WT1 protein. The five NK/T cell lymphoma lines MEC04, NK1, SNK6, 
SNK10 and SNT16 were also negative for WT1. The negative control 624-mel showed no 
expression and canonical WT1 was detected in the positive control K562 cells. This 
result showed that WT1 is not expressed in any of the EBV-transformed cell lines 
established from NPC or NK/T cell lymphoma. 
3.3 Expression of WT1 in other haematological malignancies  
As cell lines from EBV-associated malignancies proved to be negative for WT1 protein, 
cell lines from a wider range of non-EBV-associated haematological malignancies were 
tested for WT1 expression. Previous reports have shown WT1 is expressed in both acute 
myeloid leukaemia (AML) and myeloma (Hatta et al., 2005; Schmid et al., 1997). Cell 
lines from these malignancies were therefore analysed for WT1 expression with the aim 
of further studying WT1 expression in these malignancies as well as identifying tumour 
cell lines that could act as targets in T cell assays. 
Four AML lines and three myeloma lines were analysed for WT1 protein expression by 
western blotting, using the 6F-H2 antibody (Figure 3.3b). Canonical WT1 was detected 
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in three of four AML lines, HL60, KG1a and NB4. Levels of expression were high and 
comparable to levels in the positive control K562. The fourth AML line NOMO1 showed 
no expression of WT1. No WT1 expression was observed in any of the three myeloma 
lines tested, H929, JJN3 and U266. 
3.4 WT1 expression by qRT-PCR 
As shown in Figure 3.1, when LCLs are subjected to western blot analysis a different 
pattern of bands was observed when two different WT1-specific antibodies were used. 
WT1 is known to have many different splice variants (Figure 3.4). The 6F-H2 antibody is 
monoclonal and specific for a peptide in exon 1, whereas the C-19 antibody is polyclonal 
and raised against a peptide at the C-terminus of WT1. It is possible that the different 
antibodies detect different isoforms of WT1 and it is also possible that some isoforms 
are not detected due to alternative exon usage and amino acid changes in the C-
terminus. Due to the ambiguous nature of the western blot analysis, qRT-PCR was 
carried out on matched samples to confirm the data obtained. 
mRNA was extracted from the same samples of LCLs used in previous western blotting 
experiments. Levels of WT1 mRNA were then assayed by a commercial qRT-PCR assay 
spanning exon 3 and 4, designed to detect all known transcripts of WT1 (Figure 3.5a). 
Interestingly no WT1 transcripts were detected in any of the seven LCLs tested despite 
previous results showing WT1 protein was expressed in four of these lines. WT1 
transcripts were detected in the positive control cell line K562 showing the assay was 
functioning correctly and capable of detecting WT1 mRNA. 
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Figure 3.3 Expression of WT1 protein in tumour cell lines 
Western blot analysis of WT1 protein expression in tumour cell lines, using 
the WT1-specific monoclonal antibody 6F-H2. a. Expression of WT1 protein 
in cell lines from EBV-associated malignancies. WT1 protein was not detected 
in any of the lines tested. b. Expression of WT1 protein in cell lines from 
other haematological malignancies. WT1 was detected in three of four AML 
lines tested. No WT1 was detected in any Myeloma lines. 624-mel was used 
as a negative control and K562 as a positive control. Expression of actin 
protein was used as a loading control. 
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Figure 3.4 Human WT1 gene locus 
Schematic of the human WT1 gene locus on chromosome 11 at 32409325 – 
32457087. To date 26 isoforms of WT1 have been descirbed. The locus 
contains four alternative start codons -69 CTG, +127ATG, AWT1 and int 5. 
Exon variants result from the use of an alternative exon 1a or skipping exon 
5. KTS isoforms exclude three amino acids (KTS) in exon 9. A final alternative 
isoform is generated through RNA editing in exon 6 (T/C). (Adapted from 
Hohenstein and Hastie 2006) 
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To further investigate this difference between results obtained by western blotting and 
those obtained by qRT-PCR all other cell lines previously tested for WT1 protein 
expression were assayed for WT1 mRNA transcripts (Figure 3.5b and c). 
As previously shown, all NPC and NK/T cell lymphoma lines were negative for any WT1 
transcripts (Figure 3.5b). qRT-PCR data for AML and myeloma lines matched that 
obtained by western blotting in that three AML lines were WT1 positive and the 
remaining lines including all myeloma lines were negative (Figure 3.5c). However subtle 
differences were observed; the AML line NB4 showed the highest level of protein 
expression but the lowest level of WT1 mRNA transcript. 
Taken together these data could suggest that an alternative mRNA transcript is being 
expressed in LCLs and perhaps in AML lines also. 
3.5 WT1 expression by an alternative RT-PCR assay 
As the commercial qRT-PCR assay was unable to detect WT1 mRNA in lines where WT1 
protein had previously been detected an alternative RT-PCR assay was used to confirm 
the presence of WT1 mRNA in these lines. Kobayashi et al. previously detected WT1 
mRNA in multiple cell lines, including LCLs, using an RT-PCR assay. The assay uses a 
forward primer in exon 7 and a reverse primer in exon 10. 
To confirm WT1 expression in LCLs the same mRNA samples used in qRT-PCR 
experiments were used in the “Kobayashi” RT-PCR. Figure 3.6a shows control 
experiments conducted to confirm the assay’s specificity. Lane one shows a negative 
control where water rather than RNA was added to the cDNA synthesis reaction.  
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Figure 3.5 Expression of WT1 mRNA in LCLs and tumour cell lines by 
qRT-PCR 
Quantitative RT-PCR analysis of WT1 mRNA in cell lines. a. WT1 mRNA levels 
in seven different LCLs. WT1 mRNA was not detected in any LCLs. b. WT1 
mRNA levels in cell lines from EBV-associated malignancies. No WT1 mRNA 
was detected in any of the lines tested. c. WT1 mRNA levels in cell lines from 
other haematological malignancies. WT1 mRNA was detected in three of four 
AML lines. Levels in myeloma lines were below that of the negative control. 
All results are expressed relative to the level of the housekeeping gene 
GAPDH. 624-mel was used as a negative control. 
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No RT controls, where the cDNA synthesis reaction was carried out without reverse 
transcriptase are shown in lanes two and three. As the K562 no RT control was negative 
this shows the assay does not detect genomic DNA and only detects mRNA. No WT1 
mRNA was detected in the negative control 624-mel. WT1 mRNA was detected in K562; 
a PCR amplicon of approximately 500bp was observed as would be expected. The 
sensitivity of the assay was also tested by diluting the quantity of cDNA in the PCR 
reaction. Standard cDNA input was 5µg of cDNA, when K562 cDNA input was reduced to 
40ng and then 8ng a PCR amplicon could still be detected. 
Figure 3.6b shows the results of Kobayashi RT-PCR assay to detect WT1 mRNA in the 
same seven LCL mRNA samples used in previous experiments. Four out of seven LCLs 
gave a PCR amplicon of the expected size. These were the same four LCLs that showed 
expression of WT1 protein when analysed by western blot. 
The cell lines from the EBV-associated malignancies were again tested for WT1 
expression and were again all negative (data not shown). 
Figure 3.6c shows the results of Kobayashi RT-PCR assay to detect WT1 mRNA in the 
same four AML cell lines previously tested. Three of the four lines gave a PCR amplicon 
of the expected size. These were again the same three lines that showed expression of 
WT1 protein when analysed by western blot. The fourth line, NOMO1, was again 
negative for WT1 mRNA confirming all previous findings. 
Interestingly, when the myeloma lines were assayed for WT1 mRNA by the Kobayashi 
RT-PCR, two lines, H929 and U266 gave a PCR amplicon of the expected size. This is 
despite them both testing negative for WT1 in all previous experiments. 
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Figure 3.6 Expression of WT1 mRNA in LCLs and tumour cell lines by an 
alternative RT-PCR assay 
Analysis of WT1 mRNA in cell lines using an alternative “Kobayashi” RT-PCR 
assay. Standard cDNA input was 5µg. a. A PCR amplicon of size 482 bp was 
detected in K562 but was absent in water, no reverse-transcriptase (RT) and 
624-mel negative controls. The same amplicon was observed when K562 
cDNA input was reduced to 40 and then 8ng. b. Four of seven LCLs tested 
were WT1 positive. c. Three of four AML lines and two of three myeloma 
lines were also WT1 positive. Abl or gapdh were used as housekeeping gene 
controls for RT-PCR. 
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These data suggest that the Kobayashi RT-PCR assay can: i) detect an alternative WT1 
transcript in LCLs, one that is not detected by a commercial qRT-PCR assay and ii) can 
detect an mRNA transcript in myeloma cell lines that is not detected by two different 
antibodies in western blot analysis or by the commercial qRT-PCR assay. 
3.6 The effect of forskolin on WT1 expression and localisation 
As described in the introduction to this section, one of the aims of this work was to study 
how the subcellular localisation of WT1 affects the processing and presentation of WT1-
specific epitopes. A previous paper reported that forskolin can relocalise WT1 (Ye et al., 
1996). Ye et al. showed that 24h forskolin treatment caused cytoplasmic localisation of 
WT1 in 98% of C2 myoblast cells. It was not known if forskolin will relocalise WT1 in 
other cell types or what effect such relocalisation would have on the processing of WT1. 
To begin to address these questions the effect of forskolin upon WT1 expression in LCLs 
was investigated. 
An LCL previously shown to be WT1 positive by western blotting was treated with 
forskolin and then analysed for WT1 expression by immunofluorescence microscopy, 
using the WT1-specific antibody 6F-H2. To allow greater differentiation of nuclear and 
cytoplasmic regions of the LCLs (which have relatively small amounts of cytoplasm) the 
cells were cytospun onto microscopy slides. Cytospinning causes cells to flatten and 
spread out permitting easier visualisation of their cytoplasm. Figure 3.7 shows the 
results of this experiment. Bright WT1 staining was observed in the majority of cells. All 
WT1 staining was concurrent with Dapi staining showing WT1 was localised in the 
nucleus. Following treatment with 50µM forskolin levels of WT1 expression were 
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greatly reduced in LCLs. Some dim staining was observed in cells but no staining was 
observed in the cytoplasm. 
One explanation for this result could have been that WT1 was relocalised into the 
cytoplasm whereupon it was degraded. To test this theory forskolin-treated LCLs were 
incubated with 50mM chloroquine, a chemical that raises the pH of endosomes and 
lysosomes thereby inhibiting degradation of proteins by cathepsins. Addition of 
chloroquine increased levels of WT1 protein, reversing the effect caused by forskolin. No 
clear WT1 staining was observed in the cytoplasm but this may be due to the difficulty of 
imaging cytoplasm in LCLs cells. 
3.7 Measuring WT1-specific T cell responses in healthy donors and Multiple 
Myeloma patients by IFN-γ ELIspot assay 
In order to examine the antigen processing and presentation of WT1 it was necessary to 
generate T cell clones specific for epitopes within the protein. Several reports in the 
literature suggest WT1-specific CD4+ T cell clones can be isolated, not only from patients 
with malignancies such as multiple myeloma, but also from healthy donors (Azuma et 
al., 2002; Doubrovina et al., 2004; Kobayashi et al., 2006). Although WT1-specific T cell 
clones have been generated from multiple donors the number of epitope-specificities of 
WT1-specific T cells is relatively low. Also the range and frequency of WT1 T cell 
responses in healthy donors and patients has not been studied. Therefore I first aimed to 
measure the frequency of WT1 T cell responses in a number of donors. 
 
Chapter 3 - Results 
 
70 
 
 
Figure 3.7 Expression and localisation of WT1 in LCLs. 
WT1 positive LCLs were fixed and stained with the WT1-specific antibody 
6F-H2 (red). The nucleus of cells was stained with Dapi (blue). The cells were 
analysed by immunofluorescence microscopy. Bright, WT1 staining was 
observed in the nucleus of control cells. 24h, 50µM Forskolin reduced WT1 
staining. Treatment of forskolin incubated LCLs with 50mM chloroquine 
reversed this effect and bright WT1 staining was observed in the nucleus of 
these cells. 
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To examine whether WT1 T cell responses could be detected ex-vivo, I used a highly 
sensitive IFN-γ ELIspot assay. In these experiments pepmixes were used to provide the 
antigen stimulus to the T cells. Pepmixes consist of 15mer peptides that span the entire 
primary sequence of an antigen; each peptide overlaps the previous one by 10 amino 
acids. The advantage of using pepmixes is that they allow all responses to an antigen to 
be stimulated in a single ELIspot well, increasing the sensitivity of the assay. 
In cases where several weak T cell responses exist, combining them together in a single 
well may allow them to be detected, whereas individually each may be below the limit of 
detection for the assay. This pepmix ELIspot assay has been shown to be highly sensitive 
in detecting weak responses in previous reports (Hui et al., 2013). 
T cell responses were measured in 16 healthy donors and 18 multiple myeloma patients. 
A pepmix of the self-protein actin was used as a negative control. PHA, a non-specific 
stimulator of T cells was used as a positive control. A pepmix of Influenza A nuclear 
protein was used as a second positive control as most donors should have a detectable T 
cell response to this protein. A pepmix of WT1 was used to test for WT1 T cell responses. 
Figure 3.8a shows representative ELIspot results from three healthy donors and three 
myeloma patients. Figure 3.8b shows a summary off all 16 healthy donors (left) and all 
18 myeloma patients (right). Responses to the negative control actin were low in all 
donors, with a mean of 6 spots/106 PBMCs in healthy donors and 3 spots/106 PBMCs in 
patients. Responses to PHA were high and in many cases separate spots were impossible 
to count as they merged together. In such cases responses to PHA were reported as 1000 
spots/106 PBMCs. Responses to Influenza A nuclear protein varied between all donors. 
In healthy donors responses were relatively high with a mean of 214 and a range 24 to 
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870 spots/106 PBMCs. Responses to Influenza were much lower in multiple myeloma 
patients with a mean of 22 and a range 5 to 51 to 5 spots/106 PBMCs.  
Responses to WT1 protein were not detected in any of the 16 healthy donors or 18 
multiple myeloma patients tested in the ex-vivo assay. Responses were below the level of 
the actin negative control in all cases. 
3.8 Measuring WT1 T cell responses by cultured ELIspots assay 
The lack of a detectable WT1 T cell response in the ex-vivo ELIspot assay may be due to 
responses being too weak to measure directly. Another possibility is that the response is 
confined to central memory T cells which do not respond immediately following 
antigenic stimulation. Ex-vivo ELIspots are limited to the detection of effector memory T 
cells, which are generated following antigen-induced clonal expansion in-vivo. 
Therefore although ex-vivo ELIspot assays revealed no responses to WT1 in either 
healthy donors or patients it is possible that these individuals did possess WT1-specific 
T cells but they were not detected due to limitations in the methods applied. I therefore 
performed cultured ELIspots on PBMCs from the same previous donors. This involved 
stimulating PBMCs with specific antigens prior to testing in IFN-γ ELIspot assays. This 
procedure expands all antigen-specific T cell responses and aids in the detection of low 
frequency as well as central memory or naive T cells. 
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Figure 3.8 T cell responses in healthy donors and multiple 
myeloma patients by ex-vivo ELIspot 
PBMCs from healthy donors and multiple myeloma patients 
(500,000/well) were tested in ELIspot assays using indicated pepmixes 
or PHA as a control. a. Representative ELIspot assay from three healthy 
donors and three myeloma patients are shown. T cell secretion of IFN-γ 
is visualised as dark spots. b. Results from ELIspot assay in healthy 16 
donors (left) and 18 multiple myeloma patients (right). T cell responses 
were detected against influenza A nuclear protein in the majority of 
healthy donors and some patients. WT1 responses were below the level 
of actin controls in all donors. Bars represent mean +/- standard error.  
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PBMCs from a selection of the same healthy donors and myeloma patients were 
stimulated with pepmixes. As a positive control PBMCs from each donor were 
stimulated with a pepmix of the EBV protein EBNA1. A second peptide-stimulated line 
was established from each donor using a WT1 pepmix. Cells were then cultured with IL-
2 and IL-7 for 12 days. Cells were then tested for antigen specificity in a standard IFN-γ 
ELIspot assay. 
Pepmixes were dissolved in dimethyl sulfoxide (DMSO), so lines were tested against 
DMSO as a negative control. PHA was used as a positive control. EBNA1 and WT1 
pepmixes were used to test for antigen-specific T cell responses. 
Figure 3.9a shows ELIspot results from EBNA1 pepmix stimulated lines derived from 
five healthy donors (left) and five myeloma patients (right). Responses to DMSO 
negative control were low in all lines, with a mean of 45 spots/104 cells in healthy 
donors and 22 spots/104 PBMCs in patients. Responses to PHA were high and again in 
many cases separate spots were impossible to count. In such cases responses to PHA 
were reported as 1000 spots/104 PBMCs. Responses to EBNA1 pepmix protein were 
high in all 10 lines, with a mean of 262 spots/104 cells in healthy donors and 117 
spots/104 PBMCs in patients. 
Figure 3.9b shows ELIspot results from WT1 pepmix stimulated lines derived from five 
healthy donors (left) and five myeloma patients (right). Responses to DMSO negative 
control were low in all lines, with a mean of 11 spots/104 cells in healthy donors and 17 
spots/104 PBMCs in patients. Responses to PHA were again reported as 1000 spots/104 
PBMCs. Responses to WT1 pepmix protein were below or comparable to negative 
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controls in all 10 lines, with a mean of 10 spots/104 cells in healthy donors and 20 
spots/104 PBMCs in patients. 
3.9 Isolation of WT1-specific T cells 
Results from the ELIspots assays suggested that WT1 T cell responses were less 
common in our donors than might have been expected based on reports in the literature. 
Despite this fact, because these reports suggested WT1-specific T cell clones could be 
isolated from healthy donors and cancer patients I attempted to prepare such clones 
from the healthy donors and multiple myeloma patients I had screened. A number of 
different techniques were used to try to stimulate and isolate WT1-specific T cells, a 
summary of which is shown in Table 3.1. 
A number of different sources of WT1 antigen were used. Peptides representing 
previously defined WT1 T cell epitopes as well as a peptide library spanning the whole 
WT1 protein were first used to stimulate PBMCs. The pepmixes used for ELIspot assays 
were also used as a source of antigen. These were either added to PBMCs to stimulate 
WT1-specific T cells directly or loaded onto APCs such as B cells and DCs. Peptide loaded 
APCs were then cultured with PBMCs to stimulate responses. Two different markers of T 
cell activation were used to define peptide-specific T cells; these were IFN-γ and CD137. 
IFN-γ production was monitored by ELISA and CD137 positive cells were isolated by 
magnetic enrichment of cells labelled with a CD137-specific antibody. As controls, 
peptides and pepmixes of the two EBV antigens EBNA1 and LMP1 were used to 
stimulate separate PBMCs from the same donors. In all cases EBNA1 and LMP1-specific 
T cells were isolated from all healthy donors. While all these methods were capable of 
generating EBV-specific T cell clones, no WT1-specific T cell clones were isolated.  
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Figure 3.9 T cell responses in healthy donors and multiple myeloma 
patients by cultured ELIspot assay. 
PBMCs from healthy donors and multiple myeloma patients were stimulated 
with EBNA1 or WT1 pepmixes. After 12 days stimulated lines were tested in 
ELIspot assay using 5000 cells/well a. EBNA1 stimulated lines from 5 healthy 
donors and 5 multiple myeloma patients showed responses to EBNA1 
peptides. b. WT1 stimulated lines from 5 healthy donors and 5 multiple 
myeloma patients showed no responses to WT1 peptides. Bars represent 
mean +/- standard error. 
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As attempts to generate WT1-specific clones using peptides and pepmixes had been 
unsuccessful an alternative antigen stimulation mechanism was sought. DNA and RNA 
transfection of APCs causes expression of target antigens within APCs. The antigens can 
then be processed and presented to T cells in a physiologically relevant manner.  
PBMCs and APCs such as B cells and DCs were transfected with WT1 DNA or mRNA. This 
led to expression of WT1 in APCs which was confirmed by western blotting (data not 
shown). These WT1 positive APCs were then used to stimulate PBMCs from lab donors 
and myeloma patients. As a control, APCs were transfected with EBNA1 DNA or mRNA 
and used to stimulate PBMCs. The activation of peptide-specific T cells was monitored 
by IFN-γ ELISA. Control APCs were able to stimulate EBNA1-specific T cells but no WT1-
specific T cells were generated by stimulation with WT1 positive APCs.  
It was possible that over-expressed WT1 in APCs was poorly processed and presented 
by the endogenous class II pathway, which would limit the generation of WT1-specific 
CD4+ T cells. To improve the processing of over-expressed WT1, an invariant chain (Ii) 
sequence was added to the WT1 DNA producing a WT1-Ii fusion protein. The Ii 
sequence should cause the WT1 protein to be rapidly imported into the endocytic 
pathway of APCs and should therefore significantly increase the processing of WT1, 
resulting in higher levels of WT1 peptide-MHC-II complexes on the surface of the APCs. 
APCs transfected with the Ii-WT1 fusion were used to stimulate PBMCs from healthy 
donors, but were still unable to generate WT1-specific T cells. 
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3.10 Tetramer detection of WT1-specific CD4+ T cells 
All previous attempts to study WT1-specific T cells have focussed on identifying them on 
the grounds of functional output. As these experiments all failed to identify WT1-specific 
T cells a different experimental method was sought.  
MHC Tetramer detection involves the direct detection of epitope-specific T cells by 
distinguishing TCR specificity solely by its binding to peptide:MHC complexes. MHC 
tetramer technology has been used to great effect in studying the size, kinetics and 
phenotype of epitope-specific T cell responses. MHC-II tetramers have been used to 
investigate CD4+ T cell responses to HIV, influenza, Hepatitis C and more recently EBV 
(Long et al., 2013). MHC-II tetramers should therefore be able to identify WT1-specific T 
cells regardless of the T cell phenotype or functional ability. 
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Table 3.1 Methods for stimulation and isolation of WT1-specific T cells 
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Three different tetramers were designed using previously published MHC class II 
epitopes from WT1. These tetramers were then used to measure the frequency of 
tetramer-binding CD4+ T cells in CD8+ T cell–depleted PBMCs, from healthy donors. 
Figure 3.10 shows an example of one such experiment. An MHC-II tetramer specific for 
the PRS epitope of the EBV antigen EBNA2 was used as a positive control and a clearly 
defined population of tetramer positive, CD4+ T cells was detected (Figure 3.10a). 
However, when PBMCs were stained with three different WT1 MHC-II tetramers, no 
tetramer positive populations were detected (Figure 3.10b). 
These experiments were repeated using PBMCs from 5 healthy donors and 5 multiple 
myeloma patients and in all cases WT1 tetramer-specific populations were below the 
level of no tetramer controls (data not shown). 
3.11 Tetramer-associated magnetic enrichment of WT1-specific CD4+ T cells 
Though MHC-II tetramer detection of epitope-specific T cells is a highly sensitive 
method there is a lower limit to the method. It is possible that WT1 tetramer 
experiments failed to detect WT1-specific T cells because the T cells exist in very small 
numbers in the donors tested. One possible method for increasing the sensitivity of 
tetramer detection is Tetramer-Associated Magnetic Enrichment (TAME).  
TAME enables detection of extremely low frequency epitope-specific T cells in PBMCs by 
enriching the tetramer-specific populations through magnetic sorting (Figure 3.11). 
PBMCs are first stained with MHC tetramers and then tetramer positive cells are stained 
with magnetically labelled antibodies specific for the tetramer fluorophore. 
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Figure 3.10 Tetramer detection of antigen-specific CD4+ T cells 
The frequency of tetramer-binding CD4+ T cells in CD8+ T cell–depleted 
PBMCs, from healthy donors was assessed. A. A clearly defined population of 
cells was detected by the control EBNA-2 PRS tetramer. B. No tetramer 
binding cells were detecting in cells stained with WT1 tetramers 
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Figure 3.11 Tetramer associated magnetic enrichment 
TAME enables detection of extremely low frequency epitope-specific T cells 
in PBMCs by enriching the tetramer-specific populations through magnetic 
sorting.(Figure adaptor from Davis et al., 2011)  
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Stained PBMCs can then be magnetically sorted, enriching tetramer-specific T cells prior 
to flow cytometry analysis of cell populations. 
PBMCs from healthy donors were stained with a control EBNA2 MHC-II tetramer or 
WT1 MHC-II tetramers and then magnetically sorted into two populations, negative and 
positive. A third population of unsorted cells was also included and all populations were 
analysed by flow cytometry (Figure 3.12). The EBNA2 MHC-II tetramer revealed a 
clearly defined population of CD4+, tetramer-specific T cells in unsorted cells. After 
magnetic sorting this population had been enriched over 20-fold, 5% of cells in the 
positive sort were tetramer positive. 
As seen in previous experiments, staining with the WT1–ATL MHC-II tetramer revealed 
no population of tetramer-positive cells. However after magnetic sorting a small 
population of tetramer positive CD4+ T cells was observed in the positive sort fraction. 
The positive fraction contained 1% tetramer positive cells. 
This result confirms the existence of a very rare population of CD4+ T cells specific for 
the WT1 epitope ATL, in a single donor. This experiment was repeated on multiple 
donors using all three WT1 tetramers but tetramer positive cells were not detected in 
any other experiments. 
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Figure 3.12 Identification of antigen-specific CD4+ T cells by TAME assay 
PBMCs from healthy donors were stained with a control EBNA2 MHC-II 
tetramer or WT1 MHC-II tetramers and then magnetically sorted into two 
populations, negative and positive by TAME. Unsorted cells , negative and 
positive cells were then analysed for tetramer positive cells. TAME using the 
PRS tetramer enriched a population to 5% tetramer positive. TAME using the 
ATL tetramer enriched a previously undetectable population to 1% tetramer 
positive. 
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3.12 Discussion 
WT1 is a highly promising tumour antigen and WT1-specific T cells show great potential 
to produce therapeutic benefit in cancer patients. However, many questions about the 
immune response to WT1 remain to be answered. Very little is known about the 
processing mechanisms that generate WT1 peptide MHC complexes. Expression of WT1 
has been identified in particular tumour types but a definitive description is lacking and 
the ability of WT1-specific T cells to recognise WT1-positive cells has been poorly 
investigated. Finally, although WT1-specific T cells have been identified by multiple 
groups, the frequency and breadth of the WT1 T cell response in the population has not 
been explored. 
The work in this chapter sought to answer some of these questions with the overall aim 
of applying knowledge about the processing of WT1 to develop strategies to improve the 
processing of WT1 to enhance T cell recognition of WT1 positive cell lines. 
3.12.1 WT1 expression 
LCLs were chosen as a model system in which to study the processing of WT1. These 
transformed B cells have functional MHC I and MHC-II processing pathways and are an 
established model for studying antigen processing. Kobayshi et al. had shown multiple 
LCLs express WT1, but it was not known if this was the case for all LCLs. 
Monitoring the expression of WT1 presented a challenge as many different WT1 
isoforms have been identified. Protein expression was examined with two different 
antibodies specific for different regions of the WT1 protein. These two antibodies 
confirmed WT1 was expressed in some but not all LCLs. Temporal studies confirmed the 
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expression pattern in different LCLs was stably maintained over time. These differences 
would seem to suggest that WT1 expression is not triggered by EBV-infection per se but 
may occur as a result of another event that occurs for some LCLs during their 
establishment in-vitro. Although WT1 expression was not examined on a per cell basis, 
the fact that WT1 expression is essentially binary, with some LCLs strongly expressing 
the protein and others not, suggests that in the case of WT1 positive LCLs, all cells in the 
culture are expressing the protein. During the establishment of an LCL in-vitro, the 
initially polyclonal collection of B cells evolves rapidly into an essentially monoclonal 
LCL (Ryan et al., 2006). WT1 expression has been shown to activate genes that confer a 
growth advantage to haematopoietic stem cells (Alberta et al., 2003). Thus, activation of 
WT1 in a subset of B cells in an establishing LCL would lead to the final monoclonal LCL 
being WT1 positive. The reasons why some LCLs are WT1 positive and others not are 
currently unknown but they could start to be addressed by examining WT1 expression 
during formation of an LCL. Whether WT1 is expressed in particular cases of post-
transplant lymphoproliferative disease, the tumours of which are essentially LCLs that 
have arisen in immunosuppressed patients, is an important question for future work, 
particularly given the association of WT1 with poor disease-free and overall survival in 
AML and ALL (Bergmann et al., 1997; Chiusa et al., 2006; Garg et al., 2003; Inoue et al., 
1994). 
The fact that WT1 was expressed in LCLs raised the question of whether EBV-positive 
malignancies, which express a smaller subset of EBV genes, express WT1. Western 
blotting revealed that the cell lines tested did not express WT1 protein. This again 
suggests that EBV infection per se is unable to trigger WT1 expression. However, as cell 
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lines rather than primary tumour tissue were tested, it remains possible that EBV-
positive tumours express WT1 in-vivo. This means that EBV tumours may still be 
targeted by WT1-specific T cells. The expression of WT1 in some LCLs suggest that WT1 
may be expressed in EBV-related, post-transplant lymphoproliferative disorder where B 
cells show an LCL-like phenotype. 
Attempts were next made to identify other tumour cells lines that could act as targets for 
WT1-specific T cells. Three out of four AML lines tested showed expression of WT1 
protein. These cell lines could act as targets in T cells assays to study the phenotype and 
functional abilities of WT1-specific T cells. The results also suggest that AML may be an 
appropriate setting in which to study WT1 T cell responses in-vivo. 
Due to the polymorphic nature of WT1, expression was also monitored by two RT-PCR 
assays. A commercial qRT-PCR assay designed to identify all known transcripts of WT1 
by amplify a region spanning exons 3 and 4 failed to identify WT1 mRNA in LCLs 
previously shown to be WT1 positive. A second RT-PCR assay designed across exons 7-
10 did detect WT1 mRNA in the same samples. 
Exons 3 and 4 are WT1 are thought to be conserved in all transcripts of WT1. However 
as the commercial qRT-PCR failed to detect WT1 in LCLs this suggests that some LCLs 
express a WT1 transcript with different exon usage or with mutations in one or both of 
exons 3 and 4. 
WT1 mRNA was detected in AML lines by the commercial qRT-PCR assay. However 
levels of mRNA did not correlate with protein expression observed by western blotting. 
Two possibilities exist here. First, it is possible that intrinsic differences within the AML 
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lines such as variations in rates of protein translation or degradation of WT1 account for 
these discrepancies. Second, western blotting may detected WT1 protein transcribed 
from an alternative WT1 mRNA transcripts that are not detected by the commercial 
qRT-PCR. 
Another final interesting finding from the analysis of WT1 expression in cells lines came 
from using the same RT-PCR assay employed by Kobayashi and colleagues. This assay 
detected WT1 mRNA in two myeloma lines that had tested negative for WT1 in all 
previous experiments. This suggests these lines express a highly different WT1 
transcript that is not detected by either antibody or the commercial qRT-PCR assay. 
Taken together these data suggest that no single current assay can identify all forms of 
WT1. This means that the expression of WT1 may have been underestimated in some 
studies. This only adds weight to the fact that WT1 is a promising tumour antigen and 
immune responses to WT1 could have therapeutic benefit in a wide range of tumour 
settings. However as WT1 appears to be even more polymorphic than previously 
understood, a wide range of WT1-specificities may be required to effectively target WT1 
positive tumours. 
3.12.2 WT1 and forskolin 
As described above, the processing and presentation of WT1 has not been well studied. 
Work on other nuclear-resident tumour antigens has shown that relocalisation of a 
protein to the cytoplasm can increase generation of MHC class II epitopes from that 
protein. WT1 is a nuclear-resident tumour antigen and previous reports have suggested 
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it can be relocalised to the cytoplasm using forskolin. The effect of forskolin on WT1 
localisation in EBV-positive cells was therefore determined.  
Studying cellular localisation in LCLs can be difficult as they contain very little 
cytoplasm. Nevertheless, the results clearly showed that in untreated cells WT1 
appeared to be entirely nuclear. Furthermore, levels of nuclear WT1 decreased 
following forskolin treatment. Although there could be several explanations for such a 
decrease, reduced transcription or translation for example, the fact that chloroquin 
inhibited this decrease was intriguing. Although no cytoplasmic localised WT1 protein 
was observed in cells treated with chloroquine and forskolin, this may be due to 
technical difficulties in defining the small cytoplasmic area in LCLs. It should also be 
noted that given the exquisite sensitivity of T cells, only a small amount of WT1 protein 
would need to be relocalised into the lysosomal pathway to render the WT1 positive cell 
sensitive to T cell attack. Taken together, these observations were consistent with the 
hypothesis that WT1 is relocalised to the cytoplasm by forskolin whereupon it is 
degraded by a chloroquine-sensitive degradative pathway.  
3.12.3 T cell responses to WT1 
Using the ex-vivo ELI-spot assay this study showed that the numbers of WT1-specific T 
cells was below the level of detection of this sensitive assay for both healthy donors and 
multiple myeloma patients. T cells specific for influenza A nuclear protein were readily 
detected in these assays confirming the sensitivity of the ELISPOT screen. WT1-specific 
T cells are therefore present at very low numbers in healthy donors and patients, which 
would make the generation of WT1-specific T cell clones more challenging than EBV-
specific clones that can be readily detected by the ELIspot assay. 
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Interestingly, T cell responses to the influenza antigen were lower in multiple myeloma 
patients compared to healthy donors. Impaired immunity has been observed previously 
in multiple myeloma patients although the mechanisms responsible are poorly 
understood (personal communication - Frank Mussai, the University of Birmingham, 
UK). 
Although others have reported the detection of WT1-specific T cells in ex-vivo assays, it 
is perhaps not surprising that WT1-specific T cells were not detected in healthy 
individuals in these experiments. Ex-vivo ELIspots are designed to detect effector 
memory T cells. These cells only develop after antigen induced clonal expansion of T 
cells. As a tumour antigen, WT1 should not be expressed in healthy individuals and 
therefore antigen exposure is unlikely to occur. 
The reasons for the lack of WT1 T cell responses in myeloma patients are unknown. 
Reports have shown that T cell responses to tumour antigens can vary drastically over 
time and this can be linked to disease burden (Goodyear et al., 2005). The status of 
multiple myeloma patients used in this study was unknown. It is possible that a low 
disease burden in all patients accounted for the lack of effector memory T cell responses 
to WT1. 
In an attempt to expand and detect low frequency and central memory T cells, a cultured 
ELIspot protocol was used. However, this method also failed to identify any WT1-
specific T cells in either healthy donors or multiple myeloma patients. Despite this 
finding, attempts were still made to isolate WT1-specific T cell clones, based on 
successful reports of their isolation by other groups. Methods used by these groups to 
generate WT1-specific clones were used but all were unsuccessful. Additional 
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methodologies were also explored, such as expressing WT1 in DCs via RNA 
electroporation. Again, all failed to generate WT1-specific T cell clones. It should be 
noted that these methods were able to reliably and reproducibly generate T cell clones 
specific to multiple control EBV antigens, demonstrating their effectiveness.  
In a final attempt to identify WT1-specific T cell clones, MHC-II tetramers specific for 
known WT1 epitopes were used. These studies confirmed previous findings and WT1-
specific T cells were not detected. Tetramer-associated magnetic enrichment was 
employed to increase the sensitivity of tetramer detection. Using TAME, a single 
population of T cells specific to the WT1 MHC-II tetramer ATL was detected. This 
population was only observed in a single donor. 
All attempts to culture these T cells were unsuccessful. The TAME protocol involves 
sorting cells at low temperatures in low nutrient conditions. It is possible that this 
protocol damaged the tetramer-specific cells resulting in the failure to culture these 
cells. However TAME has previously been used to culture other T cells so this is unlikely. 
WT1-specific T cell clones appear to be extremely difficult to produce, a finding 
confirmed by another worker in the field who found they do not proliferate for more 
than a few days and are often not of an effector phenotype (personal communication - 
Graham Pawlec, University of Tübingen, Germany). It is therefore more likely that an 
intrinsic property of these WT1-specific T cells was responsible for the failure to culture 
these cells. The few reports of WT1 clones in the literature therefore likely reflect the tip 
of an iceberg, with many more unsuccessful attempts remaining unpublished due to 
publication bias.  
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3.12.4 Future work 
As I was unable to generate WT1-specific T cells I was unable to study the antigen 
processing of WT1. Though inhibitor experiments suggested forskolin may cause WT1, 
to relocalise into the cytoplasm, this finding was not pursued because without WT1-
specific T cell clones it would be difficult to demonstrate increased epitope presentation. 
While WT1 levels increased in cells treated with chloroquine, this increase occurred 
only in the nucleus with no staining evident in the cytoplasm. One possible model to 
explain this result would be that WT1 is predominantly nuclear-localised but with a 
proportion of protein constantly shuttling between the nucleus and cytoplasm. If the 
cytoplasmic fraction was being continually degraded by autophagy, then this shuttling 
would result in overall lower levels of WT1 in the cell as a whole. Following an inhibition 
of autophagy mediated by chloroquine, levels of WT1 in the cytoplasm would increase 
and this protein could re-enter the nucleus. Further experiments using inhibitors of 
nuclear import or export, such as ivermectin or leptomycin B respectively in addition to 
inhibitors of autophagy would be needed to test this model. 
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4. THE EFFECT OF ROSCOVITINE ON EBNA1 ANTIGEN PROCESSING 
Failure to generate WT1-specific T cell clones meant I was unable to study the antigen 
processing and presentation of WT1 epitopes. I was therefore unable to test the 
hypothesis that relocalisation of WT1 may increase its presentation to CD4+ T cells. This 
hypothesis however, should be applicable to many nuclear resident antigenic proteins. I 
therefore turned to a different nuclear-localised tumour antigen to test the hypothesis 
that pharmacological alteration of subcellular localisation could affect the generation of 
MHC class II epitopes by autophagy.  
As previously discussed in chapter 1, the original observation that subcellular 
localisation is important for presentation of MHC class II epitopes came from the work of 
Leung et al. (Leung et al., 2010). EBNA1 contains many MHC class II epitopes, however 
EBV transformed B cells (LCLs) are poorly recognised by EBNA1-specific CD4+ T cells. 
Leung and colleagues showed that this poor recognition was at least in part due to 
EBNA1’s nuclear localisation. Expression of a mutant EBNA1 with a deleted nuclear 
localisation sequence created LCLs expressing EBNA1 in the cytoplasm, enhancing their 
recognition by EBNA1-specific CD4+ T cells. 
This work was of great importance in understanding the antigen processing of EBNA1 
and highlighted another mechanism by which EBV might evade the immune system. 
However Leung used mutation of the EBNA1 NLS in order to achieve the required 
relocalisation. As such, it is difficult to imagine how the findings could be directly 
applied in a clinical setting to improve immunological recognition of EBV infected cells. 
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Identifying a pharmacological compound to relocalise EBNA1 would allow this strategy 
to be exploited therapeutically to boost the recognition of tumour cells by CD4+ T cells.  
Coincidentally, whilst considering EBNA1 as an alternative experimental system, Kang et 
al. reported that Roscovitine, a clinically approved CDK inhibitor, was able to relocalise 
EBNA1 to the cytoplasm (Kang et al., 2011). I hypothesise that Roscovitine mediated 
relocalisation of EBNA1 should increase the recognition of EBV infected cells. If correct, 
Roscovitine could be used in a clinical setting to increase the recognition of EBV-
associated malignancies by the immune system. 
I therefore decided to investigate the effect of Roscovitine on EBNA1 and any 
subsequent effect on CD4+ T cell recognition of EBV infected cells. 
4.1 Localisation of EBNA1 in Roscovitine treated cells 
Previous experiments conducted by Kang et al., focussing on sub-cellular localisation of 
EBNA1 were carried out in HeLa cells. In these experiments EBNA1 was artificially 
overexpressed, treatment of these cells with Roscovitine was shown to cause 
cytoplasmic localisation of EBNA1 in the majority of cells. It is not known however if 
Roscovitine will have this same effect on naturally expressed EBNA1 in an EBV infected 
cell. I therefore investigated Roscovitine’s effect on the subcellular localisation of EBNA1 
in a LCL which naturally expresses nuclear EBNA1. 
LCLs were treated with Roscovitine for 72h, harvested and nuclear and cytoplasmic 
extracts were obtained from cells using a nuclear/cytoplasmic fractionation kit. The 
expression of EBNA1 in these fractions was then assessed by western blotting using the 
EBNA1-specific antibody IH-4. As a control for separation of fractions the expression of a 
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nuclear resident transcription factor Sp-1 and a cytoplasmic resident protein, α-tubulin 
were also measured. Figure 4.1 shows protein expression in nuclear and cytoplasmic 
fractions of control and Roscovitine treated LCLs. A band representing EBNA1 with a 
molecular weight of 75kD was detected in all samples. Untreated control cells contained 
high levels of EBNA1 in the nucleus as would be expected. A small quantity of EBNA1 
was detected in the cytoplasmic fraction of the untreated cells. This may be due to 
contamination of the fraction with a small number of nuclei or this may suggest that 
some EBNA1 is localised in the cytoplasm of LCLs. It should be noted that Sp-1, a control 
nuclear resident protein was only detected in the nuclear fraction suggesting separation 
of fractions was carried out successfully. 
Surprisingly, and contrary to the results of Kang et al., no change in EBNA1 expression 
was detected in either the nuclear or cytoplasmic fraction after treatment with 
Roscovitine. Roscovitine treated cells contained high levels of EBNA1 in the nucleus, 
comparable to that of the untreated control. Most importantly, only very small amounts 
of EBNA1 were detected in the cytoplasm and these levels were the same detected in the 
cytoplasm of untreated control cells. 
In summary, western blot analysis of nuclear and cytoplasmic fractions from LCLs 
suggested that Roscovitine did not affect the localisation of endogenous EBNA1. This 
result was unexpected given the report from by Kang et al. Since this report studied the 
effects of Roscovitine upon over-expressed EBNA1 I altered the experimental system to 
allow me to examine the effect of Roscovitine upon overexpressed EBNA1.  
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Figure 4.1 Expression of EBNA1 in nuclear and cytoplasmic fractions of 
Roscovitine treated LCLs 
Western blot analysis of EBNA1 protein expression in nuclear and 
cytoplasmic fractions of Roscovitine treated LCLs. LCLs were treated with 
50µM Roscovitine for 72h. Cells were then subjected to nuclear/cytoplasmic 
fractionation and protein expression assayed by western blot. EBNA1 protein 
was detected using the EBNA1-specific antibody IH-4. EBNA1 was detected in 
nuclear fractions of both control and Roscovitine treated cells. EBNA1 was 
detected in cytoplasmic fractions at very low level. Roscovitine had no effect 
on the level of EBNA1 in the cytoplasm of cells. Expression of Sp-1 protein 
served as control for nuclear fractionation and α-tubulin served as control for 
cytoplasmic fractionation. 
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HeLa cells were transfected with a vector expressing GFP tagged EBNA1. Cells were then 
treated with Roscovitine and the subcellular localisation of EBNA1 was studied by 
detection of GFP using fluorescent microscopy.  
As expected, control cells showed EBNA1-GFP coincided with DAPI staining. This 
suggests EBNA1 was totally confined to the nucleus in these cells. As with previous 
experiments conducted in LCLs but again contrary to the results of Kang et al, 
Roscovitine appeared to have no effect on the sub-cellular localisation of EBNA1-GFP in 
HeLa cells. Cells treated with Roscovitine showed very similar staining and fluorescent 
pattern to untreated cells with GFP signal being detected only in the nucleus. 
It may be possible that Roscovitine does relocalise EBNA1 but this may not be detected 
as EBNA1 may be rapidly degraded once in the cytoplasm. EBNA1 is known to be 
degraded by autophagy and cytoplasmic EBNA1 is more rapidly degraded than nuclear 
EBNA1 (personal communication – Graham Taylor, the University of Birmingham, UK). 
To investigate this possibility HeLa cells expressing EBNA1-GFP were again treated with 
Roscovitine, however the  cells were also treated with chloroquine to raise lysosomal pH 
thereby inhibiting any cathepsin-mediated degradation of EBNA1. Fluorescence 
microscopy of chloroquine treated cells is shown in Figure 4.2b. Chloroquine treated 
control cells, showed EBNA1-GFP only in the nucleus. When treated with Roscovitine no 
change in the subcellular localisation was observed, EBNA1-GFP signal was only 
observed in the nucleus. Taken together the results in Figure 4.1 and Figure 4.2 suggest 
strongly that Roscovitine is unable to relocalise either stable endogenous EBNA1 or 
over-expressed GFP-EBNA1. 
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Figure 4.2 Localisation of GFP-EBNA1 in Roscovitine treated cells 
Hela cells were transfected with EBNA1-GFP and localisation monitored by 
fluorescence microscopy. a. Control cells shows GFP fluorescence is 
concurrent with DAPI staining showing EBNA1 is present in the nucleus. 
50µM Roscovitine had no effect on EBNA1 localisation. b. 50mM chloroquine 
treated cells also showed the same pattern. Chloroquine alone and 
chloroquine with Roscovitine had no effect on EBNA1 localisation. EBNA1 
remained nuclear in all conditions. 
Chapter 4 - Results 
 
99 
 
4.2 Roscovitine reduces cellular proliferation 
As well as showing Roscovitine relocalises EBNA1, Kang et al. showed that Roscovitine 
can reduce the growth of LCLs, an effect that they ascribed to Roscovitine-mediated 
relocalisation of EBNA1. However, these experiments carried out in an LCL do not prove 
the effect of reduced proliferation was dependent upon EBNA1. As Roscovitine is a 
potent inhibitor of multiple cellular CDKs it is possible that the drug inhibits 
proliferation by inhibiting CDKs rather than by relocalising EBNA1. 
To investigate this possibility, the effect of Roscovitine upon proliferation of multiple 
cell lines both EBV-positive and EBV-negative was tested. Equal numbers of different 
cell lines were treated with increasing concentrations of Roscovitine for 96 h, after this 
time total cell numbers were counted, the results of which are displayed in Figure 4.3a. 
Two different LCLs were treated with Roscovitine, LCL 1 was transformed with B95.8 
strain of EBV. LCL 2 is transformed with a strain of EBV isolated from a Chinese donor. 
Control populations showed both cell lines had proliferated over 96 h. LCL 1 reached 
nearly 2x106 cells whereas LCL 2 proliferated faster and resulted in a total cell count of 4 
x106. Importantly as the concentration of Roscovitine increased total cell numbers 
decreased. In both cell lines 30μM Roscovitine inhibited proliferation completely and 
was toxic to the cells resulting in no live cells remaining after 96h. These results are 
similar to those of Kang et al. and suggest that Roscovitine inhibits proliferation in 
EBNA1 expressing cells. It is important to note however, that this result does not show 
that changes in growth are caused by relocalisation of EBNA1 or even that it is 
dependent upon EBV being present in the cell. 
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To test if this effect was EBNA1- and EBV-specific, the effect of Roscovitine on cellular 
proliferation was tested on two different cell lines derived from the same parent line 
with differing EBNA1 expression status. Akata BL is a Japanese Burkitt’s Lymphoma cell 
line infected with EBV and therefore expresses EBNA1. Akata a3 is a mutant strain of 
this cell line that has lost the EBV virion and therefore does not express EBNA1. 
Again equal amounts of both cell lines were treated with increasing concentrations of 
Roscovitine and after 96h total cell numbers were counted. When untreated the two 
lines proliferated to similar numbers. At low levels of Roscovitine (1-10µM) the drug 
seemed to have little effect on cell number. In fact, 5µM Roscovitine seemed to increase 
proliferation of the EBV-positive Akata line. At 20µM Roscovitine both EBV-positive and 
EBV-loss Akata showed a decrease in total cell number as observed for LCLs. 30µM 
Roscovitine was toxic and resulted in no live cells being detected after 96h. The key 
result was that the effects of Roscovitine were similar regardless of EBV status of the 
cells. 
To examine the effects of Roscovitine on cellular proliferation more closely, cells were 
again treated with Roscovitine and total cell numbers measured by WST assay. This 
assay measures cellular metabolic activity via oxidoreductase enzymes and can be used 
to determine the number of viable cells. This improved technique allowed a more 
accurate assay for cellular proliferation. Again the effect of Roscovitine on two LCLs and 
two Akata lines was measured. Figure 4.3b shows the results of this experiment. In LCLs 
concentrations of Roscovitine above 5µM reduced the proliferation of cells. In both EBV-
positive and EBV-negative Akata lines proliferation of cells was reduced by 20µM 
Roscovitine. 
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Figure 4.3 Roscovitine inhibits cellular proliferation in EBNA1 positive 
and EBNA1 negative cells 
Four different cell lines were treated with increasing concentrations of 
Roscovitine and the effect on proliferation of these lines was assayed. A. Cells 
were treated with Roscovitine for 96h, proliferation was assessed by 
counting cell numbers after this time. High doses of Roscovitine inhibited 
proliferation in all cell lines regardless of EBV/EBNA1 status. B. Again cells 
were treated with Roscovitine for 96h and proliferation was measured by 
colormetric WST assay. Again Roscovitine appeared to inhibit proliferation in 
all cell lines regardless of EBV/EBNA1 status 
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These data show that although Roscovitine is able to inhibit cellular proliferation, the 
effects were the same in all cell lines regardless of EBV status and EBNA1 expression. 
Taken together, these results suggested that decreases in cell proliferation caused by 
Roscovitine are not mediated through any effect the drug may have upon EBNA1. 
4.3 The effect of Roscovitine on the recognition of EBNA1 by CD4+ T cells 
Despite results suggesting Roscovitine does not relocalise EBNA1, it is possible that 
EBNA1 is being relocalised to the cytoplasm in small quantities that cannot be detected 
by the methods used so far. If even small amounts of EBNA1 were being relocalised to 
the cytoplasm this should result in an increase in the amount of EBNA1 entering the 
autophagic pathway. This should in turn increase the amount of EBNA1 MHC class II 
epitopes being produced. T cells have previously been shown to be very sensitive to 
small changes in epitope levels and should therefore be able to accurately detect any 
EBNA1 relocalisation and subsequent change in epitope display. 
Our laboratory has previously isolated multiple CD4+ T cells specific for a number of 
different epitopes within EBNA1. A summary of these T cells is shown in Table 4.1 and 
locations of the epitopes within the EBNA1 protein is shown in Figure 4.4. How EBNA1 
class II epitopes are generated differs between epitopes. The SNP epitope is known to be 
generated by an autophagy-dependent pathway whilst all other epitopes are generated 
in an autophagy-independent manner. I hypothesise that Roscovitine relocalisation of 
EBNA1 should alter the generation of EBNA1 MHC class II epitopes and this should be 
detected by an increase in LCL recognition by SNP-specific T cells. 
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Table 4.1 List of EBNA1-specific CD4+ T cells 
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Figure 4.4 EBNA1 MHC-II epitopes 
Representation of EBNA1 protein showing the position of MHC class II 
epitopes. 
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To test this hypothesis, LCLs were treated with Roscovitine and the levels of EBNA1 
MHC class II epitopes were measured in T cell recognition assays. Following their 
treatment with Roscovitine, the LCLs were washed and co-cultured with EBNA1-specific 
CD4+ T cells for 16h without the drug. After this time, supernatants were harvested from 
the LCL:T cell co-cultures and IFN-γ production by the T cells was measured by ELISA. 
Figure 4.5a shows the results of three different T cell recognition assays, using three 
EBNA1-specific CD4+ T cell clones against LCLs treated with increasing concentrations of 
Roscovitine. If Roscovitine were relocalising EBNA1 to the cytoplasm then there should 
be an increase in LCL recognition by the SNP specific T cells, resulting in increased levels 
of IFN-γ. This was not the case. Indeed, all three concentrations of Roscovitine tested 
decreased recognition of the LCLs by the SNP-specific T cells. In contrast, recognition of 
the same LCLs by T cells specific for VYG, an EBNA1 epitope that is not processed by 
autophagy showed the reverse effect; all doses of Roscovitine caused an increase in VYG 
T cell recognition of the LCL. DR1 positive LCLs were also treated with Roscovitine to 
study the effect on a third epitope TSL. LCL recognition by TSL T cells mirrored that of 
VYG; all doses of Roscovitine caused an increase in T cell recognition. 
To further investigate this effect, aliquots of LCLs were treated with Roscovitine on 
subsequent days. After 4 days cells were used as targets in T cell assays. Again IFN-γ 
production was measured by ELISA (Figure 4.5b). As seen previously SNP T cell 
recognition was decreased upon Roscovitine treatment. The decreased recognition was 
seen to occur as early as 24 hours, was increased at 48 hours and shown to be sustained 
out to 96h. The increase in recognition seen in VYG T cells took slightly longer to occur. 
An increase was seen at 48 and 72 h and again was sustained out to 96 h. 
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Figure 4.5 T cell recognition of Roscovitine treated LCLs 
LCLs were treated with Roscovitine and the levels of EBNA1 MHC class II 
epitopes were measured in T cell recognition assays. A. T cell recognition 
assays, using three EBNA1-specific CD4+ T cell clones show Roscovitine 
decreases presentation of SNP while increasing presentation of VYG and TSL. 
B. T cell recognition assays conducted on subsequent days. 
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As these results were unexpected a number of control experiments were carried out to 
further elucidate Roscovitine’s effect on EBNA1 and to investigate any further effect 
Roscovitine has upon antigen processing and presentation. Two experiments were 
conducted to determine if Roscovitine has any effect on levels of MHC Class II molecules 
at the surface of LCLs. Firstly Roscovitine treated LCLs were incubated with EBNA1 
Class II epitope peptides and subsequently used as targets in a T cell assay. Recognition 
of these peptide loaded LCLs is shown in Figure 4.6a. Recognition of LCL by two 
different EBNA1-specific T cells, SNP and VYG is shown and no effect of Roscovitine was 
observed at any dose. This suggests surface class II levels are unaffected by Roscovitine. 
Secondly LCLs were treated with increasing amounts of Roscovitine and stained for 
surface class II levels. Figure 4.6b shows flow cytometry data of LCLs surface stained 
with an antibody against the HLA-DR class II molecule . A very small decrease in DR 
staining was observed at 20µM but all other doses of Roscovitine (0-10 µM) appeared to 
have no effect on DR levels. These data suggest that Roscovitine is not having a general 
effect on class II processing but is specifically effecting the generation of EBNA1 class II 
epitopes. 
4.4 The effect of Roscovitine on autophagy 
The different results obtained for the autophagy-dependent epitope SNP and the 
autophagy-independent epitope VYG suggested that the effects of Roscovitine upon T 
cell recognition were nevertheless related to autophagy. Recognition of the autophagy-
dependent epitope SNP seemed to decrease whereas all other class II epitopes appeared 
to increase. 
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Figure 4.6 The effect of Roscovitine on surface MHC class II levels 
Experiment to measure the effect of Roscovitine on surface MHC class II 
levels. A. Roscovitine treated LCLs were loaded with MHC class II epitope 
peptides and T cell recognition measured. No effect of Roscovitine was 
detected by this method. B. Roscovitine treated LCLs were stained with an 
antibody specific to HLA-DR and analysed by flow cytometry. Roscovitine had 
no significant effect on the levels of surface HLA-DR. 
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This mirrors the effect seen when LCLs are treated with inhibitors of autophagy such as 
3-MA and wortmannin. It was therefore possible that Roscovitine was inhibiting 
autophagy causing decreased T cell recognition of the autophagy-dependent epitope. 
Measuring autophagy in cells presents a number of technical difficulties. A number of 
methods quantify certain autophagic elements such as autophagosomes or 
autolysosomes at any stage of the autophagic process. These methods often give an 
inaccurate measure of autophagy as they do not measure the activity of the complete 
autophagy pathway, a term known as autophagic flux. Autophagic activity includes not 
just the increased synthesis of autophagy proteins such as LC3 or an increase in the 
formation of autophagosomes, but, most importantly, flux through the entire system. 
Therefore accurate measurements of autophagy require the monitoring of autophagic 
substrates dynamically over time to verify that they have reached the lysosome and, 
when appropriate, are degraded. One of the most accurate and commonly used methods 
of determining autophagic flux is to measure the lipidation and degradation of LC3 by 
western blotting (Klionsky et al., 2012). The non-lipidated and lipidated forms of LC3 
are termed LC3-I and LC3-II respectively. To measure autophagic flux, a comparison 
must be made between the amount of LC3-II in the presence and absence of inhibitors 
that prevent degradation of the protein. Preventing the degradation of LC3-II allows the 
quantification of the amount of LC3-II transiting through the autophagic pathway. If flux 
is occurring, the amount of LC3-II will be higher in the presence of the inhibitor. Smaller 
increases in LC3-II in the presence of the inhibitor represent lower levels of flux and 
larger increases represent greater levels of flux. 
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To investigate the effect of Roscovitine on autophagy, LCLs were treated with increasing 
concentrations of Roscovitine for 72h. For the final 6h cells were cultured in the absence 
and presence of Bafilomycin A1, to raise lysosomal pH and inhibit the degradation of 
LC3-II. After this time the amounts of LC3-II in control and Roscovitine treated cells 
cultured in the absence and presence of Bafilomycin A1 was measured by western 
blotting using an antibody specific to both forms of LC3. Expression of binding 
immunoglobulin protein (BiP), a housekeeping protein was monitored as a control. The 
results of this experiment are shown in Figure 4.7. A band at 16kDA was detected in the 
presence of bafilomycin A1, this represents LC3-II. Levels of LC3-II in control cells in the 
absence of Bafilomycin A1 were very low, the band is barely detectable. Control cells 
cultured in the presence of Bafilomycin A1 showed high levels of LC3-II. This increase 
represents the level of autophagic flux in the cells. Cells treated with Roscovitine showed 
similar levels of LC3-II. Levels were always very low in the absence of Bafilomycin A1 
and increased in the presence of the inhibitor. The increase was comparable at all 
concentrations of Roscovitine. This suggests that levels of autophagic flux were the same 
in all conditions and therefore Roscovitine is not affecting autophagy. 
As previously mentioned, autophagy can be technically difficult to study. Measuring 
multiple autophagy parameters is often required to confirm results. Therefore a second 
method of measuring autophagy was used to confirm that Roscovitine does not affect 
autophagy. 2GL9 cells are a cell line derived from 293 cells engineered to express a GFP 
tagged LC3 protein.  
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Figure 4.7 Western blot of LC3-II in Roscovitine treated LCLs to measure 
autophagic flux. 
LCLs were treated with increasing concentrations of Roscovitine for 72h. For 
the final 6h, cells were cultured in the absence and presence of an inhibitor of 
lysosomal degradation, Bafilomycion A1 (100nM). Levels of LC3-II were then 
measured by western blot using an LC3-specific antibody. A band was 
detected at 16kDA representing LC3-II. Control cells showed an increase in 
the amount of LC3-II in the presence of Bafilomycin A1. The same level of 
increase was observed in cells treated with all concentrations of Roscovitine 
showing Roscovitine does not affect autophagic flux in LCLs. Expression of 
BiP protein was monitored as a control. 
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When autophagy is triggered in these cells autophagic vesicles form and LC3-GFP will 
cluster in the membranes of these vesicles. Autophagic vesicles can then be observed as 
bright GFP puncta within the cytoplasm of cells. A change in the number of puncta in a 
cell can be interpreted as a change in the level of autophagy. 
The effect of Roscovitine on the number of autophagic vesicles within a cell was 
determined. Two separate experiments were conducted; the first to determine if 
Roscovitine could upregulate autophagy in resting cells and a second to determine 
whether Roscovitine could inhibit autophagy in cells where levels of autophagy were 
high. In the first experiment a control population of cells was grown in full growth media 
to determine the baseline level of autophagy in a cell. A second population, grown in full 
media was treated with 20µM Roscovitine to determine whether Roscovitine could 
trigger autophagy. As a control for activation of autophagy a third population was 
cultured in EBSS, a simple salt solution containing no amino acids or growth serum. This 
starvation should increase autophagy and cause an increase in the number of autophagic 
vesicle. Representative images are shown in Figure 4.8a. Control and Roscovitine treated 
cells show few puncta whereas puncta can clearly be seen in starved cells, one of which 
is marked by a white arrow. Total puncta per cell were counted in 20 fields from each 
condition and the results are shown in Figure 4.8b. Control populations showed a mean 
of less than 1 visible puncta per cell. When cells grown in full media were treated with 
Roscovitine no significant increase in puncta compared to untreated cells was observed. 
When starved, as suspected, numbers of visible puncta per cell increased significantly to 
over 10 puncta per cell. This suggests Roscovitine does not increase autophagy in a 
resting cell. 
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Figure 4.8 Quantification of LC3-GFP puncta to measure autophagy 
induction in Roscovitine treated cells 
The effect of Roscovitine on numbers of LC3-GFP puncta were measured in 
2GL9 cells. A. Representative images (a puncta is marked by the white 
arrow). B. Puncta were counted in cells. Starvation was able to increase the 
number of puncta. No effect of Roscovitine was observed. Statistical 
significance was determined by ANOVA and subsequent bonferroni multiple 
comparison analysis (****P< .0001). 
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To determine whether Roscovitine could inhibit autophagy in cells where levels of 
autophagy were high, a similar second experiment was conducted.  
Again a control population of cells was grown in full growth media. Three populations of 
cells were cultured in EBSS for 4 h to induce autophagy. One starved population was 
untreated as a control. Another population of cells was treated with Roscovitine and as a 
control for autophagic inhibition, a third starved population of cells was treated with 
5µM 3-MA. Figure 4.9a shows representative images and the results from counts in 
multiple fields are shown in Figure 4.9b. The results show that starvation significantly 
increased the number of puncta in the cells. As would be expected, 3-MA inhibited 
autophagy and caused a decrease in the number of puncta visible. Cells treated with 
Roscovitine had high levels of puncta in the cells comparable to those of starved 
untreated cells. This result shows that Roscovitine does not decrease autophagy. When 
taken together with the results of Figure 4.8, this suggests that Roscovitine does not 
affect autophagy in 2GL9 cells, a result that accords with the earlier data obtained by 
measuring LC3 flux. 
While both autophagy assays clearly showed that Roscovitine was not decreasing 
autophagy in cells, these results directly contradicted the results of the T cell assays that 
showed a decrease in the generation of an autophagy-dependent epitope. Therefore a 
third method of determining levels of autophagy in cells was used. As discussed in 
chapter 1, p62 is an adaptor protein, selectively degraded by autophagy. Therefore p62 
levels can be used to determine the amount of autophagy in a cell. Decreases in p62 can 
be interpreted as an increase in autophagy.  
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Figure 4.9 Quantification of LC3-GFP puncta to measure autophagy 
inhibition in Roscovitine treated cells 
The effect of Roscovitine on numbers of LC3-GFP puncta were measured in 
2GL9 cells. A. Representative images (puncta are marked by the white 
arrows). B. Puncta were counted in cells. Starvation was able to increase the 
number of puncta an effect which was ablated by 10mM 3-MA. No effect of 
Roscovitine was observed. Statistical significance was determined by ANOVA 
and subsequent bonferroni multiple comparison analysis (****P< .0001) 
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LCLs were treated with increasing amounts of Roscovitine and the amount of p62 in 
cells was then determined by western blot using a p62-specific antibody. Figure 4.10 
shows the results of this western blot. Expression of p62 was detected in control cells. 
Remarkably, as the concentration of Roscovitine increased the level of p62 protein 
decreased.  
The result of the p62 assay could be interpreted as Roscovitine decreasing the 
autophagy activity of cells. However, this conclusion conflicts with the results obtained 
by measuring LC3 flux and GFP-LC3 puncta that both showed Roscovitine did not affect 
autophagy. 
4.5 Mechanism of Roscovitine-mediated reduction in p62 protein 
Although data clearly showed that p62 levels were decreased upon Roscovitine 
treatment, it was not known how Roscovitine caused this reduction. It is possible that an 
increase in autophagy was responsible, although the earlier experiments showed 
Roscovitine did not affect autophagy. It is therefore possible that degradation by an 
alternative pathway, such as proteasomal-mediated degradation, was causing the 
reduction in p62. A third possibility was that decreased levels of p62 reflected decreased 
synthesis of p62. I conducted experiments to investigate all three possibilities. 
To quantify p62 degradation by autophagy, in the presence or absence of Roscovitine, 
LCLs were treated with two different inhibitors of autophagic/lysosomal degradation, 
Bafilomycin A1 or chloroquine. Western blots were carried out and levels of p62 
determined. The results of this are shown in Figure 4.11.  
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Figure 4.10 p62 expression in Roscovitine treated LCLs 
LCLs were treated with increasing amounts of Roscovitine and the amount of 
p62 in cells was then determined by western blot using a p62-specific 
antibody. Expression of p62 was detected in control cells. As the 
concentration of Roscovitine increased the level of p62 protein decreased. 
The expression of BiP protein was monitored as a control. 
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In control populations of cells, both bafilomycin and chloroquine caused an increase in 
p62 levels compared to untreated controls in lane one. This suggests that p62 is indeed 
being degraded by autophagy under control conditions. Cells were also treated with 
Roscovitine prior to treatment with inhibitors to determine whether Roscovitine can 
inhibit autophagic degradation of p62. Again both bafilomycin and chloroquine 
treatment of these cells caused an increase in p62 levels suggesting that even with 
Roscovitine treatment, p62 is degraded by autophagy. It is however important to 
compare control and Roscovitine treated cells directly. In the absence of inhibitors 
Roscovitine causes a decrease in p62 protein as seen previously. But in the presence of 
bafilomycin and chloroquine this decrease is still observed. This suggests that even 
when autophagy is inhibited Roscovitine still causes a decrease in the levels of p62. 
It is possible that the decrease in p62 is due to degradation by another pathway. To 
determine this, cells were treated with a proteosome inhibitor Bortezomib, results of 
which are shown in Figure 4.12a. Again western blots were carried out and p62 levels 
determined. In control population where proteosomal degradation was not inhibited 
p62 levels decreased upon Roscovitine treatment. When LCLs were treated with 
Bortezomib the amount of p62 protein was increased. This suggests that p62 is 
degraded by the proteosomal pathway. In the presence of Bortezomib, Roscovitine still 
caused a decrease in p62 levels. This shows that the decrease in p62 caused occurs when 
proteosomal degradation is inactivated and therefore suggests proteosomal degradation 
is not a significant pathway in Roscovitine-mediated reduction of p62 levels. These 
results rule out the possibility that the decrease in p62 being caused by Roscovitine is 
due to changes in levels of p62 degradation.  
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Figure 4.11 p62 expression in the absence and presence of inhibitors of 
autophagic degradation in Roscovitine treated LCLs 
To quantify p62 degradation by autophagy, in the presence or absence of 
Roscovitine, LCLs were treated with two different inhibitors of 
autophagic/lysosomal degradation, Bafilomycin A1 (100nM) or chloroquine 
(50mM). P62 protein was detected by p62-specific antibody. Results show 
that levels of p62 protein are reduced by Roscovitine in the absence and 
presence of inhibitors. 
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Therefore I hypothesised that Roscovitine may be decreasing levels of p62 by inhibiting 
de novo synthesis of the protein. 
To determine whether this was correct cells were treated with the protein synthesis 
inhibitor anisomycin. Again western blots were carried out and p62 levels determined. 
Figure 4.12b shows the results of this experiment. In control populations where protein 
synthesis was not inhibited, p62 levels decreased upon Roscovitine treatment. In the 
presence of anismoycin however Roscovitine had no effect on levels of p62 protein. This 
shows that when de novo protein synthesis is inhibited by anisomycin, Roscovitine is 
unable to reduce levels of p62 protein. This means that Roscovitine mediated reduction 
of p62 protein seen in control conditions is due to Roscovitine inhibiting synthesis of 
p62. 
Roscovitine is a known RNA pol II inhibitor. I therefore hypothesize that Roscovitine 
reduces levels of p62 protein by inhibiting the synthesis of p62 mRNA. To determine if 
this is the case, levels of p62 mRNA transcript were measured by qRTPCR. Cells were 
treated with increasing amounts of Roscovitine. mRNA was then extracted from the cells 
and levels of p62 mRNA transcript were determined. As is clearly shown in Figure 4.13 
and as would be expected from previous experiments, concentrations of Roscovitine 
above 1.0µM and up to 100µM all caused a decrease in p62 mRNA expression. This 
proves that Roscovitine mediated reduction of p62 protein is due to reduced synthesis 
of p62 and not related to autophagic degradation. 
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Figure 4.12 p62 expression in the absence and presence of proteosome 
and protein synthesis inhibitors in Roscovitine treated LCLs 
The effect of Roscovitine on levels of p62 was monitored in LCLs in the 
absence and presence of inhibitors of proteasomal degradation and protein 
synthesis. A. Roscovitine caused a decrease in p62 protein in the absence and 
presence of Bortezomib B. Roscovitine mediated decrease in p62 protein was 
ablated by anisomycin. In the presence of anisomycin Roscovitine did not 
affect p62 protein levels. BiP protein expression was measured as a control.  
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Figure 4.13 Expression of p62 mRNA in Roscovitine treated LCLs 
Cells were treated with increasing amounts of Roscovitine and levels of p62 
mRNA transcript were measure by qRT-PCR. Expression was compared to 
that of the the housekeeping gene GAPDH. Increasing concentrations of 
Roscovitine caused decrease in p62 mRNA expression. 
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4.6  The effect of Roscovitine on other short-lived, autophagy related proteins 
RNA pol II is required for synthesis of all mRNA. Roscovitine inhibits RNA pol II causing 
a decrease in the short lived protein p62. I therefore hypothesise that Roscovitine will 
also cause a decrease in other short lived proteins, which could include other autophagy 
adaptor proteins. 
To test this hypothesis the effect of Roscovitine on a number of short lived proteins was 
tested. These included the autophagy adaptors p62, CALCOCO2, NBR1 and OPTN. A fifth 
autophagy associated protein Bag 3 was also included. Bag-3 is a chaperone that 
functions with p62 to degrade ubiquitinated substrates (Carra et al., 2008; Gamerdinger 
et al., 2009). 
LCLs were treated with increasing concentrations of Roscovitine. Western blots were 
carried out on all samples and blots were then probed with antibodies against a range of 
autophagy adaptors. Figure 4.14 shows the results of this experiment. The autophagy 
adaptors p62, CALCOCO2, NBR1, OPTN and BAG-3 were all detected in control cells. As 
previously seen, increasing concentrations of Roscovitine decreased the amount of p62 
protein expressed. This result was replicated across all proteins assayed. Roscovitine 
causes a decrease in the amount of all five autophagy adaptor proteins. 
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Figure 4.14 Protein expression of autophagy adaptors in Roscovitine 
treated LCLs 
Expression of autophagy associated proteins was measured in Roscovitine 
treated LCLs with antibodies specific to p62, CALCOCO2, NBR1, OPTN and 
BAG-3. Expression of BiP was monitored as a control. Roscovitine caused a 
decrease in all proteins. 
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4.7 Discussion 
Failure to generate WT1-specific T cell clones in the previous chapter led me to 
investigate the relocalisation hypothesis in an alternative system. Previous work by 
Leung and colleagues showed that a mutation of EBNA1 that relocalised this protein 
from the nucleus into the cytoplasm could increase the presentation of MHC class II 
epitopes from the protein. Although this mutation was deliberate, an example of such 
relocalisation occurring naturally has been reported. Enhanced CD4+ T-cell recognition 
of a melanoma cell line was shown to result from a mutation in the target antigen’s NLS 
(Wang R. F. et al., 1999). Although cancer cells have high rates of mutation, such 
fortuitous events will occur only rarely. A pharmacological method to relocalise EBNA1 
into the nucleus was therefore sought. This literature search coincided with the 
publication of a paper reporting Roscovitine relocalised EBNA1 into the cytoplasm. The 
effects of Roscovitine-mediated relocalisation of EBNA1 upon  T cell recognition were 
examined in this study. In contrast to WT1, the majority of healthy EBV-positive donors 
have readily detectable EBNA1-specific T cell responses in their blood (Leen et al., 2001; 
Munz et al., 2000). Thus EBNA1 was likely to be a more amenable system in which to 
explore my hypothesis that pharmacological modification of subcellular localisation 
could enhance the presentation of MHC class II epitopes.  
4.7.1 Relocalisation of EBNA1 
The effect of Roscovitine on localisation of endogenous EBNA1 was tested by nuclear 
cytoplasmic fractionation. Results showed that Roscovitine was unable to relocalise 
EBNA1 in LCLs. At first this result appeared to contradict to the report of Kang et al. but 
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this fundamental difference may have been due to the different experimental systems 
used. 
Kang et al. suggested that Roscovitine’s mechanism of action was through reduced 
phosphorylation of the EBNA1 nuclear localisation sequence leading to reduced EBNA1 
import into the nucleus. In contrast to my experiments which used the more 
physiologically relevant approach of studying endogenously-expressed EBNA1, Kang et 
al. conducted their experiments using over-expressed EBNA1 in HeLa cells. Accordingly, 
there will be high-level ongoing transcription, translation and then nuclear import of de 
novo synthesised protein. Here Roscovitine’s effects on NLS phosphorylation and 
nuclear import would be substantial. In contrast, in cells that endogenously express 
EBNA1, most EBNA1 will already be in the nucleus, where it will be retained by binding 
to chromatin. A much smaller level of de novo EBNA1 synthesis will be occurring and 
any interference of nuclear import by Roscovitine will affect a much smaller amount of 
protein. Overall, my results suggest that Roscovitine may inhibit nuclear import of newly 
synthesised EBNA1 but may not actually relocalise a pre-existing pool of nuclear EBNA1 
to the cytoplasm.  
Levels of EBNA1 synthesis are very low in LCLs as the protein’s Gly-Ala repeat inhibits 
its translation by different but complementary mechanisms. Consequently, only a small 
amount of EBNA1 will be present in the cytoplasm to be retained  by Roscovitine-
mediated effects on NLS phosphorylation. This would suggest that Roscovitine would 
not have a detectable effect on endogenous EBNA1; this was indeed shown to be true. 
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I repeated my experiments using over-expressed EBNA1 but again saw no effect of 
Roscovitine. These results  directly contradict those of Kang et al. The reason why no 
effect of Roscovitine was observed in these experiments is not known.  
4.7.2 Roscovitine and EBNA1 MHC class II processing 
Despite the negative results of the previous experiments the effect of Roscovitine on the 
MHC class II processing of EBNA1 was explored. These experiments produced 
unexpected but none the less intriguing results. My original hypothesis was that by 
relocalising EBNA1 into the cytoplasm, Roscovitine would increase the presentation of 
EBNA1 MHC class II epitopes in an autophagy-dependent manner. My biochemical data 
suggested that Roscovitine did not relocalise EBNA1 and would therefore have no effect. 
However, my experimental data showed Roscovitine decreased the generation of an 
autophagy-dependent MHC class II epitope from EBNA1, a result seen previously using 
the autophagy inhibitor 3-MA. 
4.7.3 Roscovitine, autophagy and p62 
The decreased presentation of an autophagy-dependent epitope by Roscovitine 
suggested that, like 3-MA, Roscovitine may have been inhibiting autophagy. To examine 
this theory the effect of Roscovitine on autophagy was examined using two standard and 
widely-used approaches: measuring autophagic flux by LC3 blotting and quantifying 
autophagosome numbers in cells stably-expressing an LC3-GFP fusion protein (Klionsky 
et al., 2012). Surprisingly, these experiments suggested Roscovitine had no effect on 
levels of autophagy. As these results directly conflicted with the results of the T cell 
assays a third method of studying autophagy was used. P62 is an adaptor protein that is 
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degraded by autophagy; measuring changes in cellular p62 levels is again a widely used 
technique to measure autophagy activity (Klionsky et al., 2012). Upon treatment with 
Roscovitine the amount of p62 protein in LCLs decreased. Taken by itself, this result 
would be interpreted as an increase in the levels of autophagy. However, given the 
contradictory results from the three assays I decided to explore further the mechanism 
of how Roscovitine decreased p62 levels without apparently altering autophagy activity.  
The Roscovitine-mediated reduction in p62 I observed could have been caused by i) 
increased autophagic degradation of p62 ii) increase proteosomal degradation of p62 or 
iii) reduced protein synthesis of p62. Inhibitor studies showed that the Roscovitine-
mediated decrease of p62 levels was not affected by inhibition of autophagy- or 
proteosome-mediated degradation. However, following inhibition of protein synthesis 
Roscovitine no longer decreased p62 levels. 
As protein synthesis inhibition ablated Roscovitine’s effect on p62, I hypothesised that 
Roscovitine was inhibiting synthesis of p62 mRNA. In support of this hypothesis is the 
fact that Roscovitine is a known RNA pol II inhibitor. This theory was confirmed by 
assessing levels of p62 mRNA by qRT-PCR.  
In total, the data discussed above show Roscovitine does not affect autophagy despite 
the reduction in p62. This clearly demonstrates that measuring a single component may 
not give an accurate measurement of autophagy activity and that autophagy flux should 
always be measured by assessing the change in these components over time in the 
absence and presence of inhibitors of their degradation. 
Chapter 4 - Results 
 
129 
 
4.7.4 Roscovitine and autophagy adaptors 
In light of the knowledge that Roscovitine inhibited synthesis of p62 the effect of 
Roscovitine on the expression of other autophagy adaptors was measured. The 
expression of all tested proteins was shown to be decreased by Roscovitine. 
The fact that Roscovitine decreased levels of p62 without decreasing autophagy per se 
presented a possible explanation for the results observed for Roscovitine treated LCLs in 
the T cell assays. If EBNA1 was dependent upon an autophagy adaptor such as p62 to be 
degraded by autophagy, then decreasing cellular levels of the adaptors would decrease 
the generation of epitopes without affecting autophagy. Several autophagy adaptor 
proteins were tested and levels of all were decreased following Roscovitine treatment. 
Although pathogens such as Salmonella have been shown to be targeted for autophagic 
degradation by various adaptor proteins no viral protein has before been shown to be 
processed in this way and there are no examples of MHC class II epitopes being 
generated via autophagy-adaptor mediated autophagy. If EBNA1 was indeed being 
degraded via autophagy adaptor proteins then it would represent the first example of a 
viral antigen being degraded by this pathway. 
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5. PROCESSING OF EBNA1 VIA AUTOPHAGY ADAPTOR PROTEINS 
The data presented in Chapter 4 showed that Roscovitine specifically decreased the 
presentation of an MHC class II, autophagy-dependent epitope from EBNA1. This 
decrease occurred despite Roscovitine having no effect on levels of autophagy. However, 
Roscovitine does inhibit the expression of multiple autophagy adaptors. I hypothesised 
that autophagic degradation of EBNA1 is mediated through one or more of these 
autophagy adaptors and that Roscovitine-mediated decreases in levels of these proteins 
inhibited the generation of the autophagy-dependent MHC class II epitope, SNP. 
To test this theory expression of individual autophagy adaptors and other autophagy 
related proteins were inhibited and the effect on the presentation of the SNP epitope as 
well other autophagy-independent epitopes was measured 
5.1 siRNA Knock down of p62 
I began this work by testing whether a previously published siRNA sequence designed to 
target p62 would be able to Knock down the protein in LCLs. LCLs are a notoriously 
difficult cell line to transfect and standard siRNA/lipofectamine protocols are usually 
ineffective. High doses of siRNA (5µM) were therefore electroporated into cells using a 
previously optimised protocol. Following transfection, samples were harvested every 
24h for four days. Levels of p62 protein within cells were then determined by western 
blot using a p62-specific antibody. BiP protein was again measured as a control using a 
BiP-specific antibody. Figure 5.1 shows the amount of p62 protein in control and siRNA 
treated cells over 96h and a band representing p62 was detected in all samples. p62-
specific siRNA caused a substantial reduction in the level of p62 protein at 24, 48 and 
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72h. The effect of the siRNA was reduced at 96h but a small decrease in p62 levels could 
still be observed. This shows that electroporation of this siRNA is able to Knock down 
p62 in LCLs. 
5.2 Overexpression of EBNA1 using a doxycycline regulated system  
As siRNA only causes a transient decrease in protein levels, the effect of MHC class II 
epitope generation can only be studied over a short period of time. This creates a 
problem as pre-existing MHC class II peptide complexes will be present on the surface of 
LCLs before siRNA transfection. MHC class II complexes are relatively stable and can be 
maintained at the cell surface for multiple days (Mackay et al., 2009). These pre-existing 
complexes may make it difficult to study any changes in the production of new 
complexes, over a short period of time. It is possible to remove these complexes with 
acid treatment; however results are unreliable and vary between epitopes. 
I therefore derived a system whereby EBNA1 could be over-expressed in LCLs causing a 
readily detectable increase in the generation of MHC class II epitopes over a short period 
of time. Knock down of autophagy adaptors could then be carried out to see if this would 
interfere with the increase in epitope generation. 
To this end, I used a recently developed episomal vector, pRTS1 which is stably 
maintained in silent form in LCLs but from which antigen expression can be induced to 
high levels by doxocycline (dox) (Leung et al., 2010). 
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Figure 5.1 Expression of p62 protein in LCLs following siRNA treatment 
Western blot analysis of p62 protein expression in siRNA treated LCLs. P62 
protein was detected using a p62-specific monoclonal antibody. siRNA 
treatment reduced levels of p62 protein at all time points compared to 
untreated cells at the same time point. Expression of BiP protein was used as 
a loading control 
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Figure 5.2a shows expression of this construct in LCLs. Full length EBNA1 is detected in 
both the control empty vector and the construct encoding a modified EBNA1 protein 
with a deleted Glycine/Alanine region (E1ΔGA) but not in the EBV-negative line DG75. 
Dox induction of E1ΔGA induces high levels of the smaller-sized EBNA1 protein. 
To test the effect on generation of MHC class II epitopes, control vector and E1ΔGA LCLs 
were again dox induced for 72h and used as targets in T cell assays using a CD4+ T cell 
clone specific for the EBNA1 epitope SNP. IFN-γ release by T cells was assayed by ELISA. 
Recognition was compared to an uninduced control. Figure 5.2b shows results of this 
experiment. As expected T cells were able to recognise control LCLs expressing normal 
endogenous levels of EBNA1. This recognition was increased upon over-expression of 
E1ΔGA triggered by dox addition. 
5.3 p62 siRNA Knock down and the effect on EBNA1 MHC class II epitopes 
The dox regulated system provides an excellent model in which to study MHC-II epitope 
generation over short periods of time. Therefore this system was used to study the effect 
of p62 Knock down upon generation of such epitopes.  
LCLs stably expressing the E1ΔGA vector were transfected with p62 siRNA or a control 
siRNA targeting GFP. Cells were then incubated for 24h to allow intracellular protein 
levels of p62 to decrease. Doxycycline was then added to the media to induce expression 
of E1ΔGA and cells incubated for a further 72h.  
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Figure 5.2 Overexpression of EBNA1 ΔGA and the effect of T cell 
recognition 
Analysis of overexpression of EBNA1 ΔGA. A. EBNA1 protein was detected 
using the EBNA1-specific antibody IH-4. EBNA1 was detected in control and 
dox induced LCLs. E1 ΔGA was detected in dox induced LCLs. Expression of 
actin protein was used as a loading control (figure adapted from Leung et al., 
2010). b.  Over expression of E1 ΔGA caused an increase in LCL recognition 
by SNP-specific CD4+ T cells. 
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An aliquot of cells was harvested for western blot analysis to determine efficacy of 
Knock down. The remaining cells were used as targets in a T cell assays using the 
EBNA1-specific CD4+ T cell clone SNP. 
Figure 5.3a shows that p62 levels were reduced by siRNA transfection, note the blot only 
shows p62 levels at the 96h time point at which cells were used in T cell assays. 
Expression of p62 would have been lower at earlier time points as shown in Figure 5.1. 
Figure 5.3b shows recognition of LCLs by SNP-specific T cells. As seen previously, T cells 
were able to recognise control LCLs and this recognition was increased upon over-
expression of E1ΔGA, triggered by dox addition. SNP T cell recognition of LCLs 
transfected with p62 siRNA and treated with dox is comparable to that of LCLs 
transfected with control siRNA and treated with dox. This result suggests that reduction 
of p62 protein in antigen presenting cells using siRNA has no effect on the generation of 
the SNP epitope and subsequently recognition by SNP-specific T cells is unchanged. 
5.4 siRNA Knock down of alternative autophagy related proteins and the effect 
on EBNA1 MHC class II epitopes  
Though p62 was the first identified and most well studied autophagy adaptor, other 
proteins have also been shown to have similar functions to p62, as previously discussed. 
The previous result ruled out a role for p62 in the processing of EBNA1 but showed the 
combination of siRNA and EBNA1 over-expression provides a versatile system for 
measuring changes in the generation of class II epitopes. I therefore decided to repeat 
these experiments using siRNAs targeting the other autophagy adaptors CALCOCO2, 
NBR1 and OPTN as well as the autophagy chaperone BAG-3.  
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Figure 5.3 siRNA Knock down of p62 in LCLs and subsequent T cell 
recognition 
Analysis of p62 siRNA Knock down. A. P62 protein was detected using a p62-
specific antibody. P62 was detected in control cells , levels of protein were 
reduced by siRNA treatment. b.  Over expression of E1 ΔGA caused a increase 
in LCL recognition by SNP-specific CD4+ T cells. P62 siRNA had no effect on 
this recognition. 
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A fifth autophagy related protein was also included in these experiments. ALFY, a large 
phospoinositide-binding protein is recruited to p62 bodies as well as nuclear 
promyleocytic leukemia (PML) bodies and is required for the degradation of such 
aggregates by autophagy (Clausen et al., 2010; Simonsen et al., 2004). ALFY may 
therefore also be required for the generation of autophagy-dependent MHC class II 
epitopes. 
siRNAs designed to target five different autophagy adaptors or chaperones were 
identified from the literature. Again these had been used in easily transfectable lines. To 
test the potency of these siRNAs in LCLs, cells were transfected with siRNA targeting a 
single autophagy adaptor or siRNA targeting GFP as a control. After electroporation, 
aliquots of cells were again harvested every 24h for four days. Knock down of the 
different proteins was assessed by western blotting using antibodies specific to each 
autophagy protein.  
Figure 5.4 shows the expression of four different autophagy related proteins treated 
with control or target siRNA over 96h using antibodies specific for the proteins. 
Expression of BiP or actin was also measured as a control. Expression of the three 
autophagy adaptors CALCOCO2, NBR1 and OPTN was decreased by specific siRNA 
treatment at all time points. It should be noted that the levels of these proteins in GFP 
siRNA treated LCLs decreased over 96h. This may be due to an increase in autophagy, 
due to decreasing nutrient availability over this time. This did not seem to reduce any 
effect of target siRNAs. 
Unlike other siRNAs, BAG-3 siRNA did not seem to reduce levels of BAG-3 protein. 
Further experiments were conducted using alternative siRNA sequences or higher doses 
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of siRNA but these were also unsuccessful in reducing BAG-3 levels (data not shown). All 
BAG-3 siRNAs used had previously been proven to Knock down BAG3 in other cell lines, 
the failure of these experiments highlights the difficulty of knocking down proteins in 
LCLs.  
A fifth siRNA specific to the protein ALFY was also tested for its ability to Knock down 
protein in LCLs. ALFY is a high molecular weight protein and all attempts to resolve 
proteins of this molecular weight were unsuccessful and therefore Knock down of ALFY 
could not be confirmed. 
Having demonstrated that siRNA could Knock down four autophagy adaptors in LCLs I 
next investigated the effect of this Knock down on T cell recognition. siRNA against BAG-
3 and ALFY were included in these experiments despite Knock down not being 
confirmed in these cells: identification of an effect on T cell recognition would have led 
me to focus on these proteins again. 
The design of the experiments was the same used previously for studying p62. LCLs 
were transfected with an siRNA targeting one of the six autophagy related proteins. Cells 
were incubated for 24h to allow protein levels of autophagy adaptors to decrease. After 
this time doxycycline was added to the media and cells incubated for a further 72h to 
allow processing and presentation of over-expressed E1ΔGA. An aliquot of cells was 
harvested for western blot analysis to confirm Knock down. The remaining cells were 
used as targets in T cell assays using SNP-specific CD4+ T cells. 
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Figure 5.4 Expression of autophagy related proteins in LCLs following 
siRNA treatment 
Western blot analysis of autophagy protein expression in siRNA treated LCLs. 
Protein was detected using specific monoclonal antibodies. siRNA treatment 
reduced levels of proteins at all time points compared to untreated cells at 
the same time point (with the exception of BAG3 siRNA which did not affect 
levels of BAG3 protein. Expression of BiP or actin protein was used as a 
loading control 
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Figure 5.5 shows the results of this experiment. Again as expected, T cell recognition of 
control siRNA transfected cells increased upon the addition of dox. As seen earlier, p62 
siRNA had no effect on LCL recognition. No effect of ALFY or BAG-3 siRNA was observed 
either. However Knock down of three other autophagy adaptors did reduce T cell 
recognition. Recognition of CALCOCO2, NBR1 and OPTN siRNA treated LCLs were all 
below that of GFP siRNA treated cells. CALCOCO2 and OPTN showed similar levels of 
decrease whereas NBR1 showed the greatest decrease, completely ablating any increase 
in recognition caused by dox addition. NBR1 siRNA reduced recognition to below the 
level of uninduced cells. 
To confirm this effect was specific to the generation of the autophagy-dependent epitope 
SNP, the same LCLs were used in parallel T cell assays using CD4+ T cells specific to the 
autophagy-independent MHC class II epitope VYG. Figure 5.5b shows siRNA Knock down 
had no effect on presentation of the VYG epitope showing the previous effect was 
specific to the SNP epitope and not a general effect on class II processing. 
5.5 Presentation of endogenous EBNA1 following siRNA Knock down of 
autophagy adaptors  
The previous experiments suggest the three autophagy adaptors, CALCOCO2, NBR1 and 
OPTN are required for recognition of over-expressed EBNA1. Whether they are required 
for recognition of endogenously expressed EBNA1 is unknown. As previously mentioned 
the presence of pre-existing MHC-II peptide complexes on the surface of LCLs could 
mask a change in the generation of new complexes. This make changes in recognition of 
normal levels of endogenous protein more difficult to detect.  
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Figure 5.5 T cell recognition of LCLs following siRNA Knock down of 
autophagy-related proteins 
Analysis of autophagy protein siRNA Knock down. A. Over expression of E1 
ΔGA caused an increase in LCL recognition by SNP-specific CD4+ T cells. 
siRNA specific to CALCOCO2, NBR1 and OPTN reduced this T cell recognition. 
Statistical significance was determined by ANOVA and subsequent bonferroni 
multiple comparison analysis (*P< .05; ***P<.001) compared with control 
siRNA + doxycycline. B. Over expression of E1 ΔGA caused an increase in LCL 
recognition by VYG-specific CD4+ T cells. siRNA had no effect on this 
recognition.  
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Despite these possible difficulties, experiments were conducted on LCLs to determine 
the effect of protein Knock down by siRNA on T cell recognition of endogenous EBNA1. 
LCLs were transduced with siRNA and incubated for 96 h. After this time an aliquot of 
cells was removed for western blot analysis to determine level of Knock down. The 
remaining cells were used as targets in T cells assays using SNP-specific T cells. Figure 
5.6a shows a typical example of one such experiment. Figure 5.6b shows results of 
multiple experiments, where T cell recognition has been standardised to the level of 
recognition of control LCLs. Both CALCOCO2 and NBR1 siRNA significantly decreased 
recognition of endogenous EBNA1 by SNP-specific CD4+ T cells. These results confirm 
data obtained using E1ΔGA and support the theory that these proteins are involved in 
the generation of the SNP epitope. The over-expression system also implicated OPTN in 
the generation of SNP however in this experiment LCLs treated with OPTN siRNA 
showed only a very slight decrease in T cell recognition that was not significant.  
5.6 Processing of EBNA1 MHC-II epitopes in epithelial cells 
Previous experiments have been conducted in B cells as EBV is naturally maintained in 
these cells. However, EBV also infects epithelial cells. In fact EBV infection of epithelial 
cells causes a bigger disease burden in that nasopharyngeal carcinoma and the 10% of 
gastric carcinomas associated with EBV arise from epithelial cells. However CD4+ T cell 
recognition of epithelial cells is very poorly studied and it is not known if findings from 
experiments conducted in B cells and other APCs apply in epithelial cells. I therefore 
investigated CD4+ T cell recognition of E1ΔGA expressed in an epithelial cell line. 
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Figure 5.6 SNP T cell recognition of endogenous EBNA1 following siRNA 
Knock down of autophagy adaptors 
Analysis of autophagy protein siRNA Knock down. A. siRNAs specific to 
CALCOCO2, NBR1 and OPTN reduced T cell recognition of endogenous 
EBNA1 from LCLs by SNP-specific T cells. B. Repeat experiments revealed the 
reduction observed by CALCOCO2 and NBR1 was significant by ANOVA and 
subsequent bonferroni multiple comparison analysis (**P< .01; ****P<.0001) 
compared with control siRNA. 
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Previously Zuo et al. have used the EBV-negative melanoma line MJS to study antigen 
processing of multiple EBV proteins including EBNA1 (Zuo et al., 2011). This work 
showed that MJS cells stably transduced with the relevant HLA class II alleles could 
present EBNA1 class II epitopes when EBNA1 was over expressed following transient 
transfection. These experiments shows that MJS has a normal and functioning class II 
antigen processing and presentation pathway, this and the ease of which protein 
expression can be manipulated within these cells suggests that the MJS system would be 
perfect for studying a potential role of autophagy adaptors in the generation of class II 
epitopes from EBNA1. To ensure efficient processing of EBNA1, Zuo et al. used a 
modified EBNA1 protein localised to the cytoplasm by mutation of the proteins NLS. In B 
cells this mutation enhances epitope generation and affects the processing routes used. 
It is not known if MJS cell are able to present MHC class II epitopes from nuclear resident 
EBNA1. To investigate this, MJS cells were transfected with decreasing amounts of 
plasmid DNA encoding E1ΔGA and incubated for 72h. After this time the generation of 
the SNP peptide was measured using SNP-specific T cells. Figure 5.7a shows recognition 
of MJS cells transfected with E1ΔGA. The MJS cells were recognised by SNP T cells 
showing MJS cells can efficiently generate class II epitopes from nuclear EBNA1. To 
confirm the SNP epitope was still being processed through autophagy, MJS cells were 
transfected with E1ΔGA and incubated for 72h. For the final 24h cells were incubated 
with the autophagy inhibitor 3-MA. The generation of the SNP peptide was again 
measured using SNP-specific T cells. Figure 5.7b shows that 3-MA treatment 
significantly decreased SNP T cell recognition. This suggests that the SNP epitope is 
generated by autophagy in MJS system as it is in LCLs. 
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Figure 5.7 CD4+ T cell recognition of E1ΔGA in epithelial cells 
SNP T cell recognition of MJS cells transfected with E1ΔGA. A. SNP T cells 
recognised MJS cells transfected with decreasing concentrations of E1ΔGA. B. 
10mM 3-MA reduced SNP T cell recognition of MJS transfected with 0.1µg 
E1ΔGA DNA. Statistical significance was determined by a paired Student t test 
(*P< .05). 
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As autophagic presentation of SNP was shown to require autophagy adaptors in B cells, 
it is possible that this is also the case in epithelial cells. It is not however known, if 
autophagy adaptors are expressed in MJS cells. To investigate this important question, 
expression of each autophagy adaptor was measured in MJS cells by western blot. MJS 
cells were also treated with bafilomycin A1 to inhibit autophagic degradation of 
autophagy adaptors to confirm their degradation by autophagy. Results of this are 
shown in Figure 5.8. Results show that p62, CALCOCO2, NBR1 and OPTN are all 
expressed in MJS cells. Cells treated with Bafilomycin A1 for 4h showed increased 
expression of autophagy adaptors. This suggests that these proteins are being degraded 
by autophagy under normal conditions and therefore that MJS cells possess a fully 
functioning autophagic pathway. 
5.7 MHC class II presentation of EBNA1 following siRNA knock down of 
autophagy adaptors in epithelial cells 
Having confirmed that MJS cell present the SNP epitope in an autophagy-dependent 
manner from nuclear EBNA1, I next investigated whether autophagy adaptors were 
involved in this presentation as has been observed in previous experiments using B 
cells. 
MJS cells were transfected with siRNA specific for a single autophagy adaptor and 
incubated for 24h to allow knock down to occur. Cells were then transfected with the 
E1ΔGA expressing vector and incubated for a further 72h. After this time, cells were 
assayed for antigen presentation to CD4+ T cells specific to the SNP epitope.  
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Figure 5.8 Expression of autophagy adaptor proteins in epithelial cells 
Western blot analysis of autophagy adaptor protein expression in 
bafilomycin A1 (100nM) treated MJS cells. Protein was detected using 
specific monoclonal antibodies. All autophagy adaptors were detected in 
samples. Bafilomycin A1 treatment increased levels of protein of all 
autophagy adaptors. Expression of BiP protein was used as a loading control 
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As expected and because MJS cells do not naturally express EBNA1, mock transfected 
cells were not recognised by SNP-specific T cells (Figure 5.9). Good T cell recognition 
was observed of MJS cells co-transfected with EBNA1 and control (GFP) siRNA. As had 
been previously observed in LCLs knock down of p62 and ALFY had no effect on the 
generation of the SNP epitope. In MJS cells, Knock down of BAG-3 was successfully 
achieved using an siRNA that had previously failed to knock down the protein in LCLs. 
However knock down of BAG-3 appeared to have no effect on the recognition of the SNP 
epitope. 
Importantly, and in agreement with previous experiments conducted in LCLs, 
recognition of E1ΔGA was significantly reduced when target cells were transfected with 
siRNA specific to CALCOCO2, NBR1 and OPTN. This result confirms the experiments 
conducted in LCLs and show that all three autophagy adaptors play an important role in 
the generation of the SNP epitope, in that knock down of these proteins causes a 
significant reduction in recognition of target cells by SNP-specific T cells. 
Results of these siRNA experiments have been confirmed on both endogenous EBNA1 as 
well as over-expressed E1ΔGA in two different cells lines. It is however important to rule 
out any possible off-target effects that single siRNAs might be having. To this effect, two 
different siRNAs for each autophagy adaptor were designed. Off-target effects of siRNA 
tend to be different between different siRNAs. Targeting the same protein using 
different siRNA duplexes should have different off-target effects. If the results of reduced 
recognition are repeated when different siRNAs are used to Knock down the protein of 
interest then the effect is likely to be as a result of specific down-regulation of the target 
gene rather than off-target effects. 
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Figure 5.9 T cell recognition of E1ΔGA expressing MJS cells following 
siRNA knock down of autophagy related proteins 
Analysis of autophagy protein siRNA Knock down on the effect of SNP-
specific T cell recognition of MJS cells overexpressing E1ΔGA. siRNAs specific 
to CALCOCO2, NBR1 and OPTN reduced SNP-specific T cell recognition of 
E1ΔGA. Statistical significance was determined by ANOVA and subsequent 
bonferroni multiple comparison analysis (**P< .01; ****P<.0001) compared 
with control siRNA + EBNA1 DNA. 
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MJS cells were co-transfected with an siRNA and an EBNA1 contruct according to 
previous protocols. Cells were again assayed for epitope presentation to SNP T cells 
(Figure 5.10). Mock transfected cells were not recognised by T cells and E1ΔGA/control 
siRNA transfected cells were recognised well by SNP T cells. All other siRNAs, two 
specific to each autophagy adaptor, CALCOCO2, NBR1 and OPTN caused a significant 
reduction in T cell recognition. These results confirm that autophagy adaptor knock 
down by siRNA does cause a reduction in T cell recognition and rules out the possibility 
that any previous results are caused by off-target effects of the siRNA.  
5.8 Autophagy adaptor – EBNA1 interactions 
Classically autophagy adaptors sort cargo for degradation by binding to ubiquitin 
moieties on target proteins. However EBNA1 is not thought be ubiquitinated under 
normal conditions (personal correspondence – Lori Frappier, the University of Toronto, 
Canada). Some adaptors are known to be able to function in a ubiquitin-independent 
manner though these mechanisms are poorly understood. It is possible that the 
autophagy adaptors involved in the generation of the SNP epitope target EBNA1 to the 
autophagic pathway by binding directly to EBNA1. If this is the case EBNA1 should 
contain one or more consensus sequences where autophagy adaptors can bind. If 
autophagy adaptors are binding directly to EBNA1 via a consensus sequence then 
removal of this sequence through deletion should impair the generation of the SNP 
epitope. 
To investigate this possibility a number of EBNA1 mutants containing specific deletions 
of the EBNA1 protein were obtained (Figure 5.11). MJS cells were transfected with the 
different constructs and generation of the SNP epitope was assayed.  
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Figure 5.10 T cell recognition of E1ΔGA expressing MJS cells following 
knock down of autophagy adaptors by multiple siRNAs 
Analysis of autophagy protein siRNA Knock down on the effect of SNP-
specific T cell recognition of MJS cells overexpressing E1ΔGA. siRNAs specific 
to CALCOCO2, NBR1 and OPTN reduced SNP-specific T cell recognition of 
E1ΔGA. This result was confirmed with multiple siRNAs to each protein. 
Statistical significance was determined by ANOVA and subsequent bonferroni 
multiple comparison analysis (*P< .05; **P< .01; ***P<.001; ****P<.0001) 
compared with control siRNA + EBNA1 DNA. 
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Recognition of the different EBNA1 deletion mutants by SNP-specific T cells is shown in 
Figure 5.12a. Recognition of E1ΔGA was used as a control and good recognition of this 
construct was observed. Contrary to what might have been expected, recognition of 
EBNA1 Δ8-67 was higher than recognition of the E1ΔGA. Recognition of Δ41-376 and 
Δ395-450 was comparable to levels of control recognition. Interestingly Δ387-394 
caused a marked decrease in recognition by SNP T cells. This suggests that the deleted 
section of EBNA1 contains a region important for EBNA1 processing and presentation. 
If this region contained an autophagy adaptor binding domain then the reduction in 
recognition should be specific to the autophagy-dependent epitope SNP. Presentation of 
other EBNA1 class II epitopes should be unaffected. To test this, MJS cells transfected 
with the different EBNA1 constructs were assayed for their presentation to VYG-specific 
T cells (Figure 5.12b). VYG expression of all constructs was similar with the exception of 
Δ387-394. As observed with SNP T cells, VYG recognition of this construct was markedly 
lower than controls. 
This excludes the possibility that Δ387-394 contains an autophagy adaptor binding 
region, but perhaps more interestingly, does suggest that the region is important for 
overall processing and presentation of multiple EBNA1 class II epitopes. 
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Figure 5.11 EBNA1 deletion mutants 
Schematic of EBNA1 deletion mutants used in T cell recognition assays 
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Figure 5.12 T cell recognition of EBNA1 deletion mutants 
EBNA1-specific CD4+ T cell recognition of MJS cells transfected with EBNA1 
deletion mutants. A. SNP-specific T cell recognition. Recognition of the 
EBNA1 deletion mutant Δ8-67 was higher than control recognition of E1ΔGA. 
Recognition of the EBNA1 deletion mutant Δ387-394 was lower than control 
recognition of E1ΔGA. b. VYG-specific T cell recognition. Recognition of the 
EBNA1 deletion mutant Δ387-394 was lower than control recognition of 
E1ΔGA 
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5.9 Discussion 
The aim of the work described in this chapter was to test the hypothesis that autophagy 
adaptor proteins were involved in the processing of EBNA1 by autophagy. This 
hypothesis was formed on the basis of  Roscovitine-mediated decrease in adaptor 
proteins being coincident with decreased presentation of the autophagy-dependent 
MHC class II-restricted SNP epitope from EBNA1. Because Roscovitine could be having 
multiple effects on cells I decided to test the hypothesis by selectively decreasing cellular 
levels of each autophagy adaptor proteins and examining the effects on presentation of 
the epitope peptide.  
5.9.1 Autophagy adaptors in the processing of E1ΔGA in LCLs 
Cells that are endogenously expressing EBNA1 are pre-coated with MHC-peptide 
complexes. When supply of the epitope peptide is interrupted it can take several days 
for them to dissociate from MHC-II molecules (Mackay et al., 2009). This slow 
dissociation makes it difficult to measure the effects of inhibitors, since it can take days 
before there is sufficient decrease in MHC class II-peptide complexes to be robustly and 
reliably detected in T cell assays. This problem is compounded for experiments reliant 
upon siRNA since its effects upon target protein levels i) are transient, lasting only 24-48 
hours and ii) depend upon natural turnover of the target protein in order to become 
effective and thus do not act until sometime after their introduction into cells. Although 
long-term Knock down of cells can be achieved using shRNA, establishing Knock down in 
LCLs takes considerable time, meaning there is considerable scope for changes to occur 
in levels of autophagy activity and the antigen expression between the control and 
Knock down lines. For MHC-I peptides, stripping the pre-existing peptides from the cells 
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using acidic conditions can circumvent this problem. The denuded cells can then be 
treated with inhibitors and the effect upon reconstitution of the MHC-I peptide 
complexes is readily apparent. However, this technique cannot be used for studying 
MHC class II peptides because they are much less susceptible to elution under acidic 
conditions. Initial experiments were therefore conducted using an EBNA1 over-
expression system, looking for changes in the increase in epitopes from the over-
expressed protein.  In these experiments, Knock down of three of the five autophagy 
adaptors was shown to affect the generation of the autophagy-dependent epitope SNP. 
The fact that some, but not all autophagy adaptors effected epitope presentation 
suggested that it was a specific effect on EBNA1 presentation rather than a general effect 
upon autophagy per se. To confirm this decrease in SNP epitope presentation was  due to 
an alteration in EBNA1’s processing via autophagy, the effect on the generation of the 
VYG epitope, which is not generated by autophagy from nuclear-localised EBNA1, was 
also examined. Generation of this autophagy-independent epitope was unaffected by 
knock down of any autophagy adaptors. These results provide the first example of 
autophagy adaptors being involved in the autophagy-dependent generation of a MHC 
class II epitope from an endogenous protein.  
 
The processing of MHC class II epitopes from E1ΔGA is thought to follow the same 
pathways as naturally expressed EBNA1 (Leung et al., 2010; Mackay et al., 2009). 
However, I cannot exclude the possibility that these findings are an artefact of studying 
the processing of over-expressed antigen. Confirming these results in a more 
physiologically-relevant system therefore became a priority.  
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5.9.2  Autophagy adaptors in the processing of natural EBNA1 in LCLs 
To confirm the results observed using over-expressed E1ΔGA were physiologically 
relevant, the siRNA Knock down experiments were repeated in LCLs expressing natural 
levels of endogenous EBNA1. As previously described, studying the processing of 
naturally expressed protein is made more difficult by the presence of pre-existing 
peptide-MHC complexes at the cell surface. Despite this fact, Knock down of NBR1 and 
CALCOCO2 caused similar effects for LCLs. Generation of the SNP T cell epitope was 
reduced by Knock down of these proteins, although as might be expected for the reasons 
described above, the magnitude of the effect was reduced compared to the over-
expression system. These results were repeated and the decrease was shown to be 
statistically significant. 
Knock down of the third autophagy adaptor, OPTN did not cause a significant decrease 
in the generation of the SNP epitope in the LCL system. This difference could be for two 
reasons. First, it is possible that the effect of OPTN knock down observed in the over-
expression system was an artefact of the system and OPTN is not involved in the 
processing of natural EBNA1. Second, it is possible that there is some redundancy in the 
system and that EBNA1 can be targeted by CALCOCO2, NBR1 or OPTN. Therefore when 
OPTN was knocked down it is possible that the other two autophagy adaptors were in 
excess and they were able to compensate for any effect OPTN may have on EBNA1 
processing. 
Regardless of the differences observed for OPTN, it is clear that at least two autophagy 
adaptors, CALCOCO2 and NBR1, are important for the processing of EBNA1 via 
autophagy in B cells. 
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5.9.3 EBNA1 processing in epithelial cells 
In this chapter, experiments were also conducted to study MHC class II processing of 
EBNA1 in epithelial cells. These experiments were conducted for two reasons. Firstly, 
siRNA Knock down of proteins is technically much easier to achieve in epithelial cells 
compared to LCLs. Secondly, and more importantly, a great disease burden arises from 
EBV infected epithelial cells and despite their importance very little is known about 
antigen processing in epithelial cells or about their recognition by EBV-specific T cells. 
Previous experiments conducted by Zuo et al. have shown EBNA1-specific CD4+ T cells 
can recognise MJS cells, an epithelial line originally derived from a melanoma patient, 
transfected with DNA encoding the cytoplasmic-localised EBNA1 protein. However, 
whether MJS cells can generate EBNA1 MHC-II peptides from nuclear EBNA1 was 
unknown. 
By over-expressing EBNA1 in MJS cells I was able to show that these cells were also able 
to generate MHC class II epitopes from nuclear-localised EBNA1. I also investigated the 
mechanisms by which the SNP epitope was generated. Using inhibitors of autophagy I 
was able to confirm SNP is generated in an autophagy-dependent manner similar to that 
seen in B cells. 
Because EBNA1 processing in these epithelial cells was similar to that of B cells I next 
attempted to confirm the previous result that showed production of the SNP epitope 
required autophagy adaptors. siRNA experiments were conducted again and results 
confirmed that the three autophagy adaptors, CALCOCO2, NBR1 and OPTN all contribute 
to the generation of the SNP epitope in epithelial cells. 
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As a final experiment to confirm these results, two different siRNAs for each autophagy 
adaptor were used to rule of any possible off-target effects of individual siRNAs. These 
data again confirmed that specific Knock down of autophagy adaptors was responsible 
for the effects observed and were not due to off-target effects from the siRNA originally-
used.  
Taken together these data represent strong evidence to support the hypothesis that 
EBNA1 is specially targeted for autophagic degradation by the action of CALCOCO2, 
NBR1 and OPTN and this targeting is required for the generation of the autophagy-
dependent epitope SNP. 
I next conducted experiments to identify a possible mechanism for this targeting. The 
most well documented method of cargo identification by autophagy adaptors is via 
ubiquitination of proteins. Ubiquitin-independent mechanisms have been identified but 
these are currently less well understood. As EBNA1 is not thought to be ubiquitinated 
under normal conditions (personal communication – Lori Frappier, the University of 
Toronto, Canada) I hypothesised that autophagy adaptors may be binding a specific 
region of EBNA1, either directly or via an intermediate protein. 
To test this theory, generation of MHC class II epitopes from a range of EBNA1 
constructs each carrying specific deletions was examined. If an individual deletion 
mutant showed decreased presentation via autophagy, it would suggest that region 
could be involved in the binding of EBNA1 to an autophagy adaptor. Such an effect was 
not observed and the mechanism by which autophagy adaptors and EBNA1 are able to 
interact is yet to be elucidated. 
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Though no deletion mutant decreased presentation in an autophagy-dependent manner, 
two interesting differences were observed. Firstly, deletion of amino acids 8-67 from 
EBNA1, a region that contains a Gly/Arg rich sequence caused an increase in the 
generation of the SNP epitope. As the generation of VYG was unaffected this effect was 
likely specific to autophagy-dependent epitope generation. The mechanism behind this 
increase was not investigated; however one possibility might be that this region is 
important for inhibiting the presentation of EBNA1 through autophagy.  
The second interesting finding from these experiments was that deletion of amino acids 
387-394 caused a decrease in epitope generation. This deletion was shown to confer 
reduced T cell recognition by both SNP-specific and VYG-specific CD4+ T cells. EBNA1 
has been shown to interact with the host protein, Casein Kinase 2 (CK2) via this region 
of EBNA1. Through this interaction EBNA1 has been shown to recruit CK2 to PML 
bodies,  triggering the poly-ubiquitination and degradation of PML bodies (Sivachandran 
et al., 2010). 
I hypothesis that EBNA1 binding to CK2 is important for MHC class II processing of 
EBNA1. One possible explanation for the decrease in presentation of Δ387-394 is that 
this mutant protein is unable to disrupt PML bodies. This could possibly increase the 
amount of EBNA1 sequestered within PML bodies and therefore decrease the amount of 
EBNA1 available for MHC class II processing.
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6. MACROAUTOPHAGY AND ENDOGENOUS MHC CLASS II ANTIGEN 
PROCESSING AND PRESENTATION 
As discussed in Chapter 1, MHC class II epitopes are classically generated from 
exogenous proteins, however in certain cases class II epitopes can be generated from 
endogenous proteins. Multiple examples of endogenous MHC class II processing have 
now been identified but the factors that cause certain epitopes to be generated 
endogenously are poorly understood. One crucial factor defining endogenous class II 
processing is access to the endocytic compartment. Endogenous proteins have been 
shown to access this compartment though multiple pathways, including macro- and 
micro autophagy. However access to this compartment alone is not sufficient to allow 
processing and the generation of MHC class II epitopes. This is highlighted clearly in the 
example of MHC class II processing of EBNA1. 
In B cells EBNA1 is known to be processed endogenously and can gain access to the MHC 
class II processing pathway via autophagy (Leung et al., 2010; Paludan et al., 2005). This 
processing pathway generates an autophagy-dependent, MHC class II epitope, SNP. 
Although EBNA1 contains multiple MHC class II epitopes, only SNP is generated in this 
manner. Another epitope, VYG is generated by a second, as of yet undiscovered 
endogenous processing pathway, whereas a third, PQC is not generated at all in B cells.  
The rules defining how and why certain epitopes are processed endogenously and 
others not are poorly understood. These will be investigated in this chapter using 
EBNA1 MHC class II epitopes as a model. 
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6.1 The contribution of autophagy to the generation of EBNA1 class II epitopes 
EBNA1 expression in LCLs presents an excellent model for studying how epitope 
peptides are generated, allowing the factors that affect whether an epitope can be 
generated through autophagy or not to be investigated. Work was carried out to study 
the differences between three key EBNA1 class II epitopes SNP, VYG and PQC.  
As previously described, SNP is an autophagy-dependent epitope, VYG is processed and 
presented through an alternative pathway and PQC is not naturally processed and 
presented within B cells. Key experiments were conducted to confirm the differences in 
processing between the three epitopes. Results of these experiments are shown in 
Figure 6.1. 
To confirm the dependence upon autophagy, LCLs were treated with 3-MA, a known 
autophagy inhibitor and presentation of the three different epitopes to T cells was 
measured. Figure 6.1a shows that untreated LCLs are recognised by SNP T cells. 3-MA 
caused a reduction in SNP-specific T cell recognition of LCLs, 10mM 3-MA reduced 
recognition by over 80%. The same 3-MA treated LCLs were used in parallel T cell 
assays using VYG-specific T cells. Untreated LCLs were again recognised by VYG T cells; 
however 3-MA caused an increase in VYG-specific T cell recognition of LCLs.  
The effect of 3-MA was also tested on presentation of the third epitope PQC. PQC is not 
naturally presented in the B cell system, this result was confirmed in these experiments. 
Untreated LCLs were not recognised by PQC-specific T cells. Treatment with both 5 and 
10mM 3-MA had no effect on this and all populations of LCLs were not recognised 
(Figure 6.1a).  
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These data confirmed that generation of the SNP epitope required autophagy, whereas 
VYG did not. The data also confirmed PQC is not presented in B cells regardless of 
autophagy status. 
To further investigate the processing of these three peptides, T cell recognition of over-
expressed EBNA1 was also studied. E1ΔGA was over-expressed in LCLs using the pRTS1, 
dox inducible system described in chapter 5 
As has been previously shown, over-expression of E1ΔGA, triggered by dox addition 
causes a sharp increase in the generation of the SNP epitope (Figure 6.1b). When dox 
induced LCLs were treated with 10mM 3-MA this increase in T cell recognition was 
ablated. Recognition of the same LCLs by VYG-specific T cells was also studied. Over-
expression of E1ΔGA caused a similar increase in the generation of the VYG epitope and 
as before 3-MA treatment increased VYG T cell recognition. PQC recognition was also 
measured in this system and again the PQC epitope was not generated under any 
conditions. This confirms that over-expression of E1ΔGA does not affect the processing 
route of individual MHC class II epitopes of EBNA1. 
As previously discussed, work carried out by Leung et al. has showed that localisation of 
EBNA1 is key to defining the processing route for individual class II epitopes. Leung et 
al. showed that when EBNA1 was relocalised to the cytoplasm by mutation of EBNA1’s 
NLS all epitopes were able to be presented thorough autophagy. Experiments were 
carried out to confirm this finding, the results of which are shown in Figure 6.1c.  
The cytoplasmic EBNA1 variant E1ΔGA ΔNLS was over-expressed in LCLs again using 
the dox inducible system and generation of all three epitopes monitored in T cell assays 
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(Figure 6.1c). The pattern of SNP T cell recognition of E1ΔGA ΔNLS was similar to that of 
E1ΔGA. Dox induction caused a sharp increase in T cell recognition and 3-MA treatment 
completely ablated this recognition. Though the pattern was the same it should be noted 
that E1ΔGA ΔNLS was better recognised than E1ΔGA. 
When VYG and PQC recognition of E1ΔGA ΔNLS was studied marked differences 
between nuclear and cytoplasmic EBNA1 were observed. As with previous results dox 
induction caused a sharp increase in recognition by VYG-specific T cells however this 
time 3-MA treatment ablated this increase. PQC recognition of E1ΔGA ΔNLS was also 
very different to recognition of E1ΔGA. Over expression of E1ΔGA ΔNLS caused LCLs to 
be recognised by PQC-specific T cells. This recognition was decreased by 3-MA 
treatment. 
These results show that endogenous processing and presentation of cytoplasmic EBNA1 
can generate all three EBNA1 MHC-II epitopes in an autophagy-dependent manner 
which suggests localisation is important to this process. 
It should be noted that autophagy-dependent generation of the VYG and PQC epitopes 
from E1ΔGA ΔNLS required a longer period of time, compared to that required for the 
generation of the SNP epitope. It is possible therefore that the amount of EBNA1 in the 
cytoplasm is a limiting factor in the generation of these two epitopes by autophagy. 
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Figure 6.1 CD4+ T cell recognition of EBNA1, E1ΔGA and E1ΔGA ΔNLS. 
T cell recognition of endogenous EBNA1, E1ΔGA and E1ΔGA ΔNLS by the 
three EBNA1-specific CD4+ T cells was investigated. A. LCLs were treated 
with 3-MA and used in T cell assays. Results show 3-MA inhibits the 
presentation of SNP. B. E1ΔGA was over-expressed in LCLs by the addition of 
100nM dox and cells used in T cell assay. Over-expression increased 
presentation of SNP and VYG. SNP presentation was again inhibited by 3-MA. 
C. E1ΔGA ΔNLS was over-expressed in LCLs by the addition of 100nM dox 
and cells used in T cell assays using SNP T cells after 48 h, VYG T cells after 
72h and PQC T cells after 120h. Over-expression increased the presentation 
of all three epitopes and the 3-MA inhibited this increase in all cases. 
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6.2 The effect of increased antigen supply on the generation of EBNA1 MHC class 
II epitopes 
To further study these differences between epitopes, LCLs were induced with different 
concentrations of dox and the generation of class II epitopes was studied over time. 
Figure 6.2 shows the results of one such experiment. LCLs transduced with E1ΔGA ΔNLS 
were induced by addition of 50nM dox and the generation of the three epitopes SNP, 
VYG and PQC was observed over 5 days by measuring recognition of induced LCLs by 
EBNA1-specific CD4+ T cells. To allow comparisons between epitopes, recognition was 
standardised to maximum recognition of each T cell, measured by recognition of LCLs 
pre-incubated with epitope peptides (% of peptide pulsed). 
LCL recognition by SNP-specific T cells remained at baseline, around 2% of peptide max 
for the first 48h. After 72h of dox treatment, recognition rose sharply and after 120h had 
reached nearly 80% of peptide loaded LCLs. VYG-specific T cells showed a similar effect, 
however the increase was delayed and less dramatic. An increase in T cell recognition 
was not observed until 96h. After 120h recognition was only 10% of peptide loaded 
max. PQC-specific T cells again showed an increase after dox addition but this effect 
occurred later than both SNP and VYG and was smaller in magnitude. LCL recognition 
was not seen until 120h and was less than 2% of that of recognition of peptide loaded 
LCLs (Figure 6.2). 
This experiment, along with the data from Figure 6.1 shows that all three epitopes can 
be generated by autophagy from E1ΔGA ΔNLS. However the generation of VYG and PQC 
epitopes is delayed. 
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Figure 6.2 Generation of EBNA1 MHC class II epitopes from E1ΔGA ΔNLS 
over time 
LCLs stably transduced with E1ΔGA ΔNLS were assayed for epitope 
presentation to EBNA1-specific CD4+ T cells following 50nM dox induction. T 
cell recognition of LCLs was standardised to maximum recognition, measured 
by recognition of peptide loaded LCLs. T cell recognition of LCLs was 
increased after dox induction in all cases. The increase in recognition by VYG-
specific T cells was delayed and smaller in magnitude than that of SNP-
specific T cells and the increase in recognition by PQC-specific T cells was 
further delayed and smaller than seen with both SNP- and VYG-specific T 
cells. 
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It is known that long term dox addition causes a constant increase in the levels of EBNA1 
protein expressed from the pRTS1 vector (unpublished data). It is therefore possible 
that the limiting factor delaying the increase in PQC and VYG-specific T cell recognition 
is the amount of EBNA1 protein present in cells. It is possible that to generate VYG 
epitopes through autophagy requires more protein than that required to generate the 
SNP epitope and that the generation of the PQC epitope requires more protein still. 
Increases in dox concentration causes a linear increase in the levels of protein expressed 
in LCLs, therefore dox concentration can be varied to study levels of protein required to 
induce epitope generation. 
To determine if the differences observed in Figure 6.2 were due to amounts of EBNA1 
expressed in LCLs, recognition of LCLs induced with increasing amounts of dox was 
measured at a single time point and again standardised to levels of maximum 
recognition. LCLs were treated with increasing concentrations of dox for 120h and 
presentation of epitopes to EBNA1-specific T cells was observed. 
Figure 6.3 shows the results of this experiment. Uninduced LCLs were recognised by 
SNP-specific T cells, this recognition increased as dox concentration increased. In this 
experiment recognition peaked around 50% of peptide loaded LCLs at 20nM dox. 
Further increases in dox concentration caused no further increase in T cell recognition. 
A similar effect was observed with VYG T cells but importantly the effect was smaller 
and occurred at higher concentrations of dox. LCL recognition increased sharply and 
began to plateau at 50nM. VYG recognition was much lower than SNP recognition 
reaching only just over 10% of peptide loaded LCL. 
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PQC recognition was again lower than that of SNP and VYG and no plateau was 
observed. 100nM dox caused only 4% T cell recognition.  
These data show that all three EBNA1 MHC-II epitopes, SNP, VYG and PQC can be 
generated from E1ΔGA ΔNLS and that the generation of all three epitopes is dependent 
upon autophagy. The results also indicate that different levels of protein expression are 
required for the generation of each epitope. Generation of the PQC epitope requires the 
highest level of E1ΔGA ΔNLS expression and SNP, the epitope naturally processed by 
autophagy requires the lowest. 
As a single molecule of E1ΔGA ΔNLS should generate one molecule each of the SNP, VYG 
and PQC epitope peptides, it might be assumed the levels of protein required for the 
generation of the different epitopes would be the same. However, as this is clearly not 
the case, it is possible that VYG and PQC epitope peptides are being destroyed before 
they can be displayed on the cell surface in complex with MHC class II molecules. 
Previous work by Leung et al. using crude cellular extracts containing lysosomal 
proteases suggests that PQC may be more susceptible to destructive processing by such 
proteases though this finding was never fully investigated (Leung et al., 2010). 
I therefore hypothesise that destructive processing of epitopes is limiting the 
presentation of VYG and PQC through the autophagic pathway. That is to say, that equal 
amounts of SNP, VYG and PQC epitopes will be generated from the degradation of 
EBNA1 within lysosomes but increased sensitivity to destructive processing by 
lysosomal proteases means greater numbers of VYG and PQC epitopes will be destroyed 
before they are loaded onto MHC class II molecules and exported to the cell surface. 
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Figure 6.3 Generation of EBNA1 MHC class II epitopes from increasing 
amounts of E1ΔGA ΔNLS 
LCLs stably transduced with E1ΔGA ΔNLS were assayed for epitope 
presentation to EBNA1-specific CD4+ T cells following induction with 
increasing concentrations of dox. T cell recognition of LCLs was standardised 
to maximum recognition, measured by recognition of peptide loaded LCLs. T 
cell recognition of LCLs was increased after dox induction in all cases. The 
increase in recognition by VYG-specific T cells was smaller in magnitude than 
that of SNP-specific T cells and the increase in recognition by PQC-specific T 
cells was smaller than seen with both SNP- and VYG-specific T cells. 
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6.3 Destructive processing – a possible mechanism causing differential epitope 
display 
Leung et al. noted that when EBNA1 was provided to LCLs as an exogenous antigen the 
PQC epitope was presented less efficiently than other epitopes and was first to be lost 
when antigen supply became limited. It was also shown that PQC was more susceptible 
to lysosomal degradation than SNP and VYG. These data suggests an important role for 
destructive processing in defining which epitopes are generated by autophagy. 
I hypothesised that PQC is more susceptible to destructive processing than VYG and that 
in turn, VYG is more susceptible than SNP. To test this hypothesis a highly purified 
lysosomal fraction was isolated from multiple LCLs using density centrifugation and 
hypotonic shock to remove endosomes. Lysosomes were then lysed by freeze thawing to 
yield a pure lysosomal extract. These extracts were assayed for acid phosphatase and 
cathepsin activity. 
Lysosome extracts were tested for acid phophatase activity using a commercial assay. 
Acid phosphatase is a lysosomal resident acid hydrolase and activity of this enzyme is a 
marker for the identification of lysosomes in sub-cellular fractionations. Figure 6.4a 
shows the results of this test. Extracts from three different LCLs were tested and 
lysosomal activity was detected in all three extracts. This shows that lysosomal contents 
were successfully isolated from all three cell lines. As cathepsins are crucial lysosomal 
proteases for antigen processing and presentation extracts were also assayed for 
activity of a number of different cathepsins. Figure 6.4b shows activity of different 
cathepsins was variable between LCLs but that all cathepsins showed some. 
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Figure 6.4 Acid phosphatase and cathepsin activity in lysosomal 
extracts from LCLs 
Lysosomal extracts from three different LCLs were assayed for 
enzymatic activity. A. Acid phosphatase activity was measured by a 
commercial colourmetric assay. Results show all three extracts are 
positive for acid phophatase. B. Cathepsin activity was monitored by 
the cleavage of fluorescent tagged substrate peptides. AAN is a 
substrate for AEP. RR a substrate for cathepsin B. FR – cathepsin B and 
L. VLK – cathepsin K. VRR – Cathepsin S. Results show levels of 
cathepsins differed between all extracts but that cathepsin activity was 
detected in all lines.  
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6.4 Sensitivity of EBNA1 class II epitope peptides to destructive processing 
To test the hypothesis that destructive processing limits the generation of epitopes 
through autophagy, the sensitivity of the three epitopes SNP, VYG and PQC to 
degradation by lysosomal proteases was measured.  
A standard peptide degradation assay protocol was devised to measure degradation of 
EBNA1 peptides by lysosomal proteases. Limiting concentrations of the three peptides 
were exposed to lysosomal extracts for differing lengths of time. LCLs were then pulsed 
with these lysosome treated peptides and used as targets in T cell assays using CD4+ T 
cells specific to the three different epitopes. Recognition of these pulsed LCLs was 
measured by IFN-γ ELISA. Lysosomal degradation of peptides will reduce the amount of 
epitopes loaded onto the surface of LCLs and will therefore decrease T cell recognition of 
LCLs. Higher T cell recognition can therefore be seen as greater resistance to 
degradation. 
The results of peptide degradation assays using SNP, VYG and PQC peptides are 
displayed in Figure 6.5. To allow comparison of all three epitopes, IFN-γ release is 
displayed as a percentage of maximum achieved by pulsing LCLs with control untreated 
peptides (0h). As was expected, and matching previous results from Leung et al., the SNP 
peptide appeared more resistant to degradation by lysosomal proteases than both VYG 
and PQC. Exposure to lysosomal extract did decrease presentation to SNP-specific CD4+ 
T cells but after 8h of exposure recognition was still 50% that of maximum recognition 
seen at 0h. In contrast to this, both PQC and VYG appeared to be degraded by lysosomal 
extract much more rapidly. Recognition of LCLs by VYG and PQC-specific T cells was 
reduced to around 50% of maximum after 2h incubation with lysosomal extract. Though 
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VYG and PQC showed similar results it appeared that PQC is slightly more susceptible to 
degradation that VYG. After 8h incubation VYG recognition had fallen to 13% of 
maximum whereas PQC fell to 2%. 
These data fit with the hypothesis that epitopes that are naturally generated through 
autophagy are more resistant to lysosomal proteases than those that are not processed 
in this manner. It also correlates with the differences seen in presentation of the three 
epitopes from E1ΔGA ΔNLS in that PQC generation required the highest level of 
expression and was the most susceptible to destructive processing. 
6.5 Protecting EBNA1 MHC class II epitopes from destructive processing to 
increase T cell recognition 
Efficient presentation of EBNA1 MHC class II epitopes requires the epitope peptides to 
be resistant to destructive processing. It would appear that both VYG and PQC are not 
efficiently presented through the autophagy pathway as the epitope peptides are 
degraded by lysosomal peptidases in this pathway. 
I hypothesise that protecting VYG and PQC from destructive processing may cause these 
epitopes to be presented through autophagy. This would increase the levels and 
diversity of EBNA1 MHC class II epitopes displayed on the surface of cells and should 
increase T cell recognition of such cells.  
This could be an effective mechanism to increase T cell recognition of EBV-positive cells 
and could potentially be translated to improve immune recognition of EBV-associated 
malignancies. 
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Figure 6.5 Degradation of EBNA1 MHC class II epitope peptides by 
lysosomal peptidases 
Limiting doses of EBNA1 MHC class II epitope peptides were incubated with 
lysosomal extracts for increasing amounts of time. Peptides were then loaded 
onto LCLs and T cell recognition of LCLs was assayed. Peptide degradation is 
observed by decrease in T cell recognition. SNP T cell recognition was 
decreased as incubation time increased. After 8h recognition was 50% of that 
observed at 0h. A similar but greater effect was observed with VYG T cell 
recognition. After 8h recognition was 20% of that at 0h. Again a similar but 
greater effect was observed with PQC T cell recognition. After 8h recognition 
was 2% of that at 0h. 
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As a simple proof of principle experiment, attempts were made to protect the VYG and 
PQC epitopes from destructive processing by mutating the sequence of the epitope 
peptides. Cathepsins target specific sequences with proteins, as VYG and PQC are both 
degraded by lysosomal proteases I conclude that they must contain such cathepsin 
target sequences.  
An alanine scan library of peptides was generated for each peptide. This comprises a 
library of peptides with individual point-mutation of each amino acid from the natural 
amino acid to an alanine. As these alanine scan peptides would be used in T cell assays 
following incubation with lysosomal extracts it was important to check that they were 
recognised by T cells. Some peptides would contain mutations crucial for MHC class II 
binding or TCR recognition and therefore would not be recognised by T cells and would 
not be suitable for use in degradation assays using T cells. 
To ascertain which peptides T cells would recognise, LCLs were pulsed with individual 
peptides from VYG and PQC alanine scan peptide libraries. T cell recognition of peptide 
pulsed LCLs was then measured and compared to recognition of natural peptides 
(Figure 6.6). VYG peptides with alanine mutations at positions 9, 12, 14 and 15 were 
poorly recognised by VYG-specific CD4+ T cells. Peptides with alanine mutations at 
positions 10, 11 and 13 were not recognised at all by VYG-specific CD4+ T cells. PQC 
peptides A11-14 were not recognised by PQC-specific CD4+ T cells.  
Levels of recognition of the remaining peptides were similar to that of natural peptides 
and therefore the sensitivity of these peptides to lysosomal degradation could be 
investigated in peptide degradation assays using CD4+ T cells. 
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Figure 6.6 T cell recognition of VYG and PQC alanine scan peptide 
libraries 
LCLs were pulsed with individual peptides from VYG and PQC alanine scan 
peptide libraries (10-7µM, 1 h). T cell recognition of peptide pulsed LCLs was 
then measured. Red lines shown T cell recognition of natural peptides. VYG 
peptides A10, 11 and 13 were not recognised by VYG-specific CD4+ T cells. 
PQC peptides A11-14 were not recognised by PQC-specific CD4+ T cells. 
Recognition of PQC A15 was not measured (ND). 
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To test if the remaining peptides from the alanine scan libraries were less susceptible to 
degradation by lysosomal proteases, the peptides were incubated with lysosomal 
extracts. Degradation was again measured by loading peptides onto LCLs and measuring 
T cell recognition of these peptide loaded LCLs. 
Figure 6.7 shows T cell recognition of LCLs pulsed with alanine scan peptides following 
incubation with lysosomal extracts. Levels of recognition are given as a percentage of 
recognition of the natural peptide incubated on ice. As has been seen previously the 
natural VYG peptide was degraded and levels of recognition were approximately 30% of 
that of control, undigested peptide. Levels of degradation of all other alanine scan VYG 
peptides were similar showing that no mutation was able to protect VYG from 
degradation. 
Degradation of PQC peptides is also shown in Figure 6.7. As has been seen previously the 
natural PQC peptide was heavily degraded and levels of recognition were approximately 
10% of that of control, undigested peptide. Levels of degradation of all other alanine 
scan PQC peptides were similar. Again this showed that no mutation of the PQC peptide 
sequence was able to protect VYG from degradation. 
As no single mutation was able to alter peptide degradation, experiments to protect 
epitopes from lysosomal proteases were pursued no further.  
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Figure 6.7 Mutation of epitope peptides to protect against degradation 
by lysosomal peptidases 
Limiting doses of alanine scan peptides were incubated with lysosomal 
extracts for 16h. Peptides were then loaded onto LCLs and T cell recognition 
of LCLs was assayed. Peptide degradation is observed by decrease in T cell 
recognition. A. Recogntion of natural VYG was reduced to 28% of ice control 
by incubation with lysosomal extracts. Similar or greater decreases were 
observed for all other VYG peptides. B. Recogntion of natural PQC peptide 
was reduced to 10% of ice control by incubation with lysosomal extracts. 
Similar or greater decreases were observed for all other PQC peptides 
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6.6 Establishing a biochemical assay to measure peptide degradation by 
lysosomal proteases 
Although T cells are very sensitive and can detect very small changes in levels of peptide 
on the surface of antigen presenting cells, the magnitude of the change in response will 
differ between T cells depending on a number of different factors such as T cell avidity. A 
limiting dose of peptide was used in all previous degradation experiments and that dose 
was different for each peptide, depending on the T cell clone used. A 50% drop in IFN-γ 
production by T cells may not accurately represent a 50% reduction in epitope levels. 
Therefore although the system is probably accurate in detecting the large difference in 
destructive processing, the use of T cells may limit the ability to differentiate between 
more similarly susceptible epitopes. 
To allow a more direct comparison between epitopes a different and original system 
was devised which would allow direct quantification of peptides before and after 
incubation with lysosomal extracts. This allowed direct quantification of peptide 
degradation by lysosomal extracts and removed any errors that may be introduced by 
differences in T cell clones. 
A schematic of this biochemical peptide degradation assay is shown in Figure 6.8. 
Briefly, peptides representing the core 20 amino acids of epitopes labelled with an N-
terminal fluorophore and C-terminal biotin were generated. These peptides were then 
exposed to lysosomal extracts to allow digestion of peptides. After such time the peptide 
lysosome mix was incubated with streptavidin-coated beads. Samples were washed over 
a 1.2µm filter to remover unbound fluorophores. Beads were then analysed by flow 
cytometry to quantify uncleaved peptide levels. 
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Figure 6.8 Biochemical peptide degradation assay 
Target peptides labelled with a fluorophore and a biotin molecule are 
incubated with lysosomal proteases. Degradation of target peptides cleaves 
released the fluorophore from the biotin molecule. Peptides are incubated 
with streptavidin coated beads and unbound fluorophores removed by 
washing through a 1.2 µm filter. The beads are then analysed by flow 
cytometry and uncleaved peptides can be quantified by detection of 
fluorescence. 
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Control assays conducted using decreasing amounts of peptide showed a linear decrease 
in fluorescence of streptavidin beads (data not shown). This shows that levels of 
fluorescence directly correlate with the level of uncleaved peptide present in a sample 
and therefore this assay provides an accurate biochemical method by which to study 
peptide degradation. 
6.7 Measuring degradation of EBNA1 MHC-II epitope peptides by a biochemical 
method 
To confirm the results obtained in previous degradation experiments using T cells, 
degradation of the three EBNA1 epitope peptides SNP, VYG and PQC was measured 
using the biochemical peptide degradation assay. The results of this experiment are 
shown in shown in Figure 6.9. 
Peptides were incubated with lysosomal extracts for 16h either at 37°C or as a negative 
control on ice to inhibit any enzymatic degradation. Peptide degradation was 
determined by flow cytometry according to the biochemical peptide degradation assay. 
Figure 6.9a shows the levels of fluorescence detected in each sample representing the 
amount of intact peptide remaining. Figure 6.9b shows the decrease in fluorescence 
observed when peptides were incubated at 37°C compared to that of peptides 
maintained at 0°C on ice. The results show that 11% of the total SNP peptide input into 
the assay was degraded by incubation at 37°C. Levels of degradation were higher in both 
VYG and PQC. 34% of VYG peptide was degraded and 58% of PQC peptide was degraded. 
This assay confirms the data obtained from assays using T cells, in that SNP is most 
resistant to destructive processing and PQC is most susceptible. 
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Figure 6.9 Degradation of EBNA1 MHC-II epitope peptides by lysosomal 
proteases 
Peptides were incubated with lysosomal extracts for 16h either at 37°C or on 
ice. Peptide degradation was determined by flow cytometry according to the 
biochemical peptide degradation assay. A. Levels of fluorescence detected in 
each sample representing the amount of intact peptide remaining. B. . 
Decrease in fluorescence observed when peptides were incubated at 37°C 
compared to that of peptides maintained at 0°C on ice. SNP was reduced by 
11%, VYG by 34% and PQC 58%. 
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6.8 Autophagy-dependent epitopes from other proteins are resistant to 
degradation by lysosomal proteases 
This work has shown that presentation of EBNA1 MHC-II epitopes via autophagy 
correlates with the epitope peptide being resistant to degradation by lysosomal 
proteases. It is not known if this correlation is specific to EBNA1 MHC-II epitopes or if it 
will extend to other epitopes presented through autophagy. I hypothesised that all 
epitopes presented through autophagy will be resistant to degradation by lysosomal 
proteases. 
To test this theory, MHC class II epitope peptides from a range of proteins were tested 
for susceptibility to lysosomal degradation by the previously described biochemical 
peptide degradation assay. Five MHC class II epitope peptides from four different 
proteins were tested in this assay. The SNP peptide was tested as a control. The DRY 
peptide from NeoR, the SVS peptide from the murine influenza protein HA and the VAN 
peptide from the mycobacterium tuberculosis protein Ag85b were all tested as they had 
previously been shown to be generated by autophagy, either naturally or in the case of 
the SVS peptide, by tagging to LC3. A second peptide from the murine influenza protein 
HA, CPK was included as this protein had shown not to be generated by autophagy when 
tagged to LC3 in the same system. 
The results of biochemical peptide degradation assays using these peptides are shown in 
Figure 6.10. The peptides were incubated with lysosomal extracts for 16h either at 37°C 
or as a negative control on ice to inhibit any enzymatic degradation. Peptide degradation 
was determined by flow cytometry. Figure 6.10a shows the levels of fluorescence 
detected in each sample representing the amount of intact peptide remaining. Figure 
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6.10b shows the decrease in fluorescence observed when peptides were incubated at 
37°C compared to that of peptides maintained at 0°C on ice. 
The results in Figure 6.10b show that the DRY peptide was very stable when exposed to 
lysosomal extracts; degradation of the epitope was less than the degradation of SNP. The 
DRY epitope has previously been shown to be generated by autophagy in LCLs for 
presentation to a CD4+ T cell clone and therefore this supports the hypothesis that 
resistance to degradation is able to confer presentation by autophagy. 
Comparison of the two epitopes from the murine influenza virus protein HA showed that 
the SVS epitope that is able to be presented through autophagy is highly resistant to 
degradation. The CPK epitope that cannot be generated through autophagy is more 
labile. 25% of the CPK epitope peptides were degraded in this experiment. 
An unexpected result was observed when the degradation of the Ag85b epitope VAN 
was studied. This epitope is known to be presented through autophagy; however this 
epitope was the least resistant to degradation in that 29% of the VAN epitope peptides 
were degraded. This result was unexpected and did not fit with the hypothesis. 
However, presentation of the VAN epitope by autophagy was not observed in an LCL but 
in the murine bone marrow macrophage cell line BMA.A3. It is possible that the 
cathepsins present in the lysosomal extract from LCLs that are responsible for the 
degradation of VAN in the previous experiment are not expressed in these macrophage 
cells. It is therefore possible that VAN is resistant to lysosomal degradation in 
macrophage cells where it is naturally presented by autophagy. 
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Figure 6.10 Degradation of MHC-II epitope peptides by lysosomal 
proteases 
Peptides were incubated with lysosomal extracts for 16h either at 37°C or on 
ice. Peptide degradation was determined by flow cytometry according to the 
biochemical peptide degradation assay. A. Levels of fluorescence detected in 
each sample representing the amount of intact peptide remaining. B. 
Decrease in fluorescence observed when peptides were incubated at 37°C 
compared to that of peptides maintained at 0°C on ice. DRY showed the 
smallest decrease and VAN the largest. 
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To test this theory, lysosomal extracts were isolated from BMA.A3 cells and the 
degradation of the VAN epitope by these macrophage derived lysosomal proteases was 
measured. VAN and EBNA1 epitope peptides were incubated with increasing 
concentration of either LCL or macrophage lysosomal extracts and the degradation of 
each peptide was measured in using the biochemical peptide degradation assay. 
As seen previously, the VAN epitope peptide was susceptible to degradation by LCL-
derived lysosomal extracts. Levels of degradation were similar to the degradation of the 
VYG peptide (Figure 6.11a). When peptides were incubated with macrophage lysosomal 
extracts a very different pattern was observed. All three EBNA1 peptides were 
efficiently degraded by very low concentrations of macrophage lysosomal extracts 
(Figure 6.11b). In contrast, degradation of the VAN peptide by macrophage-derived 
proteases was very low. Indeed, the VAN epitope peptide was more resistant to 
degradation that all EBNA1 peptides including SNP across all doses of lysosomal extract. 
This result confirms that the degradation of the VAN peptide by LCL-derived proteases 
was an LCL-specific effect and that VAN is resistant to degradation in the cells where it is 
naturally processed by autophagy. This supports the theory that resistance to 
degradation is required for autophagic presentation. 
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Figure 6.11 Degradation of the VAN epitope by LCL- and macrophage-
derived lysosomal proteases 
Peptides were incubated with increasing concentrations of lysosomal 
extracts for 16h at 37°C. Peptide degradation was determined by flow 
cytometry according to the biochemical peptide degradation assay. A. Levels 
of fluorescence detected in samples incubated with LCL-derived lysosomal 
extracts. B. Levels of fluorescence detected in samples incubated with 
macrophage-derived lysosomal extracts. VAN showed moderate stability 
when incubated with LCL-derived lysosomal extracts but was highly stable 
when incubated with macrophage-derived lysosomal extracts 
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6.9 Characterising the degradation of EBNA1 MHC-II epitope peptides 
As mentioned previously, protecting MHC class II epitope peptides from destructive 
processing should increase the levels and diversity of MHC class II epitopes displayed on 
the surface of cells and would therefore increase T cell recognition of such cells. 
Previous unsuccessful attempts were made to mutate peptides to make them more 
resistant to cathepsins. A more effective method of protecting peptides from 
degradation may be to inhibit cathepsins. This is also more clinically applicable as 
tumour cells could be treated with cathepsin inhibitors to increase presentation of 
naturally expressed peptides, thus increasing T cell recognition of tumour cells.  
However as discussed in chapter 1, many cathepsins are important for MHC class II 
presentation and therefore inhibiting all cathepsins would decrease epitope display. If 
individual cathepsins could be implicated in destructive processing, it may be possible to 
specifically inhibit these cathepsins, thereby reducing destructive processing without 
affecting overall MHC class II processing. I therefore aimed to identify if individual 
cathepsins were responsible for the destructive processing of EBNA1 MHC class II 
epitopes. 
One possible mechanism for differentiating between cathepsins is to measure their 
activity at different pH. As they are resident in the lysosome, most cathepsins have an 
optimum pH in the acidic range. However some differences have been observed, for 
instance cathepsin S has been shown to active across a very broad pH range. 
Chapter 6 - Results 
 
191 
 
To determine the optimum pH for degradation of EBNA1 MHC class II epitopes, peptides 
were incubated with LCL lysosomal extracts in a range of pH buffers. Peptide 
degradation was again studied by biochemical peptide degradation assay. 
Figure 6.12 shows the results of this experiment. The optimum pH for peptide 
degradation was pH6 in all cases. However when degradation at pH5 and pH7 were 
compared subtle difference can be observed. Both SNP and PQC peptides are degraded 
more efficiently at pH7 than at pH5, whereas degradation of the VYG peptide is inhibited 
at pH7. This suggests SNP and PQC may be degraded by cathepsins that are more active 
at higher pH. 
To further elucidate the contribution of individual cathepsins to the degradation of 
epitope peptides, degradation assays were carried out in the absence and presence of 
inhibitors. The inhibitors used and their specificities are listed in Table 6.1a. The 
degradation of peptides is listed in Table 6.1b, results are recorded in terms of 
percentage of peptide remaining following degradation. The effect of inhibitors is shown 
also, in terms of inhibition of degradation as a percentage of total degradation.  
Levels of degradation in the absence of inhibitors was similar to previous experiments 
with SNP being more stable than VYG and VYG being more stable than PQC. To monitor 
the specificity of inhibitors, a control peptide containing a known cathepsin D cleavage 
site was included and over 80% of this peptide was degraded in the absence of 
inhibitors, this degradation was inhibited most effectively by inhibitors of aspartyl 
peptidases, of which cathepsin D is one. 
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Figure 6.12 Degradation of EBNA1 MHC class II epitope peptides is pH 
dependent 
Peptides were incubated with lysosomal extracts for 16h at 37°C in buffers of 
different pH. Peptide degradation was determined by flow cytometry 
according to the biochemical peptide degradation assay. Maximum 
degradation occurred at pH6 for all peptides. SNP and PQC were degraded 
more efficiently at pH7 than pH5. 
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Degradation of VYG was reduced by all inhibitors with the exception of the Cathepsin S 
inhibitor. This suggests that VYG may be degraded by multiple cathepsins. The 
degradation of PQC was reduced by fewer inhibitors. The greatest levels of inhibition 
were observed with inhibitors of cysteine proteases and the combined cathepsin B and S 
inhibitor. The cathepsin S inhibitor failed to inhibit degradation of PQC. Taken with the 
result of the combined inhibitor this may suggest just cathepsin B is degrading PQC. The 
specific cathepsin B inhibitor only caused a small decrease in PQC degradation though 
this may suggest the inhibitor is not very potent and fails to protect PQC which is a 
highly labile epitopes. 
Taken together these data suggest that VYG is degraded by multiple cathepsins and PQC 
may be specifically degraded by cathepsin B. 
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Table 6.1 Inhibition of cathepsin mediated degradation of EBNA1 MHC 
class II epitope peptides 
Peptides were incubated with lysosomal extracts for 16h on ice or at 37°C in 
the absence and presence of inhibitors. A. Inhibitors and their specificities. B. 
Fluorescence is shown as a percentage of 0°C control. Inhibition of 
degradation is colour coded according to the level of inhibition achieved as a 
percentage of total degradation. 
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6.10 Discussion 
In this chapter I aimed to investigate the factors that affect the generation of MHC class 
II epitopes via non-classical processing of endogenous proteins. As previously discussed, 
multiple examples of endogenous proteins accessing the endocytic compartment have 
now been defined. Access can occur via multiple pathways, including macro- and micro 
autophagy; however access to this compartment alone is not sufficient to generate MHC 
class II epitopes.  
EBNA1 presents an excellent model in which to study MHC class II epitope generation 
from non-classical processing of endogenous proteins. EBNA1 is able to access the 
endocytic compartment via autophagy but this pathway only generates a single MHC 
class II epitope, SNP. Other epitopes are generated in an autophagy-independent 
manner or in the case of the PQC epitope, not at all. 
6.10.1 Destructive processing of EBNA1 MHC class II epitope peptides 
Work by Leung et al. had previously suggested that PQC may be more susceptible to 
degradation by cathepsins than other EBNA1 MHC class II epitopes. I therefore 
hypothesised that destructive processing limits the presentation of two EBNA1 MHC 
class II epitopes VYG and PQC through autophagy. 
Experiments in which a cytoplasmic EBNA1 construct was over-expressed in LCLs 
showed that high levels of protein expression can force the generation of VYG and PQC 
through autophagy. This result could suggest that at high levels of protein expression 
cathepsins become limiting and therefore destructive processing of EBNA1 is impaired. 
This allows the generation of VYG and PQC. 
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As PQC presentation required higher expression of EBNA1 than VYG, I suggest that the 
PQC peptide is more susceptible to destructive processing than VYG. As SNP is naturally 
generated through autophagy, the SNP peptide should be resistant to destructive 
processing. From this I predicted a hierarchy in the susceptibility of peptides to 
degradation. SNP should be most resistant to degradation, VYG should show 
intermediate levels of resistance and PQC should be least resistant to degradation. 
6.10.2 Testing the susceptibility of EBNA1 MHC class II epitope peptides to 
degradation 
To test this predicted hierarchy all three peptides were exposed to lysosomal extracts 
from LCLs to measure degradation by lysosomal proteases. In early experiments T cells 
were used to quantify peptide degradation. LCLs were incubated with peptides pre-
incubated with lysosomal extracts. T cell recognition of these LCLs was then measured 
to quantify the amount of peptide remaining after incubation with lysosomal extracts. 
These experiments were successful and differences between the levels of degradation of 
each peptide could be readily detected. The T cell degradation assays confirmed the 
predicted hierarchy, confirming SNP was most stable and PQC most labile when exposed 
to lysosomal extracts. It was presumed and later confirmed in inhibiter experiments that 
this degradation was mediated by lysosomal cathepsins. 
Many different cathepsins with different cleavage specificities are expressed in 
lysosomes of LCLs as was confirmed in assays monitoring cathepsin activity. Different 
explanations exist for the hierarchy observed. It is possible that PQC contains multiple 
cathepsin target sites and therefore can be degraded by multiple cathepsins. It is also 
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possible that PQC is degraded by a cathepsin that is expressed at high levels in LCLs 
lysosomes and that this cathepsin is unable to degrade SNP or VYG efficiently. 
Lysosome extracts from three different LCL were tested for cathepsin activity and 
differing levels of cathepsins was detected in each. However when peptide degradation 
assays were repeated with different LCL extracts the same hierarchy was observed. This 
perhaps suggests that PQC is degraded by multiple cathepsins rather than one highly 
expressed cathepsin. 
6.10.3 Protecting epitopes to increase T cell recognition of target cells 
As destructive processing appears to limit the amount and range of MHC class II 
epitopes presented on the surface of EBV infected cells, I proposed that protecting 
epitopes from destructive processing may increase epitope display and therefore CD4+ T 
cell recognition of target cells. 
Initial attempts were made to protect epitope peptides from degradation by introducing 
point mutations into peptides with the intention of disrupting cathepsin target sites. 
This was unsuccessful in that no single point mutation was able to decrease degradation 
of either the VYG or PQC peptide. 
Although these experiments were unsuccessful they did reveal some interesting data 
about the two epitope peptides. Initially, T cell recognition of undigested peptides was 
studied and some point mutations were shown to inhibit T cell recognition of the 
peptide. These point mutations identify the amino acids within the core 20mers 
required for either binding to MHC class II molecules, so called anchor residues, or the 
amino acids that are displayed in the peptide groove to mediate peptide binding to TCR. 
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A number of explanations for the failure of point mutations to protect epitopes from 
destruction exist. First, it is possible that VYG and PQC both contain multiple cathepsin 
recognition sites and therefore a single point mutation would not disrupt cathepsin 
degradation. Second, it is possible that cathepsin recognition sites are within the key 
amino acids required for T cell recognition; these mutants were not tested in 
degradation assays as they were not recognised by T cells. Finally it is possible that 
flexibility in the cathepsin target sites meant the point mutations introduced were not 
sufficient to inhibit cathepsin targeting. 
6.10.4 Degradation of other autophagy-dependent epitopes 
Though the T cell based peptide degradation assays produced interesting data, they do 
present some limitations. As different T cell clones had to be used to measure 
degradation of different peptides, it is possible that differences in the T cells could 
introduce errors into the experiment. Also the use of T cells limited the range of peptides 
that could be tested in this assay. To test a peptide a matched T cell clone was required. 
To counter both of these problems a biochemical assay was developed to monitor 
peptide degradation by fluorescence based flow cytometry. This assay should remove 
any variability introduced by T cells and allowes any peptide to be tested. Also this assay 
was adaptable to high throughput work which would be very useful later for repeating 
assays in the presence and absence of many different inhibitors. 
First the degradation of EBNA1 MHC class II peptides was tested by this assay to confirm 
the results seen in T cell based assay. The data from the biochemical assay matched the 
data from the T cell assay again confirming the hierarchy of SNP, VYG, PQC. 
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Next the assay was used to measure degradation of other non-EBV peptides. The 
conclusion from this work so far is that resistance to destructive processing is able to 
confer epitope generation by autophagy in EBNA1. It is not known if this in an 
phenomenon specific to EBNA1 or if it is applicable to all epitope peptides generated 
through autophagy. 
Four peptides from three different proteins were tested for degradation by LCLs derived 
cathepsins. Two epitopes previously shown to be presented though autophagy were 
shown to be resistant to degradation and a third epitope not presented through 
autophagy was shown to be susceptible to degradation. However one peptide, VAN, 
known to be presented thorough autophagy was degraded by LCL cathepsins. 
VAN has been shown to be presented by autophagy in a macrophage line. It is therefore 
possible that it will be resistant to degradation by macrophage derived cathepsin. This 
was indeed shown to be the case. VAN was the most stable peptide tested in degradation 
assays using macrophages.  
Taken all together these data present very strong evidence that the range of autophagy-
dependent peptides presented by antigen presenting cells is defined by the 
susceptibility of each epitope peptide to destructive processing. Peptides that are 
resistant to destructive processing are presented by autophagy and those that are 
susceptible to destructive processing are not. 
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6.10.5  Characterising Peptide degradation 
Though previous attempts to protect peptides from destructive processing were 
unsuccessful, manipulating destructive processing to increase epitope display is still an 
attractive mechanism for increasing T cell recognition of pathogen infected cells. 
Rather than trying to alter peptides, a more therapeutically applicable method might be 
to inhibit cathepsins. Therefore attempts were made to characterise the degradation of 
MHC class II epitope peptide degradation with the intention of indentify individual 
cathepsins that could be targeted in increase epitope presentation. 
Inhibitor experiments revealed inhibitors of different classes of cathepsins were all able 
to inhibit the degradation of VYG. However the same experiments suggest that PQC may 
be specially degraded by cathepsin B. In the light of this knowledge I returned to the 
results of cathepsin activity assays. Cathepsin B activity showed the highest activity in 
all LCLs. It is difficult to compare activity of different cathepsins using different 
substrates however this may suggest that cathepsin B is highly expressed and active in 
LCLs. This provides an explanation as to why PQC is so labile and also defines cathepsin 
B as a possible target for manipulation of destructive processing to increase T cell 
recognition of EBV infected cells. 
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7. FINAL DISCUSSION 
As discussed throughout this work, increasing evidence suggests that CD4+ T cells have 
an increasingly important and therapeutically relevant role as direct effectors in 
immunotherapy. 
The main aim of this body of work was therefore to study MHC class II processing of 
tumour antigens and subsequent presentation to CD4+ T cells. A particular focus was 
placed on studying the non-classical MHC-II processing pathways involved in processing 
of endogenous antigens. 
A secondary aim was to apply the knowledge of MHC class II processing to develop novel 
strategies to improve both the range and levels of MHC class II epitopes presented to 
tumour-specific CD4+ T cells. 
7.1 Findings 
Originally work was focussed on WT1, a promising tumour antigen recognised by both 
CD8+ and CD4+ T cells. Experiments were conducted to investigate the expression of 
WT1 in a number of cell lines. A complex pattern of expression was revealed with many 
different isoforms, including previously undescribed isoforms of WT1 being expressed. 
These experiments also revealed that no single method for the detection of WT1 was 
able to identify all isoforms of WT1. 
The frequency and breadth of the WT1 T cell response in the healthy donors and cancer 
patients was also investigated in this section. Many highly sensitive methods were 
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applied and all experiments revealed that WT1-specfic T cells are exceptionally rare in 
both healthy donors and the all tested patients. 
Some attempts were made to investigate the MHC class II processing of WT1 but the 
ultimate failure to generate WT1-specific T cells limited this work. 
Later work focussed on investigating the MHC class II processing of the EBV antigen 
EBNA1. EBNA1 is a better studied tumour antigen and more is known about how 
endogenous EBNA1 is presented to CD4+ T cells. However, many questions remain about 
the mechanisms behind EBNA1 MHC class II processing. Also CD4+ T cell recognition of 
EBNA1 positive cells is relatively poor suggesting there is scope to improve the 
presentation of EBNA1 with possible important and therapeutic benefits. 
Attempts were made to improve the presentation of EBNA1 by relocalisation of the 
protein using the CDK inhibitor Roscovitine. These experiments were ultimately 
unsuccessful but did reveal a very interesting finding. Roscovitine was able specifically 
inhibit the autophagic presentation of EBNA1; inhibition was concurrent with a 
Roscovitine-mediated downregulation of the multiple autophagy adaptors. 
Correlation of reduced autophagy adaptor expression and reduction in autophagic 
presentation was explored in the subsequent chapter. siRNA experiments proved that 
three autophagy adaptors, NBR1, CALCOCO2 and OPTN were required for the 
autophagic presentation of EBNA1 MHC class II epitopes. This was a very interesting 
result and represents the first known evidence that autophagic degradation and 
subsequent generation of MHC class II epitopes is mediated through autophagy 
adaptors. 
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A final set of experiments were conducted to answer the important question of why only 
some epitopes are presented through autophagy. Originally this work was conducted 
using MHC class II epitopes from EBNA1 but was later extended to study autophagy-
dependent epitopes from a range of different proteins. The results of these experiments 
showed that destructive processing by lysosomal cathepsins limits the range of epitopes 
presented through autophagy. All autophagy-dependent epitopes tested were resistant 
to degradation, whereas epitopes not presented by autophagy were degraded by 
cathepsins. 
7.2 Conclusions and future work 
A number of important conclusions can be drawn from each section completed in this 
body of work. 
Experiments on WT1 suggest that reports in the literature regarding the expression of 
WT1 may have significantly underestimated the range of cells in which WT1 is 
expressed. Heterogeneity in WT1 expression means no single method can detect all WT1 
isoforms. This suggests WT1 may be expressed in even more tumours than is currently 
thought. The second main conclusion from the work on WT1 is that WT1-specific T cells 
are incredibly rare; this rarity is not apparent from the published literature.  
The work on Roscovitine shows that this CDK inhibitor is not able to relocalise 
endogenous EBNA1. It also proves that any inhibition of cellular proliferation caused by 
Roscovitine is independent of any effect Roscovitine may be having on EBNA1. The 
important finding from the work on Roscovitine was the preliminary data that suggested 
a possible link between autophagy adaptors and EBNA1 degradation. 
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The work on autophagy adaptors and destructive processing can be analysed together to 
create a better understanding of how EBNA1 is processed and presented. From this 
work I suggest the following model to explain the presentation of EBNA1 MHC class II 
epitopes. I propose that autophagy adaptors are required to target EBNA1 for 
degradation by autophagy. Once in the endocytic pathway lysosomal proteases degrade 
EBNA1 and generate MHC class II epitopes. However, with the exception of the SNP 
epitope, all EBNA1 MHC class II epitope peptides are susceptible to destructive 
processing by cathepsins and are therefore destroyed. As the only epitope peptide to 
survive within the lysosomal compartment, SNP alone is presented by autophagy. 
I believe this work has developed a clearer understanding of EBNA1 MHC class II 
processing. However, many unanswered questions remain. Nuclear EBNA1 is targeted 
for autophagic degradation in the cytoplasm by autophagy adaptors but the mechanism 
of this interaction has not been elucidated. Future work to identify how EBNA1 enters 
the cytoplasm and how EBNA1 and autophagy adaptors interact should be carried out. 
One possible mechanism for EBNA1 entering the cytoplasm is that newly synthesised 
EBNA1 is sequestered in the cytoplasm by autophagy adaptors prior to import into the 
nucleus. Experiments using protein synthesis inhibitors or the dox inducible over-
expression system could be used to study this possibility. At the time this thesis was 
submitted no direct interaction between EBNA1 and autophagy adaptors has been 
discovered, further EBNA1 deletion experiments as well as co-localisation experiments 
may reveal a direct interaction between EBNA1 and autophagy adaptors. 
Finally the work on destructive processing revealed a possible role for cathepsin B in the 
degradation of the PQC epitope. Further work is required to confirm this result. Purified 
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cathepsins could be used to study the contributions of individual cathepsins to 
degradation. Also further inhibitor studies including attempts to study destructive 
processing within cells should be attempted. Cell permeable cathepsin inhibitors could 
be tested for their ability to inhibit destructive processing. This may increase the 
presentation of many MHC class II epitopes, a finding that could be very therapeutically 
relevant. 
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